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ABSTRACT
Bordetella pertussis is the causative agent of whooping cough, a severe disease of 
infants characterised by repeated bouts of paroxysmal coughing. Pertussis toxin (PT) is 
a major virulence factor of B. pertussis and is a typical A/B bacterial toxin consisting of 
five subunits S1-S5 in a ratio of 1:1:1:2:1. The PT subunit genes are organised into an 
operon which is not expressed in Escherichia coli, thus hampering the use of this 
organism for vaccine production. In this research the five PT subunits were 
individually expressed in E. coli by replacing the wild-type transcriptional and 
translational signals, and in the case of the S4 subunit the leader peptide has been 
exchanged with a modified E. coli 8-lactamase leader sequence. In E. coli CAG629 all 
five PT subunits were at least partially processed, with S5 being completely processed. 
A stepwise cloning method has then been developed to construct a synthetic PT operon 
which simultaneously expresses the five PT subunits in E. coli. Western blot analysis 
indicated that in E. coli KS476 containing the synthetic PT operon, S4 and S5 were 
completely processed, SI was partially processed, whilst the majority of S2 and S3 
remained unprocessed. Periplasmic extracts contained soluble SI and S3; however the 
processed form of S2, S4 and S5 were not detected, suggesting that these subunits may 
be membrane associated or in an insoluble form. This work should allow an 
investigation of the potential of E. coli to produce detoxified PT in a background free of 
other pertussis virulence factors that may contribute to the side effects of some vaccine 
preparations presently in use. Current vaccines against whooping cough are 
administered parenterally, and generate a systemic immune response. An alternative to 
this approach is to stimulate mucosal and systemic immune responses by oral 
immunisation with live vaccine strains of Salmonella spp. In this research, the five PT 
subunits have been individually expressed in Salmonella spp. and the synthetic PT 
operon (pDP16) has then been expressed in attenuated aroA  mutants of S. 
typhimurium , SL3261 and SL7207, via the use of a temperature inducible expression 
system. In SL3261 containing individual subunit expression plasmids the S5 subunit
was found to be completely processed, while all other subunits were partially 
processed. In SL3261 (pDP16) and SL7207 (pDP16) S5 was completely processed, 
SI was partially processed, whilst S2, S3 and S4 remained unprocessed. Induction of 
the heat inducible synthetic PT operon at 39.5°C decreased the growth and in vitro 
invasiveness of SL3261 and SL7207, compared to uninduced (30°C) and partially 
induced (37°C) bacterial cells. Antibody responses were monitered following oral 
immunisation of BALB/c mice with the live vaccine strain SL7207 (pDP16) induced at 
39.5°C for 1 h. Mice orally immunised with SL7207 (pDP16) primarily produced a 
systemic antibody response which recognised the S1 subunit of PT. The protectiveness 
of this vaccine strain was assessed in a mouse intracerebral challenge assay. Mice 
immunised with one dose of S. typhimurium SL7207 (pDP16) were not protected 
following intracerebral challenge with live B. pertussis. Future work will be aimed at 
improving the processing of PT subunits and immunogenicity of this vaccine strain, 
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Bordetella pertussis is the causative agent of whooping cough, a particularly severe 
and contagious respiratory disease of infants, characterised by repeated bouts of 
paroxysmal coughing. This bacterium colonises the respiratory mucosa, having a 
specificity for ciliated cells. Colonisation of these cells ultimately results in their 
death due to production of toxic compounds by the bacteria. The inability to culture 
the organisms during the most severe stage of the disease has led to the assumption 
that the disease is mainly toxin mediated (Pittman, 1979).
1.2 Pertussis Vaccines
The incidence of whooping cough has been largely reduced by mass immunisation 
with a heat-killed whole cell vaccine routinely administered in combination with 
diphtheria and tetanus toxoids. Whole cell vaccines are manufactured in numerous 
countries, and although the basic preparation procedures are similar, the vaccines 
frequently elicit significantly different responses to the various B. pertussis antigens. 
Despite lot to lot variation, benefits associated with whole cell vaccines clearly 
outweigh the risks of side effects associated with pertussis vaccination. Some side 
effects of vaccination include fever, redness or swelling at the site of vaccination, 
persistent crying; neurological damage following vaccination has never been 
conclusively proven. Nevertheless, increasing concern about adverse effects of 
immunisation with whole cell preparations of B. pertussis has led to decreased 
acceptability of whooping cough vaccination and a consequent increase in the 
incidence of the disease (Robinson et al., 1985). It is imperative that an effective, 
non-reactogenic vaccine of higher acceptability be developed. Thus, scientific
research is presently focused on the development of recombinant whooping cough 
vaccines consisting of characterised constituents of the bacterium B. pertussis.
1.3  Progress to Date in the Development of Recombinant Pertussis 
Vaccines
Research is presently aimed at using genetic studies and recombinant DNA 
technology to produce vaccines of higher efficacy than the whole cell vaccine. Such 
new generation vaccines are likely to contain detoxified pertussis toxin (PT), 
filamentous hemagglutinin (FHA), pertactin (P69) and possibly serotype specific 
fimbriae. The genetic regulation of these virulence determinants provides vital 
information for vaccine development.
1 .3 .1  The Genetic Regulation of Bordetella pertussis Virulence 
Determinants
B. pertussis regulates the expression of its virulence determinants in a coordinated 
manner in response to environmental stimuli. Regulation occurs via a sensory 
transduction system encoded by the BvgAS (Bordetella Virulence Genes) locus 
(Stibitz and Yang, 1991; Weiss and Hewlett, 1986). Although all of the known 
virulence determinants of B. pertussis are regulated by the Bvg locus, PT and 
adenylate cyclase toxin (ACT) also require auxiliary proteins for their transcription 
(Miller et al., 1989). A Bvg accessory factor (Baf) has recently been partially 
characterised. This work indicates that Baf, a novel transcripitional regulator, 
interacts with BvgAS to transactivate ptx-lacZ fusions in E. coli (DeShazer et al., 
1995).
3





fim i (serotype specific fimbriae)
ptx  (pertussis toxin)
cyal (adenylate cyclase toxin)
Figure 1. Schematic model for virulence gene regulation on B. pertussis. Arrows indicate a positive 
influence of gene expression. BvgA specifically binds to the promoter regions of fhaB and bvgAS 
and activated transcription from these loci. Both Baf and BvgAS are needed in trans for transcription 
of ptx  (and possibly cya). The BvgAS system is necessary for activation of prn and fim  in B. 
pertussis, but it is unknown whether fim  and prn require an accessory factor for expression or if 
activation by Bvg is direct. The requirement of an additional factor (X) for the expression of Baf is 
suggested. Taken from (DeShazer et al., 1995).
The bvgAS operon encodes two proteins: BvgA a transcriptional control factor, and 
BvgS a transmembrane sensor protein. Current models suggest that BvgS activates 
BvgA by a mechanism involving phosphorylation. Activated BvgA then binds to 
specific sequences located upstream of regulated promoters to induce transcription of 
virulence determinants. The stimuli that regulate the activity of BvgAS in the human 
respiratory tract have yet to be determined. In vitro, however, the presence of sulfate 
anions, nicotinic acid and low temperature (30°C) result in the cessation of 
transcription of BvgAS activated genes and the induction of the negatively controlled 
virulence repressed genes designated vrg (Knapp and Mekalanos, 1988; Lacey, 
1960; Miller et al., 1989). The absence of these inducing factors results in the 
induction of virulence activated genes (yag) and maximal expression of the virulence 
determinants. Figure 2 summaries the role of the bvg locus in directing the 
expression of vag and vrg loci.
4
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Inactive bvg lo c u s_______________________________ No activation of vag loci
Repression lifted on vrg loci
Figure 2. Representation of the pivotal role played by the bvg locus in regulating gene expression 
in response to environmental stimuli, vag loci, v/r-activated genes; vrg loci, v/r-repressed genes. 
Taken from (Coote, 1991).
The induction and repression of the bvg locus demonstrates that B. pertussis has the 
ability to alternate between virulent and avirulent forms. This ability to alter 
expression of the virulence determinants in response to environmental signals is 
termed antigenic modulation. It has been suggested that the avirulent phase may 
represent an intracellular, pathologically dormant state associated with late infection 
and may be a strategy for immune evasion and thus persistence of the disease 
(Coote, 1991).
1 .3 .2  Vaccine Com ponents
The virulence factors of B. pertussis that are being considered as vaccine 
components have been studied in detail. Following their cloning and sequencing, the 
aim generally has been to produce these proteins using an appropriate expression 
vector system. Additionally, in the case of toxins research has been conducted to 
create mutations which detoxify the protein whilst preserving its immunogenicity.
Current research indicates that PT, FHA and P69 should be constituents of
recombinant vaccines. Evidence showing that vaccines provide increased protection 
and longer lasting immunity with the incorporation of serotype specific agglutinins 
also suggests the importance of these proteins as constituents of recombinant 
vaccines (Miller et a l, 1991). However other studies suggest that serotype specific 
fimbrial proteins offer no additional benefit as vaccine constituents (Edwards and 
Decker, 1996).
1 .3 .2 .1  P ertu ssis Toxin
The genes encoding the PT subunits are organised into an operon (Figure 3) (Nicosia 
et al., 1986; Locht and Keith, 1986), which is not expressed when cloned into 
Escherichia coli (Nicosia and Rappuoli, 1986). This protein is expressed by virulent 
B. pertussis due to the ability of the Bvg locus to transactivate the PT promoter 
(Arico e ta l , 1989).
Pr i— i n n n i  ii ii ii ii i u u u u _l
SI S2 S4 S5 S3 A B C D I E F G H
ptx ptl
Figure 3. Schematic representation of the PT operon and the pertussis toxin liberation (ptl) genes. 
The five genes are clustered within a 3.2 kilobase DNA fragment in the following order: SI, S2, 
S4, S5, S3. The ptl region of the B. pertussis chromosome is 9.5 kilobases in length and is located 
directly downstream from the PT structural genes. Pr indicates the location of the ptx-ptl promoter. 
The arrows indicate the direction of transcription, filled boxes represent signal peptides. Downstream 
of this operon, nine open reading frames have been identified coding for ptl genes, involved in PT 
excretion. Adapted from (Farizo et al., 1996).
The five PT subunits are thought to be exported individually into the periplasmic 
space where holotoxin assembly occurs, before excretion of holotoxin into the 
culture medium which is mediated by the PT liberation genes (ptl) genes (Weiss et 
a l ., 1993; Covacci and Rappuoli, 1993; Johnson and Burns, 1994). For the 
purposes of this review excretion refers to the excretion of protein into the 
extracellular environment, whilst secretion refers to secretion into the bacterial
periplasm unless otherwise stated. Secretion can be accomplished without the ptl 
gene products; excretion of PT is only possible in the presence of ptl gene products. 
A similar process has been proposed for the excretion of pullulanase from E. coli 
(Pugsley et al., 1991) and excretion of enterotoxin from Vibrio cholerae (Hirst and 
Holmgren, 1987). The ptl locus of B. pertussis encodes nine proteins (Farizo et al., 
1996; Weiss et al., 1993) that may form a gate or channel used in the transport 
process (Johnson and Bums, 1994). The process of holotoxin assembly occurs 
independently of ptl genes or other bvg-activated chaperone proteins (Walker et al., 
1991b).
Pertussis toxin, a 106 kDa hexameric protein, is a typical A/B bacterial toxin 
(Tamura et al., 1982), containing functionally distinct domains responsible for 
binding to cell surfaces and for catalytic activity. Other members in this toxin family 
include cholera, Shiga, Pseudomonas exotoxin A and diphtheria toxin. PT, in 
addition to being a presumptively vital protective immunogen, is a major component 
in bacterial pathogenesis and has been advocated as the major cause of harmful 
systemic effects (Pittman, 1979 and 1984). As shown in Figure 4, PT is composed 
of five subunits, having two functionally different activities. The A-protomer or S1 
subunit is the enzymatic portion of the toxin which is activated by the reduction of a 
single disulfide bond. Its functions include the ability to ribosylate target guanine- 
nucleotide binding G proteins (Katada and Ui, 1982), which are membrane 
associated molecules that transduce receptor-coupled agonist signals involved in the 
reduction of adenylyl cyclase. PT functions by blocking adenylyl cyclase inhibition, 
thereby resulting in the uncontrolled formation of cAMP, ultimately leading to 
cytotoxic effects. In vitro, its presence results in the clustering of Chinese Hamster 
Ovary (CHO) cells (Hewlett et al., 1983). The B-oligomer consists of subunits S2, 
S3, S4 and S5 in a ratio of 1:1:2:1 (Tamura et al., 1982) and is responsible for 
targeting toxic activity via cell surface receptor recognition. The S2 and S3 subunits 
possess greater than 70% amino acid identity (Locht and Keith, 1986; Nicosia et al.,
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1986).
These subunits each contain distinctive eukaryotic cell receptor recognition 
characteristics (Katada and Ui, 1982) and can display receptor attachment in vitro, 
recognising lactosylceramide and gangliosides from cilia and macrophages 
(Saukkonen et al., 1992). The B-oligomer presumably acts as a delivery platform for 
transmission of S1 to sensitive host cells. Other in vitro binding capabilities of the B- 
oligomer result in hemagglutination and lymphocyte mitogenicity. Dominant B and 
T-cell epitopes of S2 (residues 78-98) are positioned just above the selectin-like 
binding domain, which in eukaryotes are involved in lymphocyte trafficking. Two 
other known antigenic determinants are parallel to each other; B and T cell epitopes 
of S4 (residues 20-50) and a T-cell epitope at the interface of S3 and S4. Important 
B-cell epitopes are contained in the SI subunit, including a dominant toxin 





Figure 4. The structure of PT. A dominant mouse protective epitope is present on the SI subunit 
which also contains an internal disulfide bridge, reduction of which is necessary for enzymatic 
activity. The B-oligomer contains less dominant epitopes (but perhaps more important), a cilia 
specific adherence site is present on the S2 subunit recognising glycolipids containing 
lactosylceramide and glucosylceramide, whilst the S3 subunit possesses recognition sites for sialic 
acid in the bronchoalveolar macrophages. Not drawn to scale. Adapted from (Burnette, 1990).
Immune responses towards the S1 subunit and B-oligomer of PT have been shown 
to be important in providing protection against toxin activity and B. pertussis 
infection in animal models; research suggests that there is a correlation between 
antibody and/or cell mediated immune responses against PT and protection against 
human disease (Burnette, 1994). Several groups have developed strategies to 
produce individual PT subunits or fusion proteins for use in experimental anti-PT 
vaccines (Burnette et al., 1988a; Nicosia et al., 1987). Initial attempts include the 
expression in E. coli of separate PT subunits as heterologous proteins fused to MS2 
DNA polymerase. Whereas mice immunised with all five subunit fusion proteins 
were not protected from intracerebral challenge with virulent B. pertussis, native 
pertussis holotoxin was protective (Nicosia et al., 1987). The mouse intracerebral 
challenge assay (Kendrick test; Kendrick et al., 1947) is the standard method for 
measuring potency of commercial whooping cough vaccines. Burnette et al. 
(1988a) attempted to directly express the five PT subunits separately in E. coli. 
Initially this group expressed the five subunits with their native leader sequences 
attached, however only the S1 subunit leader sequence was found to be completely 
processed. The S2 and S5 subunits were partially processed, whilst S3 remained 
unprocessed and S4 was not expressed. When the native leader sequence was 
replaced with a methionine intiation codon the production of mature protein was 
achieved for all subunits. These proteins were expressed as insoluble inclusion 
bodies in E. coli at levels ranging from trace amounts to 43.8% of the total cell 
protein. Once again, mice immunised with all five recombinant subunit proteins 
were not protected from intracerebral challenge with virulent B. pertussis, probably 
because assembly of the holotoxin is required for the correct presentation of 
protective epitopes (Bartolini et al., 1988; Burnette et al., 1992b).
An alternative to expression of B. pertussis antigens in E. coli, is to express such 
antigens in Bordetella spp. under control of the native B. pertussis or a heterologous 
promoter. A further aim of recombinant expression is to produce detoxified PT in
9
avirulent strains of Bordetella spp. to prevent the copurification of other virulence 
determinants and to increase the growth rates and yield of protein for vaccine 
purposes. Mini-transposons have been utilised to stably integrate the PT operon into 
the chromosome of bvg-negative B. bronchiseptica ATCC10580. In this instance 
high level expression of PT from a B. bronchiseptica host promoter was achieved, 
however PT was not secretedlnto the culture medium (Walker et al., 1991b). In 
subsequent work, the same PT expression locus was transferred to virulent and 
avirulent strains of B. bronchiseptica, however PT expression was again found to be 
cell associated, suggesting the requirement of ptl gene products for secretion (Smith 
and Walker, 1996). In a recent study, a mini-transposon containing the PT operon 
was integrated into the chromosome of B. bronchiseptica and PT was found to be 
stably expressed and present in the periplasm. Stable expression was achieved by 
the use of a tightly regulated promoter under the control of an aromatic inducer 
(Suarez et al., 1997). Another strategy involved the construction of B. pertussis 
strains that overproduced genetically detoxified PT, this was achieved by 
introducing additional copies of the PT operon into the B. pertussis chromosome at 
the tox and fha  loci. These strains where found to excrete up to 80 mg/1 of PT and 
were stable under fermentation conditions (Zealey et al., 1992).
Attempts to reconstitute pertussis holotoxin from recombinant purified subunits in 
vitro have so far resulted in low yields. Following renaturation experiments, 
Burnette et al. (1992a) achieved a molar yield of 26% B-oligomer. Pertussis 
holotoxoid has also been assembled in vitro from native B-oligomer and recombinant 
SI purified and refolded from inclusion body preparations (Bartley et al., 1989). The 
production of recombinant detoxified PT in E. coli would allow its biological 
separation from those factors that may contribute to the reactogenicity of traditional 
vaccines. It would also use the wealth of fermentation and purification technology 
for recombinant E. coli in the high level expression and purification of genetically
avirulent strains of Bordetella spp. to prevent the copurification of other virulence 
determinants and to increase the growth rates and yield of protein for vaccine 
purposes. Mini-transposons have been utilised to stably integrate the PT operon into 
the chromosome of ¿>vg-negative B. bronchiseptica ATCC10580. In this instance 
high level expression of PT from a B. bronchiseptica host promoter was achieved, 
however PT was not excreted into the culture medium (Walker et al., 1991b). In 
subsequent work, the same PT expression locus was transferred to virulent and 
avirulent strains of B. bronchiseptica, however PT expression was again found to be 
cell associated, suggesting the requirement of ptl gene products for excretion (Smith 
and Walker, 1996). In a recent study, a mini-transposon containing the PT operon 
was integrated into the chromosome of B. bronchiseptica and PT was found to be 
stably expressed and present in the periplasm. Stable expression was achieved by 
the use of a tightly regulated promoter under the control of an aromatic inducer 
(Suarez et al., 1997). Another strategy involved the construction of B. pertussis 
strains that overproduced genetically detoxified PT, this was achieved by 
introducing additional copies of the PT operon into the B. pertussis chromosome at 
the tox and fha  loci. These strains where found to excrete up to 80 mg/1 of PT and 
were stable under fermentation conditions (Zealey et al., 1992).
Attempts to reconstitute pertussis holotoxin from recombinant purified subunits in 
vitro have so far resulted in low yields. Following renaturation experiments, 
Burnette et al. (1992a) achieved a molar yield of 26% B-oligomer. Pertussis 
holotoxoid has also been assembled in vitro from native B-oligomer and recombinant 
S 1 purified and refolded from inclusion body preparations (Bartley et al., 1989). The 
production of recombinant detoxified PT in E. coli would allow its biological 
separation from those factors that may contribute to the reactogenicity of traditional 
vaccines. It would also use the wealth of fermentation and purification technology 
for recombinant E. coli in the high level expression and purification of genetically
detoxified pertussis holotoxin for vaccine purposes. Previous work on the 
expression of PT in avirulent B. bronchiseptica demonstrated that recombinant 
pertussis holotoxin and dimérisation of S3 and S4 subunits occurs in the periplasm 
independent of frvg-activated gene products (Walker et a l , 1991b) These results 
suggest that after the five subunits of PT are secreted to the periplasm, pertussis 
holotoxin forms without the involvement of the ptl genes or other frvg-activated 
chaperone proteins.
The potent activities of PT requires that it be detoxified prior to its inclusion into 
acellular vaccines. Chemical methods such as gluteralderhyde, formaldehyde or 
hydrogen peroxide used to detoxify PT are not considered satisfactory since they 
produce a product with reduced immunogenicity, which may under certain 
circumstances revert to toxicity (Table 1) (Storsaeter et al., 1988). However, initial 
acellular vaccines contained chemically detoxified PT (Rappuoli, 1996). In a recent 
field trial it was found that antibody levels in children were not correlated with the 
quantity of PT antigen in vaccines, but more so with antigen deviation (Edwards et 
al., 1995). In this respect genetically detoxified PT was superior to chemically 
detoxified PT since its similar conformation to native PT resulted in superior 
immunogenicity. Additionally, only genetic detoxification can guarantee the absence 
of PT, which is toxic in minute quantities. Genetic detoxification is the current 
method of choice for the production of a suitable vaccine component.
Several genetically detoxified analogues of pertussis holotoxin, expressed in either 
B. pertussis, B. parapertussis, or B. bronchiseptica have been developed (Bartley et 
al., 1989; Burnette et a l ,  1988b; Kimura et a l, 1990b; Loosmore et al., 1993; 
Loosmore et a l, 1990; Nencioni et a l, 1990; Pizza et a l, 1989; Zealey et a l, 1992). 
The generation of a 12 base pair insertion in the SI subunit gene of B. pertussis 
(Kimura et a l, 1990b) has resulted in an excreted PT mutant with reduced enzymatic
and biological activity that was found to be protective in a mouse lethal aerosol 
challenge. Research by Loosmore et al. (1993), utilised site directed mutagenesis to 
create PT analogs containing mutations in the B-oligomer; these mutants were found 
to have toxin neutralisation activity and were protective in the mouse intracerebral 
challenge assay. However, the most promising toxoid for vaccine purposes 
(9K/129G) contains a double mutation in the SI subunit where Arg-9 is replaced 
with Lys and Glu-129 is replaced with Gly via site directed mutagenesis (Nencioni et 
al., 1990). This toxoid has been extensively characterised and found to possess 
similar biological properties to native PT, apart from toxicity as measured by a CHO 
clustering assay (Table 1). The toxoid 9K/129G is now a constitute of a licensed 
acellular vaccine preparation and was field trialled in Italy (Gustafsson et al., 1996). 
Other PT S1 subunit mutants have also been made with reduced enzyme activity and 
conserved protective epitopes (Burnette et al., 1988b; Loosmore et al., 1990; Pizza et 
a l ,  1989).
Table 1. Comparison of genetic versus chemical detoxification on the properties of PT.








B fragment + + -
Shape defined defined fuzzy
T-cell epitopes + + _c
B-cell epitopes + + -/+
a Chemical detoxification reduced toxicity by several logs, however reversion to toxicity may occur. 
b Chemical detoxification may reduce but not abolish the in vitro enzymatic activity. 
c Although formalin-treated toxoids are able to induce T-cell immunity when used for vaccination, 
they are less efficient in doing so then genetically detoxified molecules. This effect is more evident 
in vitro, where chemically detoxified toxoids are unable to stimulate antigen-specific T-cells 
(DiTommaso et al., 1994). Adapted from (Rappuoli et al., 1995)
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Apart from expression of PT or PT subunit genes in E. coli or Bordetella spp., only 
a limited number of studies have investigated production of this protein using 
alternative expression systems. High level expression and secretion of the S1 subunit 
of PT has been achieved in the Gram-positive, endotoxin-free bacterium Bacillus 
subtilis. In this system, the gene encoding the S1 protein was inserted into a alpha­
amylase secretion vector under control of the alpha-amylase gene promoter; yields of 
up to 100 mg/1 of SI were achieved (Runeberg-Nyman et al., 1987). In another 
study using the Gram-positive bacterium, Streptomyces lividans, expression and 
excretion of PT S 1 was attained. In this study the DNA encoding the S 1 gene was 
fused to the regulatory elements of the xylanase A gene (xlnA) with the coding 
region of the leader peptide (with and without the truncated structural gene of XlnA). 
Yields of the protein in S. lividans were estimated at 1 mg/1; this low yield was 
thought to be a result of susceptibility of the protein to secreted proteases (Paradis et 
al., 1996). In similar work, the S2 subunit of PT has been expressed and excreted in 
Bacillus brevis, the yield of recombinant protein was found to be 70mg/l (Kozuka et 
a l , 1996).
It has been proposed that other components of B. pertussis may confer 
immunoprotection, possibly by eliciting antibodies that inhibit bacterial attachment to 
the respiratory epithelium and prevent subsequent colonisation. In this respect 
research has focused on FHA, P69, serotype specific fimbriae and ACT.
1 .3 .2 .2  Filamentous Hemagglutinin
Filamentous hemagglutinin is the major adhesion of B. pertussis and is a secreted 
polypeptide product, appearing as fine filaments when released from the bacterium 
(Locht et a l , 1993). This protein plays a major role in bacterial attachment and 
colonisation of the epithelial respiratory tract (Reiman et a l, 1989). Studies using
Tn5 induced mutants deficient in the production of both FHA and fimbriae showed 
no decrease in virulence in infant mice as assessed by determining the LD50 
following intranasal challenge (Weiss and Goodwin, 1989). However, B. pertussis 
strains containing mutations in the structural gene fhaB  were unable to colonize the 
upper respiratory tract, but instead could be recovered from the alveoli and were 
shown to persist in the lungs (Kimura et al., 1990a). These results suggest that FHA 
may not be essential for colonisation of the lungs, but that it is important for initial 
adherence to the trachea. Efficient lung colonisation is most likely a multifactorial 
process. In vitro, FHA mediates numerous binding activities including attachment to 
cilia and then binding back to the bacterial surface, creating an adherence bridge 
(Tuomanen and Weiss, 1985; Tuomanen and Hendley, 1983).
The DNA sequence encoding FHA has been cloned and found to be composed of an 
operon containing three genes; fhaA, the structural gene fhaB, and fhaC. The gene 
encoding the structural protein FhaB has been sequenced; this information suggests it 
is derived from a longer polypeptide by COOH-terminal cleavage (Reiman et al., 
1989). The excretion of FHA into the extracellular milieu is dependant on the outer 
membrane accessory protein FhaC. The FHA structural and accessory genes are 
located adjacent to the bvgAS genes and are directly activated by the bvgA gene 
product (Figure 5). Thus,fha  genes together with bvg genes are the very first to be 
activated after entry of B. pertussis into the host. Once inside the host FHA can bind 
to both ciliated and non-ciliated epithelial cells, the first cells encountered in 
infection. The binding of FHA to ciliated cells indicates the presence of a lectin-like 
binding domain, whilst a heparin-binding domain has been shown to interact with 
non-ciliated cells. FHA also possesses a RGD binding site (Reiman et al., 1990) 
involved in its binding to the leukocyte integrin CR3, possibly the only known 
example of a prokaryote using a eukaryote recognition motif to bind an integrin. This 
interaction triggers invasion without generation of an oxidative burst, thus allowing 
intracellular survival.
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Tn5 induced mutants deficient in the production of both FHA and fimbriae showed 
no decrease in virulence in infant mice as assessed by determining the LD50 
following intranasal challenge (Weiss and Goodwin, 1989). However, B. pertussis 
strains containing mutations in the structural genefhaB  were unable to colonize the 
upper respiratory tract, but instead could be recovered from the alveoli and were 
shown to persist in the lungs (Kimura et al., 1990a). These results suggest that FHA 
may not be essential for colonisation of the lungs, but that it is important for initial 
adherence to the trachea. Efficient lung colonisation is most likely a multifactorial 
process. In vitro, FHA mediates numerous binding activities including attachment to 
cilia and then binding back to the bacterial surface, creating an adherence bridge 
(Tuomanen and Weiss, 1985; Tuomanen and Hendley, 1983).
The DRA sequence encoding FHA has been cloned and found to be composed of an 
operon containing three genes;fhaA, the structural gene/7zaB, and fhaC. The gene 
encoding the structural protein FhaB has been sequenced; this information suggests it 
is derived from a longer polypeptide by COOH-terminal cleavage (Reiman et al., 
1989). The excretion of FHA into the extracellular milieu is dependant on the outer 
membrane accessory protein FhaC. The FHA structural and accessory genes are 
located adjacent to the bvgAS genes and are directly activated by the bvgA gene 
product (Figure 5). Thus, fha  genes together with bvg genes are the very first to be 
activated after entry of B. pertussis into the host. Once inside the host FHA can bind 
to both ciliated and non-ciliated epithelial cells, the first cell's encountered in 
infection. The binding of FHA to ciliated cells indicates the presence of a lectin-like 
binding domain, whilst a heparin-binding domain has been shown to interact with 
non-ciliated cells. FHA also possesses a RGD binding site (Reiman et al., 1990) 
involved in its binding to the leukocyte integrin CR3, possibly the only known 
example of a prokaryote using a eukaryote recognition motif to bind an integrin. This 
interaction triggers invasion without generation of an oxidative burst, thus allowing 
intracellular survival.
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bvgS bvgA fhaB fimB fimC fimD fhaC
Figure 5. Schematic representation o f the structure of the bvg/fha/fim locus. The respective open 
reading frames are indicated by open boxes, filled boxes indicate signal peptide regions. The direction 
o f transcription is indicated by arrows, the dashed line represents the possible read-through that can 
occur from the fhaB gene. Not drawn to scale. Adapted from (Locht et a l,  1993).
The FHA gene has previously been cloned and expressed in E. coli (Brown and 
Parker, 1987; Delisse-Gathoye et al., 1990). Guzman et al. (1991a) have also 
successfully expressed FHA in E. coli K-12 and Salmonella typhimurium aroA at 
levels higher than those found in wild-type B. pertussis. This was accomplished by 
replacement of the native upstream signals of the gene and the modification of the 
translation initiation region to optimize translational efficiency. Additionally, 
inclusion of a section of the COOH-terminal FHA open reading frame was shown to 
be important in achieving expression of the recombinant protein. High level 
expression of FHA in E. coli may lead to the elimination of the problems 
encountered in its production from B. pertussis. These problems include the co­
purification of toxins present in B. pertussis and the safety aspects involved in 
growing a human pathogenic bacterium. Expression in S. typhimurium aroA may 
also permit the development of live vaccine carrier strains expressing pertussis 
antigens and the opportunity to develop oral whooping cough vaccines that offer 
both mucosal and systemic immunity (Charles and Dougan, 1990; Hoiseth and 
Stocker, 1981). Research has indicated that active immunisation with FHA or 
passive immunisation with antibodies to this protein significantly reduced B . 
pertussis colonisation in mice (Kimura et al., 1990a). Other studies by Roberts et al. 
(1993) and Calhill et al (1993) have shown that intranasal administration of FHA into 
mice induces protection following aerosol challenge, in addition to generating a local 
secretory antibody response in the lungs. The protection afforded by this
protein makes it a likely component for recombinant pertussis vaccines, indeed, the 
majority of acellular pertussis vaccines contain FHA. The addition of FHA to vaccine 
preparations containing only PT appears to marginally increase the protective efficacy 
of such vaccines in children (Adhoc Group, 1988).
1 . 3 . 2 . 3  P69 (Pertactin)
In addition to PT and FHA, new generation vaccines may also include P69. This 
protein is a virulence factor of B. pertussis localised in the outer membrane of the 
bacterium and is believed to play a role in attaching the bacterium to epithelial cells 
lining the respiratory tract mucosa (Leininger et al., 1992; Roberts et al., 1992). The 
gene encoding P69 (prn) has been sequenced and found to be derived from a 93kDa 
precursor by cleavage of the NH2-terminal signal peptide and removal of a COOH- 
terminal fragment (Charles et al., 1988). This protein has recently been over­
expressed in B. pertussis using chromosomally integrated genes controlled by hybrid 
PT or FHA promoters. The resulting protein was expressed at significantly higher 
levels then the wild-type protein and was found to be excreted (Loosmore et al., 
1995). High level production of P69 has also been achieved from the yeast Pichia 
pastoris using a yeast expression vector; the protein yield in this study was 3mg/l 
(Romanos eta l., 1991).
Purified P69 has been shown to contribute to the protection of mice against an 
intracerebral challenge with B. pertussis (Novotny et al., 1985; Shahin et al., 1990). 
In an intranasal challenge assay in mice it was demonstrated that P69 used alone as 
an immunogen afforded significant protection against lung colonisation and against a 
lethal challenge with a hypervirulent strain of B. pertussis (Capiau et al., 1990). In a 
study that assessed both humoral and cellular immunity against B. pertussis 
antigens, it was found that intranasal immunisation of mice with P69 greatly
increased their ability to clear B. pertussis infection in the lungs following aerosol 
challenge (Roberts et a l., 1993). In this study, protection was found to correlate 
better with T-cell proliferation of isolated spleen cells than with antibody responses, 
indicating the role of cell mediated immunity in the elimination of bacteria from the 
respiratory tract. A recent field trial in infants has demonstrated that the inclusion of 
P69 increased the protection afforded by a bivalent (PT, FHA) vaccine (Greco et al., 
1996).
1 .3 .2 . 4  Serotype Specific Fimbriae
Serotype specific fimbriae are filamentous surface antigens that stimulate antibody 
production causing bacterial cell agglutination and thus the serotype specificity of 
bacteria producing immunologically different fimbriae. At least three types of 
fimbriae are produced by B. pertussis, serotype 2 and serotype 3 fimbriae being the 
most prevalent. Using these specialised surface structures the bacteria can adhere to 
the upper respiratory tract epithelium (Urisu et al., 1986) and thus escape clearance. 
The fim  accessory genes are co-transcribed with the fhaC  accessory gene of FHA in 
a polycistronic operon (Figure 5), suggesting that fimbriae may act in conjugation 
with FHA during the initial steps of B. pertussis infection.
The serotype 2 fimbrial subunit protein has previously been expressed in E. coli 
CAG629 (a Ion protease and heat shock protease deficient strain), and its filamentous 
products have been shown to be auto-assembled in vitro (Walker et al., 1990). In 
this study, protein expression was achieved by replacement of the upstream signals 
of the fimbrial subunit gene with the lambda P r  and P l  promoters and the E. coli 
atpE translational initiation region. The detection of cell surface associated fimbrial 
structures, however, was not apparent. The use of an expression/secretion vector 
pCGVl in combination with E. coli strains containing a leaky outer membrane has
subsequently been shown to result in the excretion of fimbrial subunits into the 
extracellular medium (Guzman et al., 1995). Recombinant serotype 2 fimbriae have 
also been produced in virulent B. parapertussis and B. bronchiseptica under control 
of the lac promoter. Expression of serotype fimbriae in Bvg-negative (avirulent) B. 
bronchiseptica  was not apparent, suggesting that fimbrial accessory genes are 
important for expression of these antigens (Walker et al., 1990).
In a field trial conducted by Miller et al. (1991) an acellular vaccine containing 
fimbriae in addition to PT and FHA was trialled in infants. They found that the 
persistence of antibodies after vaccination was higher in the acellular vaccine which 
produced significantly less symptoms compared to the conventional whole cell 
vaccine. It was suggested that the inclusion of fimbrial antigens in an acellular 
vaccine may enhance protection against infection as well as disease, which was not 
found for acellular vaccines containing only PT and FHA. In contrast to this field 
trial, recent field trials have shown no increase in vaccine efficacy when fimbriae 
were included in the vaccine preparation, suggesting that they are not required for a 
protective immune response (Edwards and Decker, 1996). Clearly, additional 
research into the protective efficacy of these proteins need to be undertaken to 
determine their vaccine potential.
1 .3 .2 .5  Adenylate Cyclase Toxin
Adenylate cyclase toxin (ACT) is composed of a single polypeptide possessing both 
catalytic and toxin activities. This toxin is mainly cell associated, but is capable of 
being released into the extracellular environment. ACT acts by penetrating 
mammalian cells and interacting with calmodulin, a eukaryotic calcium-binding 
protein, generating uncontrollable levels of cyclic AMP (Confer and Eaton, 1982; 
Hanski and Farfel, 1985). Thus ACT has the same biological effect as PT but 
achieves it by a different mechanism.
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The gene encoding ACT has been sequenced and found to contain a single 
bifunctional protein (Cya A protein or cyclolysin) which endows both adenylate 
cyclase and hemolytic activities. The toxin has been expressed in E. coll, and has 
also been shown to possess protective activities in a murine respiratory model 
(Betsou et al., 1993; Sebo et al., 1991). Additionally, it has been shown that both 
active and passive immunisation with ACT significantly shortens the period of 
bacterial colonisation in the murine respiratory tract (Guiso et al., 1989; Guiso et al.,
1991). Furthermore, anti-ACT antibodies have been detected in the sera of B. 
pertussis infected humans (Arciniega et al., 1991; Guiso et al., 1993).
1 .3 .3  Field Trials of Whole Cell and Acellular Vaccines
Although acellular vaccines have been licensed for more than 15 years in Japan, 
research concerning the protective efficacy of individual components of the vaccine 
have only been conducted in detail recently. When the Japanese acellular vaccine was 
first introduced the only efficacy requirement for its potency was the mouse 
intracerebral challenge assay. Acellular vaccines have been highly successful in 
Japan, producing good antibody responses and decreased reactogenicity compared to 
whole cell vaccines (Aoyama, 1996). With the advent of improved techniques for 
antigenic characterisation, researchers have worked to produce acellular vaccines 
whose components are more genetically defined in order to reduce lot to lot variation 
and offer increased protection compared to these original acellular vaccines and 
whole cell vaccines.
As humans are the only reservoir for whooping cough, human field trials represent 
the only possible way and final step involved in realistically testing the efficacy of 
new pertussis vaccines. Field trials are generally undertaken in three phases; phase I 
and phase II trials involve immunogenicity, generation of limited safety data, study
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of doses and vaccination schemes. The phase III trials evaluate efficacy in field trials, 
household contact studies or challenge study settings where vaccinated infants are 
monitored following exposure to disease. In the mid 1980's the first phase III trial of 
major significance with respect to acellular vaccines was undertaken in Sweden at a 
time when the banning of the whole cell vaccine had resulted in a pertussis epidemic 
in that country (Adhoc Group, 1988). The vaccines tested were comprised of 
purified components from wild-type B. pertussis. The first vaccine trialled consisted 
of chemically detoxified PT and FHA, whilst the other was comprised of chemically 
detoxified PT alone. The results of this field trial found that whilst producing good 
antibody responses, neither vaccine gave adequate levels of protection in infants. 
Thus the antibody response did not correlate with the levels of protection observed. 
Both vaccines were protective against severe disease, but the mono-component 
vaccine showed no protection against infection, whilst the two component vaccine 
showed incomplete protection against infection (Storsaeter et al., 1990). These 
acellular vaccines probably gave rise to less adverse side reactions than whole cell 
pertussis vaccines, however no whole cell control was used in this trial (Table 2).
Genetically or chemically detoxified PT is the central component of new generation 
whooping cough vaccines currently being developed or licensed for general use. For 
instance, a phase III human field trial testing a vaccine containing chemically 
detoxified PT (in combination with diphtheria and tetanus toxoids) found that the 
efficacy of this single antigen was 71% (Trollfors et al., 1995). Various phase III 
field trials have also been undertaken using vaccines containing purified components 
which include combinations of genetically or chemically detoxified PT, FHA, 
fimbriae and P69 (Table 2) (Greco et al., 1996; Gustafsson et al., 1996; Schmitt et 
al., 1996). In these field trials the efficacy of all the acellular vaccines was superior 
to that of the whole cell vaccines. Additionally, rates of adverse reactions were 
substantially lower in the acellular vaccinees compared to those vaccinated with the 
whole cell preparation, however, side effects were not eliminated.
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Pa (PT*, FHA, P69) Germany 22505* 88.7* (Schmitt et a l ,  1996)
Pw 97.6*
Pa (PT*, FHA) Sweden 9829 58.9 (Gustafsson et a l ,  1996)
Pa (PT*, FHA, P69, FIM 2,3) 85.2
Pw 48.3
Pa (PT*, FHA, P69) Italy 15601 84 (Greco, étal.,  1996)
Pa (PT§, FHA, P69) 84
Pw 36
Pa (PT*) Sweden 3801 54 (Adhoc Group, 1988)**
Pa (PT*, FHA) 69
Pa = acellular pertussis vaccine.
Pw = whole cell pertussis vaccine.
^Vaccinated with Pa.
^Determined attack rates in house hold contacts o f index pertussis cases (diagnosed as spasmodic 
cough for at least 21 days with cultural or serological confirmation).
^Chemically detoxified.
^Genetically detoxified.
**No whole cell control was used.
All vaccines were given as component of DTP.
Adapted from (Boughton, 1996).
In the Italian trial, which compared the efficacy of three component vaccines 
containing genetically or chemically detoxified PT, it was found that only the 
genetically detoxified PT vaccine was able to confer protective immunity starting 
after the first vaccine dose, allowing protection of the most vulnerable (Rappuoli et
a l ,  1995),
In a study undertaken to determine the impact of the introduction of acellular 
pertussis vaccines as fourth and fifth booster doses in the USA and Canada, 27 
million whole cell pertussis DT and 5 million acellular pertussis DT doses were 
investigated for adverse reactions in children aged 15 months to seven years of age. 
The results of this study are summarised in Table 3.
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In the Italian trial, which compared the efficacy of three component vaccines 
containing genetically or chemically detoxified PT, it was found that only the 
genetically detoxified PT vaccine was able to confer protective immunity starting 
after the first vaccine dose, allowing protection of the most vulnerable (Rappuoli et 
al., 1995). Differences observed in whole cell vaccines probably due to strain 
variations, production processes or inclusion of adjuvants make comparisons 
between these vaccines difficult.
In a study undertaken to determine the impact of the introduction of acellular 
pertussis vaccines as fourth and fifth booster doses in the USA and Canada, 27 
million whole cell pertussis DT and 5 million acellular pertussis DT doses were 
investigated for adverse reactions in children aged 15 months to seven years of age. 
The results of this study are summarised in Table 3.
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Table 3. Rates of adverse events within 72 hours after whole cell or acellular pertussis 
vaccination.








All vaccines were given as a component of DTP vaccines. Rates are per 100,000 doses 
Adapted from (Rosenthal et al., 1996).
As indicated by the rates of adverse reactions shown in Table 3, the current acellular 
vaccines used in the USA and Canada are approximately three times less reactogenic 
compared to whole cell vaccines. However the future goal of researchers is to 
develop vaccines that completely eliminate adverse reactions.
Cell Mediated Immune Responses in Infants
W hooping cough has previously been considered to be a non-invasive mucosal 
infection, resulting in a toxin-mediated disease (Pittman, 1979). Thus, the majority 
of research concerning the immune response to pertussis infections has focused on 
humoral immunity. However, recent findings suggest that B. pertussis can invade 
eukaryote cells (Ewanowich et al., 1989) and the detection of antigen-specific CMI 
responses (DeMagistris et al., 1988; Mills et al., 1993; Petersen et al., 1992) has 
prompted a re-evalutation of potential protective mechanisms. In a recent study in 
was found that an acellular pertussis vaccine consisting of chemically detoxified PT 
together with FHA and P69, was able to induce an antigen-specific CMI response in 
infants following vaccination (Zepp et a l ,  1996). The CMI response was found to 
increase over the entire vaccination schedule; this response was strong and stable 
over the post-primary to pre-booster period, in contrast to declining antibody titres. 
Cytokine profiles showed a preferential induction of 11-2 and gamma interferon
producing Th-1 cells and only a low 11-10 response. The induction of a CMI 
response in the absence or with only a low antibody response may explain the 
results of a number of recent field trials that have demonstrated the apparent lack of 
correlation between serological antibody titres and protection (Adhoc Group, 1988; 
Greco et al., 1996; Gustafsson et al., 1996; Schmitt et al., 1996). CMI responses 
clearly require further investigation in order to improve the understanding of the 
persistence of protection following immunisation or natural infection with B. 
pertussis.
1 .4  Vaccine Delivery Systems
The isolation and expression of potential recombinant vaccine components against 
pertussis necessitates investigation of vaccine delivery systems. Attenuated 
Salmonella spp. have been utilised to express a variety of heterologous antigens, 
then used as experimental vaccines. Antigens of B. pertussis including FHA 
(Guzman et al., 1991a; Guzman et al., 1991b; Molina and Parker, 1990; Parker et 
al., 1990), the SI subunit of pertussis toxin (Barry et al., 1996; Walker et al., 1992) 
and P69 (Strugnell et al., 1992) have all been expressed and delivered to mice using 
this system. Although attenuated Salmonella spp. probably represents the most 
thoroughly characterised bacterial delivery system, other systems are presently under 
investigation as potential carriers of foreign antigens to the immune system.
1 .4 .1  Bacille-Calmette-Guerin (BCG)
The widespread use of the attenuated BCG vaccine against M ycobacterium  
tuberculosis has demonstrated its potential as a promising carrier of foreign antigens. 
This vaccine has shown remarkably few side effects when delivered to the very 
young (Lotte et al., 1984). Additionally, it has been shown to be an excellent 
adjuvant; killed BCG in combination with Freund's adjuvant has been shown to
stimulate cellular immunity against M. leprae. When given this vaccine, many 
leprosy suffers have in fact recovered (Dougan et al., 1989). BCG has also been 
used to express antigens from Borrelia burgdorferi, the causative agent of Lyme 
disease. Intranasal administration of this attenuated recombinant vaccine into mice 
has been shown to result in long lasting protection against subsequent challenge with 
the organism (Service, 1994).
1 . 4.2 Vibrio cholerae
Vibrio cholerae, the bacterium responsible for cholera, has also been used as a carrier 
of foreign antigens to the immune system. This bacterium triggers both serum and 
mucosal antibodies. As with Salm onella , this bacterium naturally colonises the 
gastrointestinal tract, thus is readily processed by memory cells located on Peyer's 
patches along the small intestine. A mutation in a gene locus encoding a major iron- 
repressed outer membrane protein (irgA) has been found to reduce the virulence of 
this bacterium. Insertion of foreign genes downstream of the irgA promoter could 
therefore generate antigen expression which may result in an immune response 
(Butterton et al., 1993). A potential problem with the expression of foreign antigens 
in V. cholerae is the induction of 'vector immunity' by the generation of antibodies 
against the bacterium in the host. This is a problem because there are only two strains 
or serotypes of V. cholerae. Therefore this bacterium will only have limited use as a 
delivery system, as a vaccine for one disease could effectively render this carrier 
useless as a carrier of other antigens. This is less of a problem with Salmonella  
strains which contain more than two thousand serotypes, giving plenty of scope for 
the selection of different delivery vehicles.
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1 .4 .3  Transgenic Plants
Recently, research has been undertaken towards developing oral vaccines based on 
plant expression systems with the aim of administering dietary vaccines (Moffat, 
1995). Transgenic potato tubers containing genes encoding E. coli heat-labile 
enterotoxin (LT-B) have been shown to generate serum and gut mucosal anti LT-B 
immune responses when administered by gavage or fed to mice. Additionally, these 
immunoglobulins were capable of neutralising the entertoxin in cell protection assays 
(Haq et al., 1995). Other groups have expressed the hepatitis B surface antigen in 
plants (Mason et al., 1992) and generated and assembled functional hybrid 
antibodies (Ma et al., 1995). These studies indicate the feasibility of expressing 
foreign antigens in plants for use as oral vaccines of the future.
1.5  Attenuated Salmonella as a Vaccine Delivery System
Salmonella spp. can be attenuated by the introduction of nonreverting defined 
mutations into the bacterial genome to produce live vaccine strains. Several genes 
have been identified that when mutated will attenuate this bacterium. Salmonella 
strains harbouring mutations in the aromatic amino acid synthesis pathway make 
excellent vaccines. Unlike parenteral vaccines which are delivered by intramuscular 
injection and stimulate a systemic response, live oral vaccines envoke strong 
humoral, local and cellular immune responses in the host. Because of the array of 
immune responses induced by live oral vaccine strains, they have the potential to be 
used for the delivery of heterologous antigens to the mammalian immune system. 
Several antigens from foreign bacteria, parasites and viruses have been successfully 
expressed in Salmonella vaccine strains (reviewed in Cardenas and Clements, 1992). 
Such hybrid strains have the potential to be used as multivalent vaccines against a 
number of infectious diseases.
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1 .5 .1  Immune Response to Salmonella Species
As facultative intracellular pathogens, Salmonella spp. can invade a variety of 
mammalian epithelial cells. Humoral immunity to this bacterium is mediated by 
antibodies which act to opsonise bacteria, resulting in enhanced phagocytosis by 
macrophages and neutrophils. Cellular immunity involves the generation of cytotoxic 
T-lymphocytes directed against the bacterium. The degree to which these two 
immune responses control infection has remained controversial, since the immune 
response is dependent on external variables such as route of immunisation, age of 
vaccinee and vaccination schedule (O’Hagan, 1994). However, it is now thought 
that antibodies alone cannot protect against Salmonella infections for long time 
periods after oral vaccination. Cellular immunity may play a significant role in 
generating a protective immune response (reviewed in Dougan et al., 1989).
1 .5 .2  The Advantages of Live Oral Vaccines
The majority of bacterial vaccines currently available are composed of killed micro­
organisms. These vaccines can be administered parenterally, and as such generate 
serum immune responses. Parenteral vaccines do not elicit a mucosal secretory 
immunoglobulin A (IgA) response and in general are ineffective against organisms 
that colonise mucosal surfaces and do not invade. Although such vaccines can be 
highly efficacious they may induce undesirable side effects or show unsatisfactory 
protection levels; for this reason in particular, much research has been directed 
towards the use of live, attenuated vaccines.
Live attenuated Salmonella vaccines are believed to be superior to killed vaccines 
because they provide sustained persistent antigenic stimulation in vivo . Live 
attenuated pathogens can establish a limited infection in the host, leading to an 
immune response which closely mimics that detected following infection with a
virulent pathogen. Infection by most bacterial pathogens occurs either at or via 
mucosal surfaces. In vaccinating against disease, generation of an immune response 
at these surfaces is therefore of upmost importance. Orally administered live 
attenuated vaccines strains such as Salmonella aroA are natural colonisers of the 
gastrointestinal tract and therefore readily bind M-cells of the immune system and are 
effective in inducing Th-2 cells that mediate specific IgA responses (Hoiseth and 
Stocker, 1981). This probably occurs because antigen is delivered to the B and T- 
lymphocytes of the gut associated lymphoid tissue. The primed B cells then migrate 
to the mesenteric lymph nodes and undergo differentiation. After entering the 
thoracic duct the B-lymphocytes enter general circulation and reach all secretory 
tissues of the body including the respiratory tract. The production of IgA by mature 
plasma cells allows this immunoglobulin to be transported onto the mucosal surface 
where it is available for interaction with invading pathogens (Cebra et aL, 1986). An 
illustration of the traffic of lymphocytes and the generation of mucosal immunity 
through oral immunisation is shown in Figure 6. This form of immunity is 
particularly important in protecting against enteric pathogens which include 
Salmonella spp. Such immunity cannot be satisfactorily generated by parenteral 
vaccines.
_ . . Thoracic Duct Salivary Glands
Sm all Intestine _______ M esentenc _________________________ Respiratory Tract
(Peyer’s Patches) Lymph Nodes Breasts
Genitourinary Tract
Figure 6. Generalised pathway for the stimulation of specific mucosal immune responses. Adapted 
from (Cardenas and Clements, 1992).
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1 .6  Salmonella Vaccines
The multifactorial characteristics of the Salmonella virulence factors and the lack of 
acceptable adjuvants has encouraged a great deal of research towards developing 
effective live attenuated Salmonella vaccines for oral administration. Such a vaccine 
must be immunogenic, non-reactogenic, persist in host tissue for a limited time 
period and should not carry genes for antibiotic resistance.
1 .6 .1  Typhoid Vaccine: Ty21a (gal E)
Initial studies on Salmonella spp. virulence relied on techniques that produced less 
well defined mutations than those available today. In 1975 a live typhoid vaccine, 
Ty21a was produced by chemical mutagenesis with nitrosoguanidine, so as to 
contain a mutation in the galE gene (Germanier and Furer, 1975). This strain was 
unable to incorporate galactose in sufficient quantities in the cell wall to allow the 
synthesis of smooth type lipopolysaccharides. Cells of strain Ty21a given 
intraperitoneally were found to protect mice against lethal challenge with S. typhi 
(Germanier and Furer, 1975). In human volunteers the vaccine showed a 87% 
efficacy rate, undoubtedly providing protection against typhoid.
These encouraging results led to large scale field trials conducted in Egypt, and then 
in Chile in the mid 1980's. In the Egyptian field trial child vaccinees received three 
doses of a liquid vaccine and results showed an efficacy of 96%. The South 
American trial was established in an area with a greater endemic rate of typhoid, and 
a different vaccine formulation was used. Results showed'that the Ty21a vaccine 
delivered in an enteric-coated-capsule gave an efficacy of 67% over a three year 
period when administered to healthy young adult Chileans (Wahdan et ah , 1982; 
Wahdan et al., 1980). The Ty21a typhoid vaccine is now licensed in a number of 
countries including the United States and Australia.
Although Ty21a has proved successful as an effective typhoid vaccine, it does 
exhibit a number of disadvantages. This vaccine requires multiple doses to achieve 
acceptable immunogenicity (Tacket et al., 1992a) and is age dependent (Murphy et 
a l., 1991). Additionally, the level of efficacy achieved is highly effected by the 
vaccine formulation used and the immunisation schedule (Levine et al., 1989). Also, 
the chemical mutagenesis method used to produce the vaccine inadvertently resulted 
in m ultiple genetic lesions beyond those targetted (Levine et a l., 1987). The 
problems surrounding Ty21a have spurred the development of new oral typhoid 
vaccines. A number of individual genes in which mutations give rise to attenuated 
Salmonella strains have now been identified.
1 .6 .2  Acya Acrp R egu la to ry  M utan ts
Apart from aro vaccine strains, the most thoroughly characterised Salmonella  
mutants are the cya crp strains. These mutants lack adenylate cyclase and the cAMP 
receptor protein respectively. Consequently such mutants exhibit slower growth than 
wild type strains because these products are required for expression of numerous 
genes and operons for carbohydrate transport and catabolism, glycogen synthesis 
and amino acid and peptide transport and catabolism (Curtiss et al., 1993). Human 
field trials in healthy adult volunteers showed that these S. typhi mutants were highly 
immunogenic when given as a single oral dose. However, fever and bacteremia 
occurred in 2 out of 12 volunteers (Tacket et al., 1992a).
1 .6 .3  phoP  and  om pR  R egulatory  M utan ts
S. typhimurium phoP  mutants are unable to survive within macrophages in vitro and 
are avirulent in mice. The avirulence of this strain results from insertion of a 
transposon into phoP , a regulatory gene responsive to phosphate levels and to 
intracellular conditions within macrophages, such as low pH. Although these strains
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exhibit a poor ability to colonise the intestinal tract, they are highly immunogenic 
(Galan and Curtiss, 1989). Transposon mutagenesis has also lead to the isolation of 
strains deficient in one or more outer membrane proteins. The ompR gene is thought 
to encode a positive regulator for the expression of other outer membrane proteins, 
including a tripeptide permease and other as yet uncharacterised proteins involved in 
nutrient transport and the exclusion of harmful substances from the bacterial cell. 
These ompR  mutants were avirulent in mice following oral or intravenous 
immunisation and were found to persist for several weeks in murine tissues (Dorman 
et aL, 1989).
1 .6 .4  htrA Regulatory Mutants
The htrA gene is important for the survival of Salmonella in vivo. The product of this 
gene is a stress induced serine protease, DegP. This gene product is necessary for 
growth at elevated temperatures where it functions to remove incorrectly folded 
proteins in the periplasm. Unlike aro mutants, these strains do not exhibit replication 
in vivo and persist at lower levels in tissues than aro mutants. However either 
combined with aro A or on their own these mutants make good single dose vaccines 
(Chatfield et al., 1992).
1 .6 .5  Salmonella aro Auxotrophic Mutants
The aroA gene encodes an enzyme involved in the bacterial perchorismate pathway 
which leads to chorismate synthesis, that in turn, leads to the generation of aromatic 
amino acids including para-aminobenzoic acid and 2,4-dihydroxybenzoate, as 
indicated in Figure 7. Bacteria which lack this gene product either do not replicate or 
only do so to a limited extent as these two amino acids are essential but not available 
in mammalian tissues. Salmonella aroA are still invasive, but the absence of these 
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Figure 7. The common aromatic biosynthetic pathway, to chorismic acid, and the products derived 
from it which cannot be synthesized by aroA mutants. Adapted from (Cardenas and Clements, 
1992).
S. typhimurium aroA strains were first developed in 1981 by the insertion of the 
tetracycline resistant transposon TnlO  into the aroA gene (Hoiseth and Stocker, 
1981). These derivatives were shown to be avirulent and non-reverting. 
Immunoprotection of mice against a virulent strain of S. typhi was also conferred by 
this vaccine strain. In order to provide further evidence for their effectiveness as oral 
vaccines, a number a studies have been undertaken using different strains of 
Salmonella with mutations in the aroA gene. In a study conducted using mice 
innately hyper-susceptible to S. typhimurium, it was found that S. typhimurium  
aroA SL3235 induced high levels of long lasting immunity against challenge with 
virulent S. typhimurium  (Killar and Eisenstein, 1985). Another study has utilised 
transposons in order to generate stable auxotrophic mutations in aroA of S. 
typhimurium strains which were virulent in mice. This aroA mutant was tested for its 
ability to induce protective immunity in BALB/c mice and was found to be an 
effective oral and intravenous vaccine, persisting for several weeks in the liver and 
spleen (O’Callaghan etal., 1988).
S. typhimurium aroA strains administered as live oral vaccines have, in general, been 
found to be safe in immunogenically competent and immunologically compromised 
chicken, sheep and calves. These vaccines showed protection against lethal challenge 
with virulent S. typhimurium  generating both antibody and CMI (Mukkur
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et al., 1987; Smith et al., 1984; Stocker et al., 1983). S. typhimurium  strains 
harbouring defined mutations in several aro genes including aroA, aroC  and aroD 
either alone or in combination have been found to be attenuated to a similar level and 
have the same immunogenic properties. Such vaccines with more than one genetic 
lesion would be attractive for human use since the possibility of reversion of a 
double mutant would be remote (Chatfield et a l, 1993). Human field trials in healthy 
adult volunteers, using a S. typhi double aro mutant (aroC, aroD) CVD908, have 
shown that this strain was significantly more immunogenic after a single dose than 
the current Ty21a after multiple doses, however bacteremias were observed in half of 
the adult volunteers (Tacket et al., 1992a and 1992b). In another aroC, aroD strain, 
CVD906, it was found that although this strain was highly immunogenic, fever was 
observed in a significant proportion of volunteers (Hone et al., 1992). Recently 
research has focused on new attenuating mutations in CVD906 and CVD608 vaccine 
strains. These strains have been further engineered by deletion in htrA, the resulting 
strains were assessed for immunogenicity in human adult volunteers. These strains 
were found to be well tolerated and antibody responses against S. typhi 
lipopolysaccaride and H antigens were observed in at least 75% of volunteers 
(Tacket et al., 1997). If these S. typhi strains are found to be safe and confer 
protection, they may be considered as replacements for S. typhi Ty21a, as carriers of 
heterogenous antigens and for protection against typhoid.
1 .6 .6  A ttenua ted  Salm onella spp. as a C arrie r of Foreign Antigens
With the use of live oral Salmonella vaccines, a new strategy has emerged to deliver 
foreign antigens to the immune system via the oral route. This is achieved by 
introducing and expressing DNA from other pathogens into the live Salmonella 
vaccine. Oral administration of these multivalent vaccines enable immunisation 
against salmonellosis, as well as the potential induction of both mucosal and 
systemic immune responses against the foreign antigen.
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One of the first antigens to be delivered by Salmonella aro mutants was the B 
subunit of the heat labile enterotoxin (LT-B) of E. coli (Clements et al., 1986; 
Maskell et al., 1987). Using this antigen, it was possible to detect both systemic and 
secretory antibody responses to the secreted LT-B protein. This initial work 
encountered problems with plasmid instability when the tac promoter was used. 
Although the use of the lac repressor stabilised the plasmid, expression was reduced 
to an extent such that no immune response against the antigen was detected 
(Fairweather et al., 1990).
Research using S. typhimurium aroA SL3261 showed that it was possible to 
generate an antibody response against an intracellular protein (Brown et al., 1987). 
In this work, 8-galactosidase was used as the antigen and was found to produce a 
circulating antibody response when administered intravenously to mice. 
Additionally, a delayed type hypersensitivity response was detected when purified 8- 
galactosidase protein was injected into the footpads of previously immunised mice.
Attenuated S. typhimurium  WR4017 has been used to develop vaccines against 
Plasmodium spp. which cause malaria in a variety of animals. Oral immunisation of 
mice with S. typhimurium transformed with the circumsporozoite gene was found to 
induce protective cell-mediated immunity to sporozoites following challenge (Sadoff 
et al., 1988).
Recently it has been shown that it is possible to obtain simultaneous protection from 
more than one disease using Salmonella typhimurium aro A SL3261 mutants (Khan 
et al., 1994). In this study a modified vector (pTECH 1) contained the fragment C 
from tetanus toxoid, a potent immunogen, fused to the 28kDa glutathione S- 
transferase (P28) from Schistosoma mansoni. Mice orally immunised with a single 
dose of the salmonella-tetanus-P28 construct produced antibodies against both 
fragment C and P28 and were protected against challenge with virulent Salmonella
typhimurium  and tetanus toxin. Preliminary data suggests that this vaccine also 
confers protection from challenge with schistosomula (Chatfield et al., 1995). This 
research is the first to demonstrate that it is possible to confer protection against three 
diseases using a single dose of a tri-valent oral vaccine.
Numerous heterologous antigens and antigenic epitopes from other parasites, 
bacteria and viruses have been expressed in Salmonella spp ., some of which are 
included in Table 4.
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Table 4. Heterologous antigens expressed in attenuated Salmonella.





S. typhimurium aroA aroD
(Fairweather, et al., 1990) 
(Strugnell et al., 1990)
0  antigen Vibro cholerae S. typhi Ty21a (Tacket et al., 1990)
O antigen Shigella flexneri S. typhi Ty21a (Baron et al., 1987)
28kDa OMP Nesseria
meningitidis
S. typhimurium aroA (Tarkka et al., 1989)
M protein Streptococcus
pyogenes
S. typhimurium aroA (Poirier et al., 1988)
V ira l
Nucleoprotein Influenza A S. typhimurium aroA (Bao and Clements, 1991)
gpD Herpes Simplex S. typhimurium aroA (Bowen et al., 1990)




S. typhimurium WR4024 (Aggarwal et al., 1990)
gp63 Leishmania major S. typhimurium aroA (Yang et al., 1990)
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Table 4. Heterologous antigens expressed in attenuated Salmonella. (Continued)
Antigen Organism Host Reference
E p ito p e s
LTB-HBsAg Hepatitis B S. dublin aroA 
S. typhimurium cya crp asd
(Schödel et al., 1990)
Flagellin-M Streptococcus
pyogenes
S. dublin aroA (Newton et al., 1991)
Adapted from (O’Hagan, 1994).
1 .6 .7  Stability of Foreign Genes in Salm onella  spp.
A major problem with the use of attenuated Salmonella spp. as a carrier of 
heterologous proteins is to obtain stable expression of the foreign gene at levels 
sufficient to provoke an appropriate immune response whilst ensuring expression is 
controlled in such a way so that it is not deleterious to the host. Plasmids represent 
the primary method used to express foreign genes in Salmonella. However, the use 
of plasmids in antigen delivery systems has several drawbacks. Plasmid instability 
represents a major disadvantage when using these forms of expression systems, 
which can lead to complete loss of the plasmid (O’Callaghan et al., 1988). The use 
of high copy number plasmids or a strong promoter can result in the over-expression 
of foreign proteins, a process that may be lethal to the bacterial cell (Shatzman et al., 
1983). Yet another disadvantage is the use of antibiotic selection. Although this 
enables the maintenance of adequate levels of an unstable plasmid in vitro, the use of 
antibiotic selection for human vaccines is undesirable.
A number of alternative strategies have been developed to overcome these problems 
of plasmid instability and host viability. Integration of the recombinant antigen gene 
into the bacterial chromosome represents a method used to obtain stable expression 
of foreign DNA. A system that uses a defective transposable element which stably
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inserts into the bacterial chromosome to express any gene of interest has been 
developed (Flynn et al., 1990). This delivery system, used in S. typhimurium aroA 
has been shown to generate a cytotoxic T-lymphocyte response against foreign 
antigens in mice. The drawback with this system is that only one copy of the gene is 
expressed. A system using non-antibiotic resistant mini-transposons that allows the 
cloning and stable insertion of foreign genes into the chromosome of Gram-negative 
bacteria (Herrero et al., 1990) may also be useful for expression of foreign antigens 
in Salmonella spp. An alternative approach is to utilise plasmids carrying a gene 
essential for survival of the Salmonella in its host. In one system the asd gene, which 
codes for aspartate B-semialdehyde dehydrogenase which is important in amino acid 
biosynthesis and synthesis of bacterial peptidoglycan components, has been used. 
This plasmid system was found to be very stable in Salmonella (Nakayama et al., 
1988).
1 .6 .8  Promoters for in vivo Expression
Unregulated high level expression of foreign proteins in Salmonella may be lethal to 
the bacterium. This problem may be overcome using in vivo activated promoters that 
allow the expression of the foreign gene only at a certain phase of its lifecycle or only 
when the bacteria occupy a particular cellular compartment (Dougan, 1994). The 
genetic regulation of certain genes in response to environmental signals such as 
osmolarity, oxygen tension, the concentration of certain nutrients or intracellular 
location, all represent potential avenues for the regulation of expression of foreign 
gene products in Salmonella.
Plasmid stability has also been shown to be influenced to a large extent by the type of 
promoter used to express the foreign gene. Thus it would be desirable to use a 
promoter that is efficiently regulated so as to be only active when bacteria enter the 
host or when they interact with cells of the immune system. The nirB gene, which
encodes the E. coli NADH-dependent nitrite reductase is tightly regulated by its 
prom oter in response to nitrite and by changes in the oxygen tension of the 
environment, becoming active under anaerobic conditions (Peakman et al., 1990). 
Using this promoter, and altering the oxygen tension in fermentor systems, the high 
level expression of P69 from B. pertussis has been attained (Oxer et al., 1991). This 
promoter has also been introduced into S. typhimurium aroA aroD vaccine strain 
BRD509. In this study, the strain containing the nirB promoter regulating the 
expression of the immunogenic fragment C of tetanus toxin was found to be stable 
and persisted in the tissues of immunised mice, whereas the strain containing a 
plasmid with fragment C under the expression of a tac promoter was highly unstable 
(Chatfield e ta l ,  1992).
Another in vivo inducible promoter that has been characterised is the phoE  promoter. 
The PhoE protein is a pore-forming outer membrane protein (Benz and Bauer, 
1988), and bacterial phosphate starvation results in the induction of the pho regulon. 
The expression of this promoter has been found to be induced following 5. 
typhimurium  invasion of eukaryotic cells. Thus this promoter is considered a 
suitable candidate for regulated expression of foreign antigens to the immune system 
(Janssen et al., 1995). In other work a method for the in vitro selection of promoters 
activated by the intracellular milieu encountered by S. typhi following invasion of 
eukaryotic cells has been developed (Staendner et al., 1995). This method may be 
useful where the lack of a suitable animal model prevents analysis of disease 
pathogenesis, and may provide insights into the topology of gene expression during 
infection (Staendner et al., 1995).
1 .6 .9  A tten u a ted  Salm onella spp. as a C a rrie r  of Pertussis Antigens
Vaccines that provide both systemic and local protection in the respiratory tract may 
offer better protection against disease and infection compared to the conventional
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whole cell vaccine or acellular vaccines derived from B. pertussis. Oral vaccination is 
capable of stimulating immunity at distant sites such as the respiratory mucosa where 
bacterial colonisation occurs. Pertussis vaccines administered orally would also 
eliminate the risk of blood borne diseases and increase vaccine availability in the 
Third W orld where such vaccination would be in greatest demand. Researchers 
investigating novel delivery systems for antigens of B. pertussis have investigated 
the potential of several attenuated Salmonella strains.
In a previous study, recombinant SI subunit of PT was expressed in an attenuated 
aroA mutant of S. typhimurium, SL3261 and in the human typhoid vaccine strain 
Salmonella typhi Ty21a (Walker et al., 1992). This recombinant strain was used to 
orally immunise mice, and was found to induce IgG and IgA antibodies against the 
SI subunit of PT in the lungs and IgG in the sera of vaccinated mice. In a similar 
study, the S 1 subunit of PT was fused to the tetanus toxin fragment C and expressed 
in the S. typhi vaccine strain CVD908; intranasally immunised mice engendered a 
systemic anti-Sl IgG antibody response (Barry et al., 1996). However, to achieve 
protective immune responses it would be desirable to have the entire PT holotoxoid 
present, and not just SI or the B-oligomer (Nencioni et al., 1991). S. typhimurium 
aroA has also been used to express a plasmid encoding FHA of B. pertussis 
(Guzman et al., 1991a; Parker et al., 1990). In the latter study, IgG and IgA specific 
antibodies were detected in lung washes and IgG in the sera of mice following oral 
immunisation. Similarly, P69, a surface localised antigen of B. pertussis was 
expressed from the chromosome of the S. typhimurium aroA aroD vaccine strain 
BRD509 and low level anti-P69 antibodies were detected only following a murine B. 
pertussis aerosol challenge. This study also detected a CMI response in spleen cells 
specific for P69 prior to challenge (Strugnell et al., 1992). Subsequent work was 
aimed at constructing a vaccine strain capable of stimulating secretory, humoral and 
CMI against P69. In this work P69 was found to be expressed at high levels in the 
cytoplasm of BRD509 under the control of the nirB promoter. Although no anti-P69
response was detected following oral immunisation of mice, priming of the immune 
system was observed following subcutaneous boosting with purified P69 (Anderson 
et al., 1996).
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1 .7  Specific Aims
Although a great deal of research has been conducted on the development of acellular 
vaccines against whooping cough, to date, all antigens of B. pertussis used for 
vaccine development have been purified from this bacterium. Expression of wild­
type PT in other bacterial species such as E. coli has previously been attempted 
(Nicosia and Rappuoli, 1987), however factors such as differences in ribosomal 
binding sites and promoter recognition resulted in a very weakly active promoter in 
E. coli. Expression of these antigens in E. coli, for example would overcome 
potential problems associated with the process of purification of antigens from 
virulent B. pertussis. Such problems include the co-purification of other components 
that may contaminate vaccines preparations. Additionally, B. pertussis is a 
fastidious, slow growing organism, so expression of antigens in E. coli would 
significantly increase yields whilst reducing vaccine cost. The first aim of this work 
is to express the individual pertussis toxin subunits in E. coli, then to subsequently 
construct a recombinant pertussis toxin operon capable of simultaneous expression 
of the five PT subunit genes.
In addition to improving methods of vaccines preparation, research into the 
development of novel vaccine delivery systems is still in progress. Oral vaccination 
is capable of stimulating immunity at distant sites such as the respiratory mucosa 
where colonisation occurs during B. pertussis infection. Such a vaccine delivery 
system would increase vaccine acceptability and availability, thus contributing to the 
immunisation of the infant population, who are susceptible to potentially fatal B . 
pertussis infection. The development of oral immunisation systems will be facilitated
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by the expression of recombinant antigens in attenuated Salmonella spp. It may be 
feasible and advantageous to use Salmonella aro mutants as carriers of PT subunits 
for vaccine purposes. Studies to determine immune responses to these antigens will 
also be undertaken using a murine model. Using this antigen delivery system there is 
the potential to envoke strong local and mucosal immune response to all of the PT 
subunits. The expression of the SI subunit of PT (Barry et al., 1996; Walker et al.,
1992), FHA (Guzman et al., 1991a; Molina and Parker, 1990; Parker et al., 1990) 
and P69 (Anderson et al., 1996; Strugnell et al., 1992) in Salmonella spp. has 
previously been achieved, this together with PT expression in Salmonella spp. may 
constitute a more effective vaccine delivery system against pertussis when compared 
to the current whole cell or acellular vaccines.
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2 . MATERIALS AND METHODS
2 .1  Bacterial Strains and Expression Plasmids
The bacterial strains used in this work are described in Table 5.
Table 5. Bacterial Strains used in this study.
Strain Reference or Source
E. coli
JM109 Alacpro thi endA recA gyrA hsdR~ hsdM+ 
Sm F'traA 36 pro AB lactfZ Ml 5 supE
(Yanisch-Perron et al., 1985)
CAG629 lorThtpRl 65 ::Tnl 0 C. Gross
876 pep- R. Brownlie
EC538 J. McCarthy
YA21 (Mizushima and Yamada, 1975)
KS476 F-AlacX74 galE thi rpsL (strA)
AphoA (PvuII) lpp5508 degP41 (APst-Kan)
J.E.G. Beckwith and K. Strauch
H179 lorT R. Brownlie
S. typhimurium
SL5283 galE503 derivative of LB5000 B. Stocker
hsdSB121 leu-3121
SL3261 aroA (Hoiseth and Stocker, 1981)




Tohamal (Kasuga et a l 1954)
The strains E. coli JM109 and E. coli CAG629 lon'htpR165::TnlO  (C. Gross) were 
used for construction of expression plasmids and initial testing for recombinant PT
41
subunit expression respectively. All E. coli and Salmonella strains were routinely 
grown at 30°C in LB (Appendix A.vi) or on Z agar (Appendix A.v) (Walker and 
Pemberton, 1988) supplemented with ampicillin (100 |ig/ml). B. pertussis was grown 
on BG agar (Appendix A.iii) at 37°C.
The expression plasmids used in this work were pJLA506 (Walker et al., 1992) and 
pCGVl (Guzman et al., 1994), both derivatives of pJLA503 (Schauder et al., 1987). 
Plasmid pCGV 1 contains an alkaline phosphatase insertional inactivation screening 
system and allows the export of recombinant proteins with a modified ß-lactamase 
leader peptide.
2 .2  PCR Amplification of Pertussis Toxin DNA
2.2.1 Oligonucleotide Primers
The primers (Appendix H) used for PCR amplification (Sambrook et al., 1989) of PT 
DNA are described in Table 6. Each PT subunit gene was PCR amplified using Taq 
DNA polymerase (Boehringer Mannheim) from the native PT operon originating 
from pTX42 (Locht and Keith, 1986) using primers synthesised on an Applied 
Biosystems model 380B DNA synthesiser. All the 5' primers with the exception of 
S4 were designed to incorporate the Ndel restriction enzyme site (underlined) within 
the 5' sequence. The S4 5' primer, was designed to incorporate a NheI restriction 
enzyme site and part of the modified ß-lactamase signal peptide. All 3' primers were 
designed to incorporate an EcoRl restriction enzyme site (underlined) within the 3' 
sequence. The corresponding PT subunit amino acid sequence is also shown whilst 
the modified ß-lactamase sequence is italicised.
Table 6. Nucleotide sequence of the PCR primers used to amplify PT subunit DNA.
Primer Sequencea
SI 5' Ndel Met Arg Cys Thr Arg Ala lie 
5'-GGCATATG CGT TGC ACT CGG GCA ATT-3’ 
Nde I
SI 3’ EcoRl Tyr Ser Phe Stop
5'-TAT TCG TTC TAG ACC TGG GAA TTC CC-3’ 
3'-ATA AGC AAG ATC TGG ACC CTT AAG GG-5’
EcoRl
S2 5’ NdeI Met Pro lie Asp Arg Lys Thr 
5’-GGCATATG CCG ATC GAC CGC AAG ACG-3’ 
Ndel
S2 3' EcoRl Ser Leu Cys Stop
5'-TCC TTA TGC TGA GAC GCT GAA TTC CC-3’ 
3’-AGG AAT ACG ACT CTG CGA CTT AAG GG-5’
E coR l
S3 5’ NdeI Met Leu lie Asn Asn Lys Lys 
5'-GGCATATG CTG ATC A AC A AC AAG A AG-3’ 
Nde I
S3 3' EcoRl Ser He Cys Stop
5’-TCG ATA TGC TGA GCC GCC GAA TTC CC-3’ 
3'-AGC TAT ACG ACT CGG CGG CTT AAG GG-5’
EcoRl
S4 5’ Nhel
Phe Cys Leu Pro Val Phe Ala 
5'-TT GCTAGC TTT TGC CTT CTT GTT TTT GCT 
Nhel
Asp Val Pro Tyr Val Leu 
GAC GTT CCT TAT GTG CTG GT 3'
S4 3’ EcoRl
Asp Cys Pro Stop
5'-GAT TGC CCC TGA AGG CGA GAA TTC CC-3' 
T-CTA ACG GGG ACT TCC GCT CTT AAG GG-5'
EcoRl
S5 5' Ndel Met His Thr He Ala Ser He 
5'-GGCATATG CAT ACC ATC GCA TCC ATC-3’ 
Ndel
S5 3’ EcoRl Tyr Cys Glu Stop
5'-TAT TGC GAA TGA ACC CTT GAA TTC CC-3' 
T-ATA ACG CTT ACT TGG GAA CTT AAG GG-5'
EcoRl
a The nucleotide sequence of all 3' primers is given as the lower of the two nucleotide sequences 
presented, the upper sequence represents the complementary sequence encoding the COOH end of the
PT subunit.
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2 .2 .2  PCR Protocol
The amplification of the appropriate PT subunit DNA was performed in 0.5 ml 
microcentrifuge tubes (Sarstedt) in a total volume of 100 p,l using a Hybaid Thermal 
Cycler. The reaction mixture consisted of the following reagents listed in Table 7.
Table 7. The polymerase chain reaction mix.
Reagenti Volume Final Concentration
Sterile gdf^O 78.5 pi
10 x PCR buffer* 10.0 pi 1 X
dATP 2.0 pi 200 pM
dCTP 2.0 pi 200 pM
dGTP 2.0 pi 200 pM
dTTP 2.0 pi 200 pM
5'Ndel primer 1.0 pi 0.2 pM
3'EcóKl primer 1.0 pi 0.2 pM
Taq DNA polymerase 0.5 pi 2.5 Units/100 pi
Experimental template 1.0 pi 1 ng/100 pi
f  All PCR reagents except for Taq DNA polymerase and 10 x PCR buffer were obtained 
from Perkin Elmer Cetus.
* Appendix B.xii.
The reagents were added to sterile tubes in the order listed in Table 7. Following 
addition of reagents, 50 |il of mineral oil was overlayed and the solution spun at 
15,000 g for 1 min in an Eppendorf centrifuge. The PCR reaction cycle performed to 
amplify PT subunit genes is shown in Table 8.
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Table 8. PCR amplification cycle.
Step Temperature Time
Step 1.1 95°C 5 min
1.2 50°C 1 min x 1 cycle
1.3 70°C 1 min
Step 2.1 95°C 1 min
2.2 50°C 1 min x 35 cycles
2.3 70°C 1 min
Step 3.1 70°C 5 min x 1 cycle
Step 4.1 37°C holding temperature
Following PCR amplification, products were frozen at -20°C to facilitate the removal 
of the mineral oil overlay which remained in a liquid form.
2 .3  Detection of Pertussis Toxin DNA
2.3.1 Agarose Gel Electrophoresis
Agarose gel electrophoresis (Sambrook et al., 1989) was performed using either the 
Bio-rad Mini Sub™ DNA Cell or the Pharmacia Gel Electrophoresis Apparatus. DNA 
samples to be electrophoresed where mixed with 0.2 volumes of agarose gel loading 
dye (Appendix D.i) prior to electrophoresis. All agarose gels consisted of 1% 
agarose/TAE. Gels were run at 50 V using 1 x TAE running buffer (Appendix B.i) for 
between 1 and 2 h depending on the expected size of the DNA fragment.
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2.3.2 Determination of the Size of Restriction Fragments
Bacteriophage Lambda DNA digested with HindlU was included in each agarose gel 
to provide reference fragments of known molecular weight (Murray and Murray, 
1975). The size of the restriction fragments was determined from a standard curve of 
log molecular weight of reference fragment against relative mobility (Preifer, 1984).
2.3.3 Staining of Agarose Gels
Agarose gels were stained (Sambrook et al., 1989) in a solution consisting of 1 pg/ml 
ethidium bromide for approximately 20 min. The gel was then viewed under ultra­
violet light.
2 .4  Plasmid DNA Extraction
2.4.1 Qiagen Extraction
The extraction of plasmid DNA was undertaken in accordance with manufacturers 
instructions as described in the following section. A bacterial culture was grown to 
A595 0.5 in a 37°C shaker incubator. The culture was then centrifuged at 3,000 g for 
15 min. The volumes of buffer described in the following protocol are suitable for 
midi preparations, and need to be adjusted according to the column size used. The 
bacterial pellet was resuspended in 4 ml of buffer PI (Appendix E.i). Following 
suspension, 4 ml of buffer P2 (Appendix E.ii) was gently added to the mixture and 
incubated at room temperature for 5 min. After incubation, 4 ml of buffer P3 
(Appendix E.iii) was added and mixed immediately by inverting the tube 6 times, then 
the solution was incubated on ice for 20 min. Subsequently the solution was 
centrifuged at 30,000 g for 30 min at 4°C and the supernatant was promptly removed. 
If the supernatant was found to be turbid a second centrifugation at 30,000 g for 15
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min at 4°C was undertaken. A Qiagen-tip 100 was then equilibrated by the addition of 
4 ml of QBT (Appendix E.iv) buffer to the column, which was allowed to empty by 
gravity flow. The supernatant was then applied to the column and allowed to empty by 
gravity flow. The Qiagen tip was then washed with 2 x 10 ml of buffer QC (Appendix 
E.v). Following the washes, the DNA was eluted from the column with 5 ml of buffer 
QF (Appendix E.vi). To precipitate the DNA, 0.7 volumes (3.5 ml) of isopropanol 
was added to the DNA eluant which was subsequently centrifuged at 15,000 g for 30 
min, then the supernatant discarded. Finally the pellet was washed with 5 ml of 70% 
ethanol, air dried for 5 min and redissolved in a suitable volume of gdH20 .
2.4.2 Small Scale Plasmid Extraction
Plasmid DNA was isolated by the method of Naumovski and Freidburg (1982). The 
appropriate bacterial strain was grown overnight on agar plates with selection. 
Individual colonies were then suspended in sucrose solution (Appendix E.vii) with 1 
mg/ml lysozyme. The suspension was left at room temperature for 30 min. 
Subsequently, 0.3 ml of Triton X-100 solution (Appendix E.viii) was added and the 
tube was inverted twice prior to a 15 min incubation at 65°C. The cell suspension was 
then centrifuged for 30 min at 16,000 g. The supernatant was transferred to a clean 
Eppendorf tube to which 10 drops of saturated phenol was added. The tube was 
shaken vigorously and centrifuged for 15 min. The aqueous upper DNA layer was 
removed carefully with a Pasteur pipette and added to a clean tube with 1 ml of diethyl 
ether, this was then shaken and centrifuged for 1 min and the upper ether layer 
discarded. The extraction with ether was then repeated. Following the extraction, 50 
pi of 3 M sodium acetate pH 7.0 was added prior to vortexing the solution. Ice cold 
ethanol (1 ml) was mixed gently into the solution and the tube was placed at room 
temperature for 5 min. The solution was then centrifuged for 5 min, the ethanol 
removed and the pellet air-dried for 10 min. The DNA pellet was suspended in 50 pi 
gdH 20  to which 1 jul of 10 mg/ml RNase was added. The DNA suspension was
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incubated at 37°C for 30 min and vortexed prior to use. Following plasmid extraction 
the DNA samples were digested using appropriate restriction enzymes then 
electrophoresed on an agarose gel to determine whether the correct insert had been 
cloned.
2.4.3 Extraction of DNA from Agarose Gels
Following the separation of DNA fragments by agarose gel electrophoresis, the DNA 
was extracted and purified from the gel using the Bresa-Clean™ DNA purification kit 
(Bresatec). Firstly, the band was excised from the gel and the volume of agarose by 
weight was estimated. Three volumes of Bresa-salt™ was then added to the tube 
containing the DNA and this was incubated for 5 min at 55°C to dissolve the agarose. 
Then, 5 (il plus 1 [il/|ig DNA of Bresa-bind™ was added and the suspension 
incubated for 5 min at room temperature to bind the DNA to the resin. The suspension 
was centrifuged for 5 seconds and the supernatant discarded. The pellet was washed 
with Bresa-wash™ using a volume equivalent to the amount of Bresa-salt™ used 
previously, and centrifuged for 5 seconds. The DNA was recovered by resuspending 
the pellet in gdFkO using a volume twice that of the resin used. Following incubation 
at 50°C for 5 min, the solution was centrifuged and the supernatant containing DNA 
was recovered. The recovery rate and purity of the DNA fragment was then assessed 
by agarose gel electrophoresis.
2 .5  Construction of Recombinant Clones
2.5.1 TA Cloning™ of PCR Products
The appropriate PCR fragments were cloned using the Invitrogen TA Cloning™ kit in 
accordance with the manufacturers instructions.
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2.5.1.1 Plasmid pCR™II Vector Ligation Reaction
The ligation reaction was comprised of:
6 pi sterile H2O
1 jil 10 x ligation buffer
2 |il plasmid pCR™II vector 
1 |il PCR product
1 |ll T4 DNA ligase
This reaction mix was then incubated at approximately 12°C overnight.
2.5.1.2 TA Cloning™ Transformation
The tube containing the ligation reaction was spun briefly in an Eppendorf centrifuge 
then placed on ice. Then, 2 |L i l  of 0.5 M B-mercaptoethanol was added to the 
competent cells and mixed gently. A 1 jil sample of the ligation reaction was added 
directly to the competent cells and the mixture placed on ice for 30 min. The mixture 
was placed in a 42°C water bath for exactly 1 min then placed rapidly back on ice for 2 
min. Next, 450 |ll of SOC medium (Appendix A.vii) was added to the transformation 
mixture and the vial was shaken at 37°C for 1 h at 225 rpm. The mixture was then 
placed on ice prior to plating out on X-gal agar plates (Appendix A.ii) containing 100 
|ig/ml ampicillin for selection of the plasmid bearing colonies.
2.5.2 Restriction Endonuclease Digestion of DNA
All DNA restriction enzyme digestions (Sambrook et al., 1989) were undertaken 
using 0.1-0.5 |Ltg of DNA, 2 jllI  of the corresponding incubation buffer and 5-10 units 
of restriction endonuclease made up to a total volume of 20 |il with gdH20 . The 
restriction enzymes used are shown in Table 9. Digestion was carried out by 
incubation at 37°C for 1 h. The sticky ends formed by digestion were separated by 
heating to 65°C for 5 min then placing the reaction mixture on ice for 5 min.
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Table 9. Restriction enzymes and buffers.
Enzymea Recognition site Buffo- (x 10)
Bam H i G GATCC Tris-HCl, 10 mmol/1; NaCl, 100 mmol/1; 
MgCl2, 5 mmol/1; ß-mercaptoethanol,
1 mmol/1; pH 8.0 (at 37°C).
Eco RI G AATTC Tris-HCl, 50 mmol/1; MgCl2 10 mmol/1; 
DTT, 1 mmol/1; pH 7.5 (at 37°C).
Hind m A AGCTT Tris-HCl, 10 mmol/1; NaCl, 100 mmol/1; 
MgCl2, 5 mmol/1; ß-mercaptoethanol,
1 mmol/1; pH 8.0 (at 37°C).
Nde I CA TATG Tris-HCl, 50 mmol/1; MgCl2 10 mmol/1; 
DTT, 1 mmol/1; pH 7.5 (at 37°C).
N o tl GC GGCCGC Tris-HCl, 50 mmol/1; MgCl2 10 mmol/1; 
DTT, 1 mmol/1; pH 7.5 (at 37°C).
Pst I CTGCA G Tris-HCl, 50 mmol/1; MgCl2 10 mmol/1; 
DTT, 1 mmol/1; pH 7.5 (at 37°C).
Sal I G TCGAC Tris-HCl, 50 mmol/1; MgCl2 10 mmol/1; 
DTT, 1 mmol/1; pH 7.5 (at 37°C).
Xho I C TCGAG Tris-HCl, 50 mmol/1; MgCl2 10 mmol/1; 
DTT, 1 mmol/1; pH 7.5 (at 37°C).
a All restriction endonucleases were obtained from Boehringer Mannheim.
2.5.3 A lkaline Phosphatase  T rea tm en t of Vector DNA
Alkaline phosphatase (AP) (Boehringer Mannheim) catalyses the removal of 5’- 
phosphate residues from DNA. AP from calf intestine was used for this purpose to 
enable efficient ligation with PT subunit DNA, following purification of the desired 
DNA fragments. To 20 pi of DNA, 5 pi of 10 x AP dephosphorylation buffer 
(Appendix B.ix) was added followed by 25 pi of gdH20 and 1 pi of AP. This mixture 
was incubated at 37°C for 30 min. An additional 1 pi of AP was then added and the 
mixture was again incubated at 37°C for 30 min. The enzyme was then inactivated at 
65°C for 15 min.
Table 9. Restriction enzymes and buffers.
Enzyme3 Recognition site Buffer (x 10)
Bam HI G GATCC Tris-HCl, 10 mmol/1; NaCl, 100 mmol/1; 
MgCl2, 5 mmol/1; ß-mercaptoethanol,
1 mmotyl; pH 8.0 (at 37°C).
Eco RI G AATTC Tris-HCl, 50 mmol/1; MgCl2 10 mmol/1; 
DTT, 1 mmol/1; pH 7.5 (at 37°C).
Hind III A AGCTT Tris-HCl, 10 mmol/1; NaCl, 100 mmol/1; 
MgCl2, 5 mmol/1; ß-mercaptoethanol,
1 mmol/1; pH 8.0 (at 37°C).
Nde I CA TATG Tris-HCl, 50 mmol/1; MgCl2 10 mmol/1; 
DTT, 1 mmol/1; pH 7.5 (at 37°C).
Not I GC GGCCGC Tris-HCl, 50 mmol/1; MgCl2 10 mmol/1; 
DTT, 1 mmol/1; pH 7.5 (at 37°C).
Pst I CTGCA G Tris-HCl, 50 mmol/1; MgCl2 10 mmol/1; 
DTT, 1 mmol/1; pH 7.5 (at 37°C).
Sal I G TCGAC Tris-HCl, 50 mmol/1; MgCl2 10 mmol/1; 
DTT, 1 mmol/1; pH 7.5 (at 37°C).
Xho I C TCGAG Tris-HCl, 50 mmol/1; MgCl2 10 mmol/1; 
DTT, 1 mmol/1; pH 7.5 (at 37°C).
a Ail restriction endonucleases were obtained from Boehringer Mannheim.
2.5.3 Alkaline Phosphatase Treatment of Vector DNA
Alkaline phosphatase (AP) (Boehringer Mannheim) catalyses the removal of 5’- 
phosphate residues from DNA. AP from calf intestine was used for this purpose to 
enable efficient ligation with PT subunit DNA, following purification of the desired 
DNA fragments. To 20 jul of DNA (1.0 pg), 5 pi of 10 x AP dephosphorylation 
buffer (Appendix B.ix) was added followed by 25 pi of gdH^O and 1 pi of AP. This 
mixture was incubated at 37°C for 30 min. An additional 1 pi of AP (20 Units) was 
then added and the mixture was again incubated at 37 °C for 30 min. The enzyme was 
then inactivated at 65°C for 15 min.
50
2.5.4 L igation  of DNA w ith T4 Ligase
The insert DNA and the vector DNAf were digested separately, then mixed together 
and placed at 65°C for 1 min, then at 37°C for 10 min followed by 10 min at room 
temperature. After this time 4 pi obligation buffer (B.viii) was added to the mixture, 
followed by 1 pi of T4 DNA ligase (Boehringer Mannheim). The solution was then 
mixed gently and incubated at 10°C overnight to allow ligation to proceed.
2.5.5 P re p a ra tio n  of C om petent Cells
The appropriate bacterial strain was sixteen-streaked out on a Z agar plate (Appendix
A.v) and grown overnight at 37°C. The bacteria were then inoculated into 200 ml of 
sterile LB and grown up in a shaking incubator at 37°C until the culture reached A56O 
0.5 (3-4 h). The cells were then transferred into a sterile centrifuge tube and collected 
by centrifugation at 4,500 g for 10 min at 4°C. The supernatant was discarded and the 
bacterial pellet was placed on ice for 10 min. The cells were then resuspended in 100 
ml of cold 0.1 M MgCl2. The centrifugation step was then repeated, then the cells
were resuspended in 10 ml of cold 0.1 M CaCl2. To obtain the optimum 
transformation efficiency, the cells were left overnight prior to use.
2.5.6 T ran sfo rm atio n  of B acterial Cells
Competent cells (200 pi) of the appropriate strain, were added to the ligation mixture 
and resuspended. The mixture was placed on ice for 1 h, then incubated at 37°C for 5 
min. Following incubation, the mixture was spun for 1 min in an Eppendorf 
centrifuge and the supernatant discarded (Cohen ct ¿2/., 1972). The pellet was 
resuspended in 0.5 ml of LB and incubated for 1 h at 30°C. The transformation mix 
was then plated out onto Z agar (Appendix A.v) with the appropriate selection and
incubated overnight at 30°C.
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2.5.4 Ligation of DNA with T4 Ligase
The insert DNA (1 pg) and the vector DNA (0.5pg) were digested separately, then 
mixed together and placed at 65°C for 1 min, then at 37 °C for 10 min followed by 10 
min at room temperature. After this time 4 pi of ligation buffer (B.viii) was added to 
the mixture, followed by 1 jllI  of T4 DNA ligase (1 Units) (Boehringer Mannheim). 
The solution was then mixed gently and incubated at 10°C overnight to allow ligation 
to proceed.
2.5.5 Preparation of Competent Cells
The appropriate bacterial strain was sixteen-streaked out on a Z agar plate (Appendix 
A.v) and grown overnight at 37°C. The bacteria were then inoculated into 200 ml of 
sterile LB and grown up in a shaking incubator at 37 °C until the culture reached A560 
0.5 (3-4 h). The cells were then transferred into a sterile centrifuge tube and collected 
by centrifugation at 4,500 g for 10 min at 4°C. The supernatant was discarded and the 
bacterial pellet was placed on ice for 10 min. The cells were then resuspended in 100 
ml of cold 0.1 M MgCl2. The centrifugation step was then repeated, then the cells 
were resuspended in 10 ml of cold 0.1 M CaCl2. To obtain the optimum 
transformation efficiency, the cells were left overnight prior to use.
2.5.6 Transformation of Bacterial Cells
Competent cells (200 pi) of the appropriate strain, were added to the ligation mixture 
and resuspended. The mixture was placed on ice for 1 h, then incubated at 37°C for 5 
min. Following incubation, the mixture was spun for 1 min in an Eppendorf 
centrifuge and the supernatant discarded (Cohen et al., 1972). The pellet was 
resuspended in 0.5 ml of LB and incubated for 1 h at 30°C. The transformation mix 
was then plated out onto Z agar (Appendix A.v) with the appropriate selection and
incubated overnight at 30°C.
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2.5.7 Selection of Potential Recombinant Clones
2.5.7.1 PCR Clones
Potentially recombinant clones (white colonies) were selected by the inability to 
degrade X-gal after induction with IPTG and resistance to ampicillin (100 pg/ml). 
Non-recombinant colonies appear blue on X-gal agar (Appendix A.ii).
2.5.7.2 Expression Vector Clones
Potentially recombinant clones were selected for on the basis of ampicillin resistance 
(100 |Xg/ml) for pJLA506; in the case of pCGV l, XP agar (Appendix A.iv) which 
differentiates between the ability (blue colonies) and the inability (white colonies) to 
degrade the substrate XP supplemented with ampicillin (100 pg/ml) was used.
2.5.8 Fractionation of Bacterial Cells
Bacterial cells were fractionated to determine the subcellular location of processed PT 
subunits according to the method of Comelis et al. (1982). Bacterial cultures were 
grown overnight at 30°C, then used to inoculate 1 1 of LB. The culture was then 
grown until an A56O 0.8 was reached then the culture was temperature induced for 1 h 
at 42°C. Following induction, the culture was centrifuged at 15,000 g for 5 min. The 
pellet was then washed twice with an equal volume of 10 mM Tris-HCl (pH 8). The 
pellet was resuspended in 0.5 volumes of fractionation buffer (Appendix B.vii) at 
32°C for 30 min. The suspension was then centrifuged at 9,000 g for 15 min and the 
pellet was subsequently resuspended in 0.25 volumes of ice cold gdH20  at 4°C for 30 
min. The suspension was centrifuged at 10,000 g for 30 min at 4°C. Following 
centrifugation, the supernatant containing the periplasmic fraction and the pellet 
containing the cytoplasmic fraction were retained. Intact cells were removed
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from the periplasmic and extracellular fractions using a Sartorius EasyFlow crossflow 
system (0.2 pm  cut-off). Fractions were then concentrated using a Sartorius 
EasyFlow crossflow system (10,000 molecular weight cut-off).
2 .6  DNA Sequence Analysis of Recombinant Clones
The annealing of prim er to the double-stranded template and the subsequent 
sequencing reactions (Sanger et al., 1977) were performed essentially as described in 
the Pharmacia sequencing kit manual.
2.6.1 Annealing of Primer to Template
The concentration of template DNA was adjusted so that 32 pi contained 1.5-2 pg of 
DNA. The double stranded template DNA was then denatured by the addition of 8 pi 
of 2 M NaOH, the tube was vortexed and incubated at room temperature for 10 min. 
Then, 7 pi of 3 M sodium acetate (pH 4.8) and 4 pi of gdH20  was added, along with 
120 pi of 100% ethanol, The tube was then mixed and placed on ice for 15 min. The 
DNA was then collected by centrifugation at 15,000 g for 15 min. The pellet was 
subsequently washed with 70% ethanol, recentrifuged for 10 min and air dried prior 
to being resuspended in 10 pi of gdH20. The concentration of the primer was adjusted 
to 2.5-5 pM , such that 2 pi contained 5-10 pmol of primer. The primer (2 pi), and 2 
pi of annealing buffer (Appendix B.xi) was added to the 10 pi of denatured template 
DNA. This mixture was vortexed, centrifuged briefly and incubated at 65°C for 5 min. 
The mixture was allowed to slowly cool to room temperature over a period of at least 
30 min.
2.6.2 Sequencing Reactions
For a short run (up to 500 nucleotides) 2.5 pi of the A mix-short, C mix-short, 
’G’ mix-short and T  mix-short respectively, were pipetted into corresponding tubes. 
T7 DNA polymerase (Pharmacia) was then diluted on ice (1:4) using cold enzyme
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buffer (Appendix B.x). Next, 2 jitl of the diluted T7 DNA polymerase, 3 pi of 
labelling mix-dATP (Appendix B.xiii) and 1 |il of [alpha-32P]dATP (Bresatec), per 
template were added to an Eppendorf tube placed on ice. This labelling mix was added 
to the template DNA mix and the components mixed gently then centrifuged and 
placed at room temperature for 5 min. Whilst this reaction was in progress the four 
tubes containing the sequencing mixes were warmed in a 37°C water bath for at least 1 
min. After the labelling reaction had been incubated for 5 min, 4.5 pi of this reaction 
was transferred into each of the four pre-warmed sequencing mixes, which were then 
incubated at 37°C for 5 min. Following this incubation, 5.5 pi of the stop solution 
(Appendix D.iii) was added to each tube and the tubes were placed on ice. A 3 pi 
aliquot of each reaction was then transferred to a separate tube and the samples 
denatured at 75°C for 2 min prior to being loaded onto the sequencing gel.
2.6.3 Sequencing Gel Set-up
The sequencing apparatus (IBI Base Runner) was set up and the sequencing gel 
(Appendix C.iii) was poured and allowed to set for at least 3 h. The gel was then 
placed in the buffer chamber and the chamber filled with 1 x TBE buffer (Appendix
B.ii), then pre-warmed for 1 h at 40 W prior to the samples being loaded. A 2 pi 
aliquot of each sample was loaded onto the gel which was electrophoresed for the 
appropriate time (3-6 h) at 40 W.
After the electrophoresis was complete, the gel was fixed by pouring a fixing solution 
(Appendix G.iv) over the gel surface and soaking for approximately 20 min. The gel 
was then transferred to a supporting sheet of filter paper and covered with plastic 
wrap, then dried using a vacuum gel dryer (Bio-rad). Once the gel was completely dry 
it was placed in a film cassette and an appropriate sized sheet of X-ray film (Fuji) was 
overlayed. The film was then left to expose for an appropriate time prior to 
development. The autoradiograph was then placed in developer (Appendix G.v;
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Kodak) for 1 min, immersed in H2O, then placed in fixer (Appendix G.vi; Kodak) for 
1 min, prior to being rinsed in H2O. The DNA sequence was then read from the 
autoradiograph.
2 .7  D etection o f P ertu ssis Toxin S ubun it Expression
2.7.1 T em p era tu re  Induction  of R ecom binant E xpression S tra in s
For induction of PT subunit expression, overnight cultures were diluted to an A56O 
0.4 and grown with aeration until an A56O 0.8 was reached then subsequently 
temperature induced at 37°C, 39.5°C or 42°C for 1 h (Walker et al., 1992). A 1 ml 
culture sample was taken following temperature induction. The sample was 
centrifuged at 16,000 g for 5 min then the supernatant removed and the pellet 
resuspended in 100 |il of 0.7% saline, to which an equal volume of PAGE sample 
buffer (Appendix D.ii) was added. The sample was then placed in a boiling water bath 
for 10 min prior to separation by PAGE.
2.7.2 SD S-Polyacrylam ide Gel E lectrophoresis (PAGE)
All resolving gels used to detect PT subunits were 15% acrylamide gels (Appendix
C.ii), with a 4% stacking gel (Appendix C.i). PAGE was undertaken according to the 
method of Laemmli (1970) using 1 x SDS-PAGE running buffer (Appendix B.iii). 
For SDS-PAGE the Bio-rad Mini Protean II™ gel system was used. Gels were 
electrophoresed at 150 V for approximately 2 h. Approximately 3.2 p,g of PT was 
used as a positive control on SDS-PAGE gels. All SDS-PAGE gels also contained 
low molecular weight markers (Bio-rad), in the case where the gel was subjected to 
Western blot analysis, prestained low molecular weight markers (Bio-rad) were used.
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Kodak) for 1 min, immersed in H2O, then placed in fixer (Appendix G.vi; Kodak) for 
1 min, prior to being rinsed in H2O. The DNA sequence was then read from the 
autoradiograph.
2 .7  Detection of Pertussis Toxin Subunit Expression
2.7.1 Temperature Induction of Recombinant Expression Strains
For induction of PT subunit expression, overnight cultures were diluted to an A560 
0.4 and grown with aeration until an A560 0.8 was reached then subsequently 
temperature induced at 37°C, 39.5°C or 42°C for 1 h (Walker et al., 1992). A 1 ml 
culture sample was taken following temperature induction. The sample was 
centrifuged at 16,000 g for 5 min then the supernatant removed and the pellet 
resuspended in 100 jul of 0.7% saline, to which an equal volume of PAGE sample 
buffer (Appendix D.ii) was added. The sample was then placed in a boiling water bath 
for 10 min prior to separation by PAGE.
2.7.2 SDS-Polyacrylamide Gel Electrophoresis (PAGE)
All resolving gels used to detect PT subunits were 15% acrylamide gels (Appendix 
C.ii), with a 4% stacking gel (Appendix C.i). PAGE was undertaken according to the 
method of Laemmli (1970) using 1 x SDS-PAGE running buffer (Appendix B.iii). 
For SDS-PAGE the Bio-rad Mini Protean II™ gel system was used. Gels were 
electrophoresed at 150 V for approximately 2 h. Approximately 3.2 fig of PT was 
used as a positive control on SDS-PAGE gels. All SDS-PAGE gels also contained 
low molecular weight markers (Bio-rad), in the case where the gel was subjected to 
Western blot analysis, prestained low molecular weight markers (Bio-rad) were used. 
Within each SDS-PAGE gel equivalent amounts of protein were added to each lane. In 
most instances, western blots were repeated to confirm expression or processing of 
PT subunits.
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2.7.3 Coomassie Blue Staining of SDS-PAGE Gels
Proteins were visualised on SDS-PAGE resolving gels using Coomassie blue stain 
(Appendix G.i). After development for 3 h, excess stain was removed by soaking in 
destain (Appendix G.ii) for 4 h.
2.7.4 Antibodies Specific for PT Subunits
2.7.4.1 Polyclonal Antibodies
Polyclonal antibodies against a common epitope shared by S2 and S3, and an epitope 
of S5, were developed. Two 16mer synthetic peptides conjugated to diphtheria toxoid 
were commercially synthesised: anti-S2/3 (RVHVSKEEQYYDYEDC) and anti-S5 
(EDSPYPGTPGDLLELC) using a previously published method (Lee et al., 1980) 
(Chiron Mimotopes). These two peptides were chosen on the basis of their antigenic 
index and hydrophilicity (Kyte and Doolittle, 1982) determined using the Entrez 
Database. Approximately 100 nmoles of each peptide was resuspended then 
emulsified with Freund’s complete adjuvant (Sigma) (1:2) in a total volume of 1 ml; 
these emulsions were used to subcutaneously immunise two New Zealand white 
rabbits (day 0). On day 14 the rabbits were boosted as for day 0 except using 
Freund's incomplete adjuvant (Sigma). On day 35 the rabbits were exsanguated by 
heart puncture, then blood was collected and allowed to clot for 2 h at room 
temperature. The clot was then displaced and serum collected by centrifugation at 
3,000 g for 10 min.
2.7.4.2 Monoclonals Antibodies
Monoclonal antibodies used in this study were the following: anti-Sl, E19 derived 
from culture supernatant (Walker et al., 1991a); anti-S4, 6DX3 derived from ascites
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fluid (Witviet et al., 1989); and anti-S5, 2D6 precipitated in (NFLO2SO4 (Bigio et al., 
1988).
2.7.5 Western Blot Analysis
2.7.5.1 Semi-dry Transfer
Western blot analysis was undertaken according to a modified method of Burnette et 
al. (1981). The stacking gel was removed from the resolving gel containing low 
molecular weight prestained markers (Bio-rad) and cut down to minimal size. The gel 
and an equivalent size sheet of nitrocellulose (0.45 Jim, Bio-rad) was equilibrated in 
western transfer buffer I (Appendix B.iv) for 15 min. The same buffer was also used 
to wet 10 sheets of filter paper cut to the same size. Five sheets of filter paper were 
then placed on a Trans-Blot® SD Transfer Cell (Bio-rad), and air bubbles were 
removed by gently rolling the surface with a glass rod after addition of each sheet. The 
nitrocellulose was then placed on top of the filter paper and again air bubbles were 
removed. The gel and the 5 remaining sheets of filter paper were then added. The 
transfer apparatus was run at 15 V for 20 min.
2.7.5.2 Wet Transfer
The gel and a similar size piece of Immobilon™-P, PVDF (Millipore) were 
equilibrated in western transfer buffer II (Appendix B.v) for 20 min. The Bio-rad 
Mini Trans-Blot® Cell was then assembled and electrophoresis undertaken at 100 V
for 1 h at 4°C.
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2.7.5.3 Blocking and Western Blot Development
Following transfer, the nitrocellulose was blocked using low fat milk (0.1%), made 
up to 10% in PBS (Appendix B.vi) for 1 h on an orbital shaker. After blocking, the 
solution was discarded and the first antibody diluted 1:500 in PBS was added, and 
rocked gently for 1 h at room temperature. The first antibody was removed and the 
membrane washed in PBS (3 x 10 min). The final wash was discarded then the 
second antibody (goat anti-mouse or anti rabbit IgG, HRP conjugate; Bio-rad) diluted 
1:500 in PBS was added and rocked for 1 h at room temperature. The membrane was 
again washed in PBS (3 x 10 min). The colour development solution (Appendix
G.vii) was added to the membrane and it was left to develop until bands became 
visible. The membrane was then removed from the colour development solution, 
washed with gdibO and allowed to dry.
2 .8 .  Tissue Culture Methods and in vitro Intracellular Survival 
Assays
Intracellular survival assays were performed by Dr C. Guzman (GBF-National 
Research Centre for Biotechnology, Braunschweig, Germany). Briefly, the human 
intestinal epithelial cell line Henle 407 (ATCC CCL-6) was maintained in DME with 
10% FCS, 5 mM glutamine and 1 mM pyruvate, in an atmosphere containing 5% CO2 
at 37°C. Trypsinized cells were seeded at a concentration of approximately 2 x 105 
cells in tissue culture plates (12 by 4.5 cm2; Flow). These were incubated for 18 to 24 
h and then washed three times in PBS (pH 7.4) (Appendix B.vi). For infection of 
m onolayers, bacteria in the exponential growth phase were harvested by 
centrifugation, resuspended to a density of 108 CFU/ml in DME, overlaid onto the 
monolayer of cells, and incubated for 45 min at 37°C with 5% CO2. Unattached and 
loosely attached bacteria were removed by washing the monolayers three times with 
PBS. For invasion assays, DME containing gentamicin (100 Jig/ml) was then added;
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this concentration of gentamicin killed extracellular bacteria and thereby prevented any 
reinfection of cells. Monolayers were incubated for 4 h or 24 h then washed three 
times with PBS. The number of invading bacteria was determined by lysing the 
eukaryotic cells with the addition of 1 ml of 1% Triton X-100 (vol/vol) to each well 
and calculating the viable counts on Z agar plates (Appendix A.v).
2 .9  Assessment of Antibody Response and Protectiveness of 
Pertussis Toxin Subunit Producing Strains
2.9.1 Mouse Immunisation and Sample Collection
Six- to eight-week-old female BALB/c mice were immunised and caged separately in 
groups of up to six. The groups were immunised with one dose on day 0 and boosted 
with identical doses 30 and 40 days later. The mice were sacrificed 10 days after the 
last booster, and the samples were collected. For immunisations, S. typhimurium 
aroA SL3261 and SL7207 strains were grown and induced at 37°C or 39.5°C for 1 h, 
as previously described (2.7.1). Once the appropriate optical density had been reached 
the cells were recovered by centrifugation and resuspended in an equal volume of 
sterile PBS and 3% sodium bicarbonate to approximately 1 x 10  ̂ CFU for oral 
immunisation. Mice were anaesthetised in an enclosed chamber using anaesthetic 
ether. The cell suspension (0.1 ml) or PBS was administered orally by gavage tube. 
For the positive control, 0.1 ml of (100 Jig/ml) gluteralderhyde detoxified PT (Munoz 
et a l., 1981) in 20 mM PBS 500 mM NaCl (pH 7.6) was administered 
intraperitoneally.
Mice were sacrificed by cervical dislocation, then exsanguinated by cutting the 
brachial artery, and serum was separated and stored at -20°C. After exsanguination the 
trachea was isolated and exposed. Lung washes were collected after pertracheal 
cannulation and gentle washing with 0.7 ml of ice-cold PBS containing 2 mM
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phenylmethylsulfonyl fluoride as a protease inhibitor. Lung washes were centrifuged 
at 3,000 g for 5 min to remove debris and stored at -20°C.
2.9.2 Enzyme Linked Immunosorbent Assays (ELISAs)
For the determination of subclass specific antibodies against PT in sera and lung 
washes, ELISAs were performed as follows: Titertek 96-well plates were coated with 
pertussis toxoid (kindly supplied by R. Rappuoli) diluted in 0.1 M NaHCC>3 (pH 9.6) 
(60 ng in 50 jllI  per well) and incubated at 4°C overnight. The wells were blocked with 
100 j-il of 10% FCS in PBS for 2 h at 37°C. Plates were subsequently washed three 
times with PBS containing 0.05% Tween 20, and 100 ]il of serum samples (diluted 
1:50) or lung washes (diluted 1:5) in 10% FCS in PBS was added to each well. After 
2 h at 37°C, the plates were again washed, and 100 |il of HRP conjugated rabbit anti­
mouse antibody for IgG or IgA heavy chains (Kirkegaard and Perry Laboratories) 
diluted 1:2,000 and 1:400 respectively in 10% FCS in PBS was added to each well 
and incubated for 2 h at 37°C. The plates were again washed and then developed by 
the addition of 100 pi of substrate solution (Appendix G.iii). After an appropriate time 
at room temperature, the reaction was stopped by the addition of 50 (il of 2 M H2SO4 
and the A450 was determined with a Bio-rad Model 3550 microplate reader. Each 
serum or lung wash sample was individually assayed, and control PBS immunised 
mice were used as the blank for ELISA reading. The titre was expressed as the 
reciprocal of the highest dilution of test serum or lung wash that gave an absorbance 
reading twice that of background. The background absorbance was determined using 
PBS immunised mice sera. Western blot analysis of sera from vaccinated mice was 
performed as described above to determine the subunit specificity of the antibody 
response. Sera from mice immunised with pertussis toxoid was diluted 1:1,000 whilst 
all other sera from vaccination experiments was diluted 1:16.
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2.9.3 Intracerebral Challenge
The Kendrick test (Kendrick et al., 1947) was used to test the efficacy of experimental 
pertussis vaccines and was performed at the Therapeutic Goods Administration, 
Sym onston, A ustralia. Five week old female ARC Swiss female mice were 
immunised and caged separately in groups of 16. The mice were anaesthetised using 
0.2 ml of a 6 mg/ml solution of Nembutal (Boehringer Ingelheim) administered 
intraperitoneally. The mice were then orally immunised with one dose of the cell 
suspension or PBS on day 0, then challenged intracerebrally with 20 fil of 10"3-3 of
B. pertussis 18-323 (TGAL passage 18323 L6dH4, 2nd passage B5/6-7/6 1982) 
using a Hamilton syringe on day 14. The mice were then held for 14 days then the 
number of survivors were counted. Mice that died within 48 h following challenge 
were excluded from the assay. The reference vaccine used for this assay was the 
A ustralian standard for pertussis, SS546 (CSL, A ustralia) adm inistered 
intraperitoneally (C dose, which consists of killed B. pertussis cells, and is formulated 
to give 50% survival after challenge).
2.10.1 Statistical Analysis
Antibody responses for specific isotypes between treatment groups within the same 
ELISA series were compared using a Tukey multiple comparison test for unequal 
sample sizes as described by Zar (1984).
61
3 . RESULTS
3 .1  Expression of Pertussis Toxin in E. coli
The expression of PT in E. coli w ould represents a major step towards the 
development of new generation recombinant pertussis vaccines. Using E. coli as a 
host it may be possible to obtain higher yields of PT with less expense compared to 
expression in Bordetella spp. However, there has been little success in expressing 
native PT subunits or holotoxin in E. coli from B. pertussis promoters. This is 
probably due to differences in the ribosomal binding sites and promoter recognition 
sequences between E. coli and B. pertussis (Nicosia et al., 1987). In one notable 
study (Burnette et al., 1988a), all the PT subunits apart from S4 were expressed in 
E. coli with their native leader sequences attached; the S 1 subunit was the only 
subunit completely processed. The replacement of the native leader sequence with a 
methionine initiation codon resulted in the production of mature protein, in the form 
of insoluble inclusion bodies for the five PT subunits. The work presented in this 
section represents a novel method of overcoming the difficulties encountered in the 
expression of foreign proteins in E. coli, and shows that a recombinant PT operon 
can be expressed in this host whilst still using, in the most part, native leader 
sequences. PT subunit expression in E. coli has been achieved by utilising a cloning 
strategy that enables the foreign proteins to be expressed using bacteriophage 
Lambda Pr  and Pl  promoters and an E. coli ribosomal binding site located upstream 
of the cloning site.
3 .1 . 1  PCR Amplification of the Pertussis Toxin Genes
The individual PT subunits genes encoding SI to S5 were amplified from the native 
PT operon (Locht and Keith, 1986) using primers that incorporated a 5' NdeI site 
and a 3' EcoRl site in the oligonucleotide sequence (Table 6). All PT subunit genes
shown in Figure 8 were amplified without the replacement of their native leader 
sequences.
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Figure 8. Agarose gel electrophoresis of PCR amplified PT subunit genes. Lane 1, SI; lane 2, S2; 
lane 3, S3; lane 4, S4; lane 5, S5. Lane 6 contains Lambda HindlU molecular weight markers, the 
size of which, in base pairs, are indicated by arrows.
3 .1 .2  E xpression of the Indiv idual Pertussis Toxin Subunit Genes in 
E. coli C A G 6 2 9
Following PCR amplification, the individual PT genes were cloned into the PCR 
cloning vector pCR™II (2.5.1.1) via use of the A overhang generated by Taq DNA 
polymerase during PCR amplification. Figure 9 represents the strategy used to clone 
PT subunit genes into pCR™II; in this case the SI subunit gene was cloned into
pCR™II.
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All PT subunit gene PCR products were then subcloned into the expression vector 
pJLA506 using the restriction enzymes Ndel and EcoRl (Figure 10A). Subsequently 
it was found that the S4 subunit was not expressed from pJLA506 in E. coli 
CAG629 (result not shown). Thus, in the case of the S4 subunit gene a new 5' 
primer was synthesised. This primer encoded an NheI restriction enzyme site and the 
COOH-terminus of a modified 6-lactamase leader sequence (Table 6) which, when 
subcloned into the vector pCGVl with Nhe  I and E coR l restriction enzymes, 
reconstituted the modified 6-lactamase signal peptide (Guzman et al., 1994) (Figure 
10B).
The expression plasmids containing the individual PT subunit genes were 
transformed (2.5.6) into the protease deficient E. coli CAG629 (Table 5). A protease 
deficient E. coli strain was used to prevent the possible degradation of PT subunits 
following induction of expression. After induction (2.7.1) of mid log-phase cultures 
at 42°C for 1 h, whole cell extracts were subjected to SDS-PAGE (2.7.2). 
Electrophoresed proteins were visualised by staining the gel with Coomassie blue 
(2.7.3) or Western blot analysis (2.7.5). Recombinant SI, S2, S3, S4 and S5 were 
detected at levels significantly higher than those found in B. pertussis Tohama I 
(Figure 11A-F). In contrast to a previous study (Burnette et al., 1988a), each subunit 
was at least partially processed as assessed by analysis of the molecular weights of 
immunoreactive gene products suggesting that each subunit is being secreted into the 
E. coli periplasm.
3 .1 .3  G row th  R ate of E. coli CAG629 S tra ins Expressing the
Ind iv idual Pertussis Toxin Subunits following T em pera tu re  
In d u c tio n
The possibility that the expression of foreign proteins in E. coli CAG629 may be 
detrimental to cell physiology was addressed by assessing the growth rate of strains
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All PT subunit gene PCR products were then subcloned into the expression vector 
pJLA506 using the restriction enzymes NdeI and EcoRl (Figure 10A). Subsequently 
it was found that the S4 subunit was not expressed from pJLA506 in E. coli 
CAG629 (result not shown). Thus, in the case of the S4 subunit gene a new 5’ 
primer was synthesised. This primer encoded an Nhel restriction enzyme site and the 
COOH-terminus of a modified 13-lactamase leader sequence (Table 6) which, when 
subcloned into the vector pCGV l with N hel and E coR l restriction enzymes, 
reconstituted the modified 13-lactamase signal peptide (Guzman et al., 1994) (Figure 
10B). This vector had previously successively been used to express and secrete the 
serotype 2 fimbriae in E. coli (Walker et al., 1990).
The expression plasmids containing the individual PT subunit genes were 
transformed (2.5.6) into the protease deficient E. coli CAG629 (Table 5). A protease 
deficient E. coli strain was used to prevent the possible degradation of PT subunits 
following induction of expression. After induction (2.7.1) of mid log-phase cultures 
at 42°C for 1 h, whole cell extracts were subjected to SDS-PAGE (2.7.2). 
Electrophoresed proteins were visualised by staining the gel with Coomassie blue 
(2.7.3) or Western blot analysis (2.7.5). Recombinant SI, S2, S3, S4 and S5 were 
detected at levels significantly higher than those found in B. pertussis Tohama I 
(Figure 11A-F). In contrast to a previous study (Burnette et al., 1988a), each subunit 
was at least partially processed as assessed by analysis of the molecular weights of 
immunoreactive gene products suggesting that each subunit is being secreted into the 
E. coli periplasm.
3 .1 . 3  Growth Rate of E. coli CAG629 Strains Expressing the
Individual Pertussis Toxin Subunits following Temperature 
Induction
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Figure 9. A schematic representation of cloning of the SI subunit gene into pCR™n. The PT 
subunit gene (SI) was amplified by PCR using the SI 5' Ndel and 3' £c<?RI primers, then ligated 
into the cloning vector pCR™II. PT subunit genes SI to S5 (open arrows) and the PT promoter 
(filled arrow) are indicated. The pCR™II cloning vector contains the lacZ alpha fragment and 
multiple cloning site (open arrow), FI origin (cross hatched box), pBR322 origin (ori), Kanamycin 
(Kan) and Ampicillin (Amp) resistance genes (open boxes). The direction of transcription is 
indicated either by thin arrows or the orientation of open arrows. Plasmids are not drawn to scale, 
and only relevant restriction sites are shown.
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Figure 10. Plasmid vectors for the expression of single PT subunits. Expression vector (A), 
pJLA506 was used to express the PT subunit genes SI, S2, S3 and S5 (open arrows) whilst (B), 
pCGVl, a derivative of the former which contains the NH2 -terminal of the modified 8-lactamase 
signal sequence (filled box) was used to express the S4 subunit (open arrow). Both expression 
plasmids contain the Lambda promoters Pr  and Pl  (filled arrows), atpE ribosomal binding site 
(between the Xhol and Ndel restriction enzyme sites of the vectors), bacteriophage fd transcriptional 
terminator (cross-hatched box), ampicillin resistance gene and Lambda c l ^ 57 temperature sensitive 
represser gene (open boxes). Plasmid pCGVl also contains an alkaline phosphatase gene (open 
box). The direction of transcription is given either by thin arrows or the orientation of open arrows. 
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Figure 11. Expression of individual PT subunits in E. coli CAG629 compared with PT expression 
in B. pertussis Tohama I. In all panels lane 1 contains CAG629 (pJLA506) except panel D which 
contains CAG629 (pCGVl). Lane 2 contains the recombinant PT expression plasmid in CAG629: 
panel A, SI; panel B, S2; panel C, S3; panel D, S4; panel E, S5. In all panels lane 3 contains B. 
pertussis Tohama I and lane 4 contains purified PT. Panel F shows the Coomassie stained gel 
corresponding to panel A. The filled arrowheads indicate processed PT subunits whilst the open 
arrowheads indicate PT subunit pre-proteins.
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harbouring the individual PT subunits following temperature induction. The growth 
rate of E. coli CAG629 either alone or harbouring the expression plasmid pJLA506 
remained the same and was not adversely affected by temperature induction at 42°C 
(2.7.1) (Figure 12A). However all strains harbouring PT expression plasmids, apart 
from S I, showed a decrease in growth rate compared to vector only strains 
following temperature induction at 42°C (Figure 12B-F).
3 .1 .4  C onstruc tion  of a Synthetic Pertussis Toxin O peron
Since the expression of all five PT subunits in E. coli CAG629 proved successful, 
the next goal towards recombinant PT production in E. coli was to express the PT 
subunits simultaneously in this host, using a single expression vector. Thus, a 
stepwise cloning strategy for the construction of a synthetic PT operon was 
developed by employing a pair of restriction enzymes that generate identical sticky 
ends after restriction enzyme digestion of DNA. The expression vectors pJLA506 
and pCG V l both contain a unique X h o l  site adjacent to and 5' of the vector 
ribosome binding site. Each plasmid also contains a Sail site 3' and adjacent to the 
stop codon. In this work, for instance, the S5 subunit was cloned as a Xhol/Sall 
fragment into the Xhol site of the S 1 expression plasmid; a recombinant operon was 
formed where both subunits are in the same orientation. As Sail and Xhol restriction 
fragments have the same "sticky ends” they ligate together, disrupting the recognition 
sequence of both enzymes. Thus the S5+S1 operon produced, once again contains a 
single X h o l restriction site (Figure 13). Repetition of this cloning process has 
yielded a synthetic operon containing the 5 PT subunits.
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harbouring the individual PT subunits following temperature induction. The growth 
rate of E. coli CAG629 either alone or harbouring the expression plasmid pJLA506 
remained the same and was not adversely affected by temperature induction at 42°C 
(2.7.1) (Figure 12A). However all strains harbouring PT expression plasmids, apart 
from SI, showed a decrease in growth rate compared to vector only strains 
following temperature induction at 42°C (Figure 12B-F). The growth rate of E.coli 
CAG 629 expressing pJLA506 was equivalent to that of E. coli CAG629 (pCGVl) 
(results not shown).
3 . 1 .4  Construction of a Synthetic Pertussis Toxin Operon
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the next goal towards recombinant PT production in E. coli was to express the PT 
subunits simultaneously in this host, using a single expression vector. Thus, a 
stepwise cloning strategy for the construction of a synthetic PT operon was 
developed by employing a pair of restriction enzymes that generate identical sticky 
ends after restriction enzyme digestion of DNA. The expression vectors pJLA506 
and pCG V l both contain a unique X ho l site adjacent to and 5' of the vector 
ribosome binding site. Each plasmid also contains a Sail site 3' and adjacent to the 
stop codon. In this work, for instance, the S5 subunit was cloned as a Xhol/Sall 
fragment into the Xhol site of the S1 expression plasmid; a recombinant operon was 
formed where both subunits are in the same orientation. As Sail and Xhol restriction 
fragments have the same "sticky ends" they ligate together, disrupting the recognition 
sequence of both enzymes. Thus the S5+S1 operon produced, once again contains a 
single X ho l restriction site (Figure 13). Repetition of this cloning process has 
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Figure 12. Growth curves of E. coli CAG629 expressing the individual PT subunits following 
temperature induction at 42°C. Panel A, CAG629 and CAG629 (pJLA506); panel B, CAG629 
(pJLA506) and CAG629 (pJLA506 SI); panel C, CAG629 (pJLA506) and CAG629 (pJLA506 S2); 
panel D, CAG629 (pJLA506) and CAG629 (pJLA506 S3); panel E, CAG629 (pJLA506) and 
CAG629 (pCGVl S4); panel F, CAG629 (pJLA506) and CAG629 (pJLA506 S5). The time of 
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Figure 13. Construction of plasmids for the expression of multiple PT subunits. Each atpE 
ribosomal binding site and PT subunit gene flanked by 5’ Xhol and 3' Sail restriction enzyme sites 
is indicated as an open arrow. The 6-lactamase leader sequence (filled box) fused to the mature S4 
subunit is also indicated. Both expression plasmids contain the Lambda promoters Pr  and Pl  (filled 
arrows), bacteriophage fd transcriptional terminator (cross-hatched box), ampicillin resistance gene 
and Lambda cl^857 temperature sensitive represser gene (open boxes). The direction of transcription 
is given either by thin arrows or the orientation of open arrows. Plasmids are not drawn to scale, and 
only relevant restriction sites are shown.
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3 .1 .5  Simultaneous Expression of Pertussis Toxin Subunits in E. coli
Using the cloning strategy described previously, a number of plasmid constructs 
possessing different combinations of PT subunit genes were assessed for PT subunit 
expression in E. coli (Figure 15). To investigate expression, the following E. coli 
strains were used: CAG629, EC538, H179, KS476, YA21 and 876. These host 
strains were chosen since they possess genotypes that favour the expression of 
foreign proteins (Table 5). In this cloning strategy, for instance, the S2 gene was 
cloned 5* of SI, resulting in pDP13, which was found to be capable of expression of 
S2 and SI in the six E. coli strains investigated. The S5 gene was then cloned 5' of 
S2 in pDP13 to produce pDP15 (S5+S2+S1). In this case however, expression of 
the three PT genes was variable, depending on the E. coli host; SI (Figure 14, lane 
6), S2 and S5 (result not shown) were expressed in EC538, H179, KS476, YA21 
and 876, but not in CAG629. The addition of S4, 5' of S5 in pDP15 resulted in 
pDP17 (S4+S5+S2+S1). Variable expression of PT subunit genes was also 
observed in this construct; the addition of S4 abolishing expression of the proximal 
S5 subunit in all six E. coli strains, whilst SI (Figure 14, lane 7) and S2 (result not 
shown) were expressed in EC538, and all other E. coli strains except CAG629 
(result not shown). Another series of constructs were produced, whereby S5 was 
cloned 5’ of S 1, generating pDPl 1; S 1 (Figure 14, lane 4) and S5 (result not shown) 
were expressed by this construct in E. coli EC538 and in the other E. coli strains. 
The addition of S2 5’ of S5 in p D P ll produced pDP18 (S2+S5+S1); in this 
construct SI and S2 were expressed, whilst S5 was not detected, which was the 
case for all the E coli strains investigated (results not shown). The replacement of S2 
with S4 in pDP18 generated pDP12 (S4+S5+S1). In this construct S4, S5 and SI 
were expressed in all six E. coli strains. Two similar constructs, pDP14 (S2+S3) 
and pDP19 (S3+S2), were also produced, both capable of expressing S2 and S3 in 
all E. coli strains. The DNA fragments containing S2 and S3 in pDP14 and pDP19 
were then cloned 5’ of S4 in pDP12 resulting in pDP16 (S2+S3+S4+S5+S1) and
7 1
pDP2Q (S3+S2+S4+S5+S1) respectively, all five PT subunit genes were expressed 
in both of these construct in all six E. coli strains investigated (Figure 15).
1 2 3 4 5 6 7 8
Figure 14. Representative Western blot analysis of SI subunit expression in E. coli EC538. Lane 1 
contains the E. coli CAG629 (pJLA506 SI); lane 2, E. coli EC538 (pJLA506); lane 3, E. coli 
EC538 (pJLA506 SI); lane 4, E. coli EC538 (pDPll); lane 5, E. coli EC538 (pDP13); lane 6, E. 
coli EC538 (pDP15); lane 7, E. coli EC538 (pDP17); lane 8 contains purified PT. The SI subunit 
of PT was detected using anti-Sl antiserum. The filled arrowhead indicates processed SI subunit 
protein, whilst the open arrowhead indicates SI subunit pre-protein.
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Expression of individual subunits
SI S2 S3 S4 S5
- - - -
pDP13 Efxsr> + +
pDP15 n £ > H 2 > t i C > + / - +/- +/-
pDP17 lg>C«C>lll>+/- +/- + -
p D P ll g>m>+ +
pDP18 m>n|>[sT>+ + -
pDP12 nB>6XiC>+ + +
pDP14 HD€> + +
pDP16 + + + +
pDP19 [ ¡ 3 > [ S 2 > + +
pDP20 + + + +
Figure 15. Simultaneous expression of multiple PT subunits in E. coli. PT subunit gene constructs 
shown with their corresponding ability to express subunit proteins in E. coli. The wild type PT 
operon is not expressed in E. coli (Nicosia et al., 1986) (shaded arrows). Recombinant PT subunit 
genes are given as open arrows; expression is indicated by a plus symbol (+) whilst no detectable 
expression is indicated by a minus symbol (-). For certain constructs, PT subunit expression was 
detected in all E. coli strains tested except E. coli CAG629 (+/-).
The plasmids (pDP20 and pDP16) harbouring the five PT subunits differed only in 
the orientation of the S2 and S3 subunit genes. It was noted that in pDP20 
expression of the S2 subunit was reduced compared to expression of this subunit in 
pDP16 (result not shown), thus pDP16 was used for subsequent work. Western blot 
analysis of PT subunit expression in E. coli KS476 containing the synthetic PT 
operon (pDP16), indicated that S4 and S5 were completely processed, SI was 
partially processed, whilst the majority of S2 and S3 remained unprocessed (Figure 
16A-D).
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Figure 16. Western blot analysis of PT subunit expression in E. coli KS476 containing pDP16. In 
all panels lane 1 contains KS476 (pJLA506), except in panel C which contains KS476 (pCGVl), 
whilst lane 2 contains the recombinant single PT subunit expression plasmid in KS476: panel A, 
SI; panel B, S2; panel C, S4; panel D, S5. Panel B lane 2* contains KS476 bearing the S3 subunit 
expression plasmid. Lane 3 contains KS476 (pDP16). Lane 4 contains purified PT. PT subunits 
were detected using specific antiserum: panel A, anti-Sl; panel B, anti-S2 and S3; panel C, anti-S4, 
and panel D, anti-S5. The filled arrowheads indicate processed PT subunits whilst the open 
arrowheads indicate PT subunit pre-proteins.
3 .1 .6  DNA Sequence A nalysis of pDP16
The recombinant PT operon (pDP16) constructed in this study was confirmed by 
DNA sequence analysis (2.6; Sanger et al., 1977) The DNA sequence of the 
synthetic PT operon of pDP16 is shown in Figure 17.
X h o l
CTCGAG XAATT*TAClr AA CATTA rT&CGTTTTAACTGAAACAAACTQQAQACTCAT ATG CCG ATC GAC CGC AAG ACG CTC TGC CAT CTC CTG TCC
M et Pro H e A sp A r g L y s Thr Leu C ys HI n [.Oil U ni
GTT CTG CCG TTG GCC CTC CTC GGA TCT CAC GTG GCG CGG g c c T t c c ACG CCA GGC ATC GTC ATT CCG CCG CAG GAA CAG ATT ACC
L eu Pro L eu A la Leu Leu G l y S e r H is V a l  A la A rg A la S e r T hr Pro G l y H e V a l H e Pro Pro G in G lu G in l i e Thr
CAG CAT GGC AGC CCC TAT GGA CGC TGC GCG AAC AAG ACC CGT GCC CTG ACC GTG GCG GAA TTG CGC GGC AGC GGC GAT CTG CAG
G in H is G l y S e r Pro T y r G l y A rg C y s A la A sn  L y s T hr A rg A la Leu T hr V a l A l a G lu Leu A rg G l y S e r G l y A sp Leu G in
GAG TAC CTG CGT CAT GTG ACG CGC GGC TGG TCA ATA IT T GCG CTC TAC GAT GGC A CC TAT CTC GGC GGC GAA TAT GGC GGC GTG
G l u T y r L eu A r g H is V a l T hr A rg G l y T rp S e r  M et Phe A l a Leu T y r A sp G l y T hr T y r Leu G l y G l y G lu T yr G l y G l y V al
ATC AAG GAC GGA ACA CCC GGC GGC GCA TTC GAC CTG AAA ACG ACG TTC TGC ATC ATG ACC ACG CGC AAT ACG GGT CAA CCC GCA
l i e L y s A sp G l y T hr Pro G l y G l y A la Phe A sp  Leu L y s T hr T hr Phe C y s H e M et T h r T hr A rg Asn Thr G l y G in P ro A la
ACG GAT CAC TAC TAC AGC AAC GTC ACC GCC A CT CGC CTG CTC TCC AGC ACC AAC AGC AGG CTA TGC GCG GTC TTC GTC AGA AGC
T h r A sp H is T y r T y r S e r A sn V a l T hr A la T hr A r g Leu Leu S e r S e r T hr A sn S e r A r g Leu C y s A la V a l Phe V a l A rg S e r
GGG CAA CCG GTC ATT GGC GCC TGC ACC AGC CCG TAT GAC GGC AAG TAC TGG AGC ATG TAC AGC CGG iTTG CGG AAA ATG CTT TAC
G l y G in P ro V a l H e G l y A la C y s T hr S e r Pro T y r A sp G l y L y s T y r T rp S e r M et T y r S e r A rg Leu A rg L y s Met Leu T y r
CTG ATC TAC GTG GCC GGC ATC TCC GTA CGC GTC CAT GTC AGC AAG GAA GAA CAG TAT TAC GAC TAT GAG GAC GCA ACG TTC GAG
L eu H e T y r V a l A la G l y H e S e r V a l A rg V a l  H is V a l S e r L y s G lu G lu G in T y r T y r A sp T yr G lu Asp A la Thr Phe G lu
F co R I BamHl [ S a ll / X h o l)
ACT TAC G CC CTT ACC GGC ATC TCC ATC TGC AAT CCT GGA TCA TCC TTA TGC TGA GACGCT GAATTC GGATCC GTCGAG TAA TTT
T h r T y r A l a L eu T h r G l y H e S e r H e C y s A sn  Pro G l y S e r S e r L eu C y s S t o p
a c c a a c a c t a c t a c g t t t t a a c t g a a a c a a a c t q q a q a c t c a t ATG CTG ATC AAC AAC AAG AAG CTG CTT CAT CAC ATT CTG CCC ATC CTG
M et Leu H e A sn A sn L y s L y s L eu Leu H is H is H e Leu Pro H e Leu
GTG CTC GCC CTG CTG GGC ATG CGC ACG GCC CAG GCCTGTT GCG CCA GGC ATC GTC ATC CCG CCG AAG GCA CTG TTC ACC CAA CAG
V a l L eu A l a L eu Leu G l y M et A rg T hr A la G in  A la V a l A la Pro G l y H e V a l H e Pro Pro L y s A la Leu Phe Thr G in G in
GGC GGC G CC TAT GGA CGC TGC CCG AAC GGA A CC CGC GCC TTG ACC GTG GCC GAA CTG CGC GGC AAC GCC GAA TTG CAG ACG TAT
G l y G l y A l a T y r G l y A rg C y s Pro A sn G l y T h r A r g A la L eu Thr V a l A la G lu L eu A r g  G l y Asn A la G lu Leu G in T hr T yr
TTG CGC CAG ATA ACG CCC GGC TGG TCC ATA TAC GGT CTC TAT GAC GGT ACG TAC CTG GGC CAG GCG TAC GGC GGC ATC ATC AAG
L eu A r g G in M et T hr Pro G l y T rp S e r M et T y r  G l y Leu T y r A sp  G l y T hr T y r Leu G l y  G in A la T yr G l y  G l y l i e l i e L y s
GAC GCG CCG CCA GGC GCG GGG TTC ATT TAT CGC GAA ACT TTC TGC ATC ACG ACC ATA TAC AAG ACC GGG CAA CCG GCT GCG GAT
A sp A l a P ro P ro G l y A la G l y Phe H e T y r A r g  G lu T hr Phe C y s H e Thr T hr M et T y r L y s Thr G l y G in Pro A la A la A sp
CAC TAC TAC AGC AAG GTC ACG GCC ACG CGC CTG CTC GCC AGC ACC AAC AGC AGG CTG TGC GCG GTA TTC GTC AGG GAC GGG CAA
H i s T y r T y r S e r L y s V a l Thr A la T hr A rg L eu  Leu A la S e r T hr A sn S e r A rg L eu C y s A la V a l Phe V a l A rg A sp G l y G in
TCG GTC ATC GGA GCC TGC GCC AGC CCG TAT GAA GGC AGG TAC AGA GAC ATG TAC GAC GCG CTG CGG CGC CTG CTG TAC ATG ATC
S e r V a l H e G l y A la C y s A la S e r Pro T y r G lu  G l y A rg T y r A rg A sp M et T y r  A sp A l a Leu A rg A rg Leu Leu T yr Met l i e
TAT ATG T CC GGC CTT G CC GTA CGC GTC CAC GTC AGC AAG GAA GAG CAG TAT TAC GAC TAC GAG GAC GCC ACA TTC CAG A CC TAT
T y r M et S e r G l y L eu A la V a l A rg V a l H is V a l  S e r L y s G lu G lu G in T y r T y r  A sp T y r G lu A sp A la Thr Phe G in Thr T yr
F c o R I BamH I ( S a ll/ X h o l)
G CC CTC A CC GGC ATT TCC CTC TGC AAC CCG GCA GCG TCG ATA TGC TGA GCCGCC GAATTC GGATCC GTCGAG TAA TTTACCAA CACTA
A l a L eu T h r G l y H e S e r L eu C y s A sn Pro A l a  A la S e r H e C y s S t o p
Mie  I
CTACGTTTTAACTGAAACAAACTqOAQACTCAT ATG AGT ATT CAA CAT TTC CGT GTC GCC CTT ATT CCC TTT IT T GCT AGC TTT TGC CTT
Met S e r  H e Gin H i s Phe Arg Val A l a L eu l i e Pro Phe Phe Ala S e r Phe Cys Leu
CCT GTT TTT g c t Tg a c GTT CCT TAT GTG CTG GTG AAG A CC AAT ATG GTG GTC ACC AGC GTA GCC ATG AAG CCG TAT GAA GTC ACC
Pro Val Phe A l a A sp V a l Pro T y r V a l Leu V a l  L y s T h r A sn M et V a l V a l T hr S e r V a l A la Met L y s Pro Tyr G lu V a l Thr
CCG ACG CGC ATG CTG GTC TGC GGC ATC GCC GCC AAA CTG GGC GCC GCG GCC AGC AGC CCG GAC GCG CAC GTG CCG TTC TGC TTC
P ro T h r A r g M e t L eu V a l C y s G l y l i e A la A l a  L y s L eu G l y A la A l a A la S e r S e r Pro A sp A la H is V a l Pro Phe C y s Phe
GGC AAG GAT CTC AAG CGT CCC GGC AGC AGT C CC ATG GAA GTC ATG TTG CGC GCC GTC TTC ATG CAA CAA CGG CCG CTG CCC ATS
G l y L y s A sp L eu L y s A r g Pro G l y S e r S e r P ro M et G lu V a l M et Leu A rg A l a V a l Phe M et G in G in A rg Pro Leu A rg Met
TTT CTG GGT CCC AAG CAA CTC ACT TTC GAA GGC AAG CCC GCG CTC GAA CTG ATC CGG ATG GTC GAA TGC AGC GGC AAG CAG GAT
Phe Leu G l y Pro L y s G in Leu Thr Phe G lu G l y  L y s Pro A la Leu G lU Leu H e A rg Met V a l G lu C y s S e r G J y L ys G in A sp
Eco  R I BajnHl ( S a i l / X h o l ) S S
TGC C CC TGA AGGCGA GAATTC GGATCC GTCGAG TAATTTACCAACACTACTACGTTTTAACTGAAACAAACTGGAGACTCAT ATG CAT ACC ATC 
C y s  P ro  S t o p  M et H is  Thr I l e
GCA T CC ATC CTG TTG T CC  GTG CTC GGC ATA TAC AGC CCG GCT GAC GTc Tg CC  GGC TTG CCG A CC CAT CTG TAC AAG AAC TTC ACT  
A l a  S e r  I l e  L eu  L eu  S e r  V a l  L eu  G l y  M et T y r  S e r  Pro A l a  A sp  V a l  A l a  G l y  L eu  Pro T hr H is  Leu T yr L y s  A sn Phe Thr
GTC CAG GAG CTG GCC TTG AAA CTG AAG GGC AAG AAT CAG GAG TTC TGC CTG ACC GCC TTC ATG TCG GGC AGA AGC CTG GTC CGG
V a l  G in  G iu  L e u  A l a  L eu  L y s  L eu  L y s  G l y  L y s  A sn  G in  G iu  Phe C y s  L eu  T hr A l a  Phe M et S e r  G l y  A rg  S e r  Leu V a l A rg
GCG TGC CTG T CC  GAC GCG GGA CAC GAG CAC GAC ACG TGG TTC GAC ACC ATG CTT GGC TTT GCC ATA TCC GCG TAT GCG CTC AAG
A l a  C y s  L eu  S e r  A sp  A l a  G l y  H is  G iu  H is  A sp  T hr T rp  Phe A sp  T hr M et Leu G l y  Phe A la  Met S e r  A la  T y r  A la  Leu L ys
AGC CGG ATC GCG CTG ACG GTG GAA GAC TCG CCG TAT CCG GGC ACT C CC GGC GAT CTG CTC GAA CTG CAG ATC TGC CCG CTC AAC



































































F e o R I BamHl ( S a l l / ^ h o l )
GAA
G lu
TGA ACCCT T  < 
S t o p




GCA ATT CGC CAA ACC GCA AGA ACA GGC TGG CTG ACG TGG CTG GCG ATT CTT GCC GTC ACG GCG CCC GTG ACT TCG
A la H e A rg G in T hr A la A rg T hr G l y Trp Leu Thr T rp Leu A la l i e Leu A la V a l Thr A la Pro V a l Thr S e r
GCC L a c GAT CCT CCC GCC ACC GTA TAC CGC TAT GAC TCC CGC CCG CCG GAG GAC GTT TTC CAG AAC GGA TTC ACG
A l a A sp A sp Pro Pro A la T hr V a l i y r A rg T yr A sp S e r A rg Pro Pro G lu A sp V a l Phe G in A sn G l y Phe Thr
AAC GAC AAT GTG CTC GAC CAT CTG ACC GGA CGT TCC TGC CAG GTC GGC AGC AGC AAC AGC GCT TTC GTC TCC
A sn A sn A sp A sn V a l Leu A sp H is Leu Thr G l y A rg S e r C y s G in V a l G l y S e r S e r A sn S e r A la Phe V a l S e r
CGC TAT ACC GAG GTC TAT CTC GAA CAT CGC ATG CAG GAA GCG GTC GAG GCC GAA CGC GCC GGC AGG GGC
S e r A rg A r g T y r T hr G lu V a l T yr Leu G lU H is A rg M et G in G lu A la V a l G lu A la G lu A rg A la G l y A rg  G ly  S a i l
GGC TAC ATC TAC GAA GTC CGC GCC GAC AAC AAT TTC TAC GGC GCC GCC AGC TCG TAC TTC GAA TAC GTC
Phe l i e G l y T y r l i e T yr G lu V a l A rg A la A sp A sn A sn Phe T yr G l y A la A la S e r S e r T yr Phe G lu T yr
GCC GGC CGT ATC CTC GCC GGC GCG CTG GCC ACC TAC CAG AGC GAA TAT CTG GCA CAC CGG CGC ATT
G l y A sp A sn A l a G l y A rg l i e Leu A la G l y A la Leu A la T hr T y r G in S e r G lu Tyr Leu A la H is A rg A rg
AGG GTA ACG CGG GTC TAT CAC AAC GGC ATC ACC GGC GAG ACC ACG ACC ACG GAG TAT TCC AAC GCT
A sn l i e A r g A rg V a l T hr A rg V a l T yr H is A sn G l y l i e T hr G l y G lu T hr T hr Thr Thr G lu T y r S e r
A sn A la
A CT CGC GCC AAT CCC AAC CCC TAC ACA TCG CGA AGG TCC GTA GCG TCG ATC GTC GGC ACA TTG GTG
S e r G in G in T h r A rg A la A sn Pro A sn Pro T y r Thr S e r A rg A rg S e r V a l A la S e r
H e V a l G l y T hr Leu


































S e r  S e r  G lu  A la  M et A l a  A la  Trp S e r  
E c o R I BamHl Sal  I 
TAG ACCTGG GAATTC GGATCC GTCGAC 
S t o p
G lu A rg A la G l y G lu
Figure 17. The 3308 base pair nucleic acid sequence of the recombinant PT operon encoded by 
pDP16 which directs expression of the five PT subunits in E. coli. The atpE translation initiation 
region is underlined, whilst the Shine-Dalgamo sequences are given in bold print. The leader peptide 
processing points for each subunit are given by arrows and the modified 8-lactamase leader peptide 
fused to the S4 subunit is italicised. Relevant restriction enzyme sites are given above the nucleotide 
sequence whilst sites where Sail and Xhol restriction sites have ligated together are indicated in 
brackets above the nucleotide sequence (Sall/Xhol).
3 .1 .7  Growth Rate of E. coli KS476 (pDP16) following Temperature 
Induction
The growth rate of E.coli KS476 harbouring the recombinant PT operon was 
assessed following temperature induction at 42°C. It was found that E. coli KS476 
(pDP16) showed a reduction in growth compared to vector only or plasmid-less 
strains following temperature induction at 42°C (Figure 18).
Time (min)
Figure 18. Growth rate o f E. coli KS476 (pDP16) following temperature induction at 42°C 
compared to vector-only or plasmid-less strains. The time of induction is indicated by an arrow.
3 .1 .8  C e llu la r L ocation  o f E xpressed  Pertussis Toxin Subun its in 
E. coli K S476 (pD P16)
Since all five PT subunits were shown to be at least partially processed in E. coli 
KS476, the possibility that periplasmic extracts may contain pertussis holotoxin was 
investigated by sub-cellular localisation experiments. Fractionation studies (2.5.8) 
using KS476 (pDP16) revealed that processed SI and S3 subunits (Figure 19) were 
found in the soluble periplasmic fraction after osmotic shock whereas S2 (Figure 
19B), S4 and S5 were not detected (results not shown), suggesting that the 
processed form of these subunits may be membrane associated or in an insoluble 
form. The majority of all PT subunit proteins detected in this assay were found to be 
cytoplasmic.
B
1 2 3 4 5
P>
Fieure 19 Western blot analysis o f KS476 (pDP16) fractionation experiments. In all panels lane 1 
contains whole cell extract; lane 2, cytoplasmic fraction; lanes 3. periplasmic fraction; lane 4, 
extracellular fraction; lane 5, purified PT. Panel B, lane 4 was taken ftom another western blot. PT 
subunits were detected using specific antiserum: panel A, anti-Sl, panel B anU-S2 and S3. e 
filled arrowheads indicate processed PT subunits whilst the open arrowheads indicate PT subunit pre­
proteins.
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3 .1 .9  D iscussion
The ability to express recombinant pertussis holotoxin in E. coli would provide a 
safe alternative to acellular whooping cough vaccine manufacture. In this research, 
the five PT genes have been individually expressed in E. coli CA G 629 and 
subsequently, a recombinant operon capable of simultaneously expressing the five 
PT genes has been constructed. The recombinant PT plasmids examined in this work 
were found to produce greater amounts of PT subunit protein compared to B . 
pertussis Tohama I. In contrast to a previous study (Burnette et aL, 1988a), we have 
achieved individual PT subunit expression using native leader sequences, and in the 
case of S4 using a modified leader sequence, with at least partial leader peptide 
processing of each subunit in E. coli CAG629.
For studies of simultaneous expression of PT subunits in E. coli, the results obtained 
indicated that expression of each subunit was dependent upon the position of each 
subunit gene in the synthetic operon. The positioning of the PT subunits in the 
following order, S2+S3+S4+S5+S1 (pDP16) and S3+S2+S4+S5+S1 (pDP20) 
resulted in expression of all five subunits. Signal peptide processing of the PT genes 
was found to be dependent on the host cell strain used; E. coli KS476 seemed to 
process the greatest amount of PT subunit protein especially for S4 and S5, 
compared to all other E. coli strains investigated. Fractionation experiments to 
determine the cellular location of PT subunits indicated that in E. coli KS476 
(pDP16), SI and S3 were exported to the periplasm. Processed forms of S2, S4 and 
S5 were not detected in soluble periplasmic extracts, indicating that these subunits 
may be in an insoluble form or membrane associated. Surprisingly, processed forms 
of SI and S3 were also detected in the extracellular fraction. The absence of SI and 
S3 pre-proteins in these fractions precludes the possibility that the supernatant 
contains the cellular contents of bacterial cells lysed during induction. Possibly, 
expression of the five PT subunits has resulted in a weakening of the E. coli outer
membrane, resulting in the release of the soluble periplasmic contents. The growth 
rate of E. coli KS476 (pDP16) following induction at 42°C was found to be reduced 
compared to vector only or plasmid-less strains (results not shown), indicating the 
expression of PT subunits in E. coli KS476 had an adverse effect on cellular 
physiology.
3 .2  Expression of Pertussis Toxin Subunits in S. typhim urium  
aroA spp.
The expression of PT subunits in S. typhimurium aroA would provide a means by 
which to deliver an oral pertussis vaccine; other B. pertussis antigens such as FHA 
(Guzman et aL, 1991a; Parker et al., 1990) and P69 (Strugnell et al., 1992) have 
previously been expressed in Salmonella spp. B. pertussis is a respiratory pathogen, 
thus vaccines capable of inducing local mucosal immune responses at the site of 
colonisation are desirable. Previous research has shown that it is possible to express 
the SI subunit of PT in Salmonella spp. either as a native protein (Walker et al., 
1992) or as a fusion to the tetanus toxin fragment C (Barry et al., 1996). 
Additionally, it was possible to stimulate a lung mucosal immune response in mice 
following oral (Walker et al., 1992) or intranasal (Barry et al., 1996) immunisation 
of mice with S. typhimurium aroA SL3261 and S. typhi CVD908 respectively. The 
PT subunits S2 to S5, have not previously been expressed in Salmonella spp. In this 
research, all five PT subunits were expressed in a vaccine strain of S. typhimurium 
aroA for oral immunisation against pertussis. The five PT subunits in the form of 
holotoxoid are thought to be required for the correct presentation of protective 
epitopes (Bartolini et al., 1988; Burnette et al., 1992b). S. typhimurium aroA strains 
were initially chosen as vaccine vectors in this work because aroA mutants of 
Salmonella spp. have been extensively characterised and are considered safe for 
human use (Tacket et al., 1992). S. typhimurium aroA SL3261 specifically, was 
chosen for expression and immunisation studies since it had previously been used
successfully to engender an immune response against the SI subunit in mice (Walker 
et al., 1992).
3 .2 .1  E xpression  of the Indiv idual Pertussis Toxin Subunit Genes in 
S. typh im urium  aroA
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To facilitate transformation into Salmonella vaccine strains, extracted plasmid DNA 
was first transformed into S. typhimurium aroA SL5283 R 'M +(Table 5). Plasmid 
DNA was subsequently extracted and transformed into S. typhimurium aroA  
SL3261. After induction of mid log-phase cultures (2.7.2) at 42°C for 1 h, whole 
cell extracts were subjected to SDS-PAGE (2.7.2) and then Coomassie blue staining 
(2.7.3) or Western blot analysis (2.7.5). Western blot analysis revealed that the 
recombinant S5 subunit was completely processed, whilst all other PT subunits were 
partially processed in S. typhimurium aroA SL3261 (Figure 20). All recombinant PT 
subunits were detected at levels significantly higher than those found in B. pertussis 
Tohama I (results not shown).
A  B
1 2  3 1 2 V  3
C
1 2  3
Figure 20. Western blot analysis o f individual PT subunit expression in S. typhimurium aroA  
SL3261. In all panels lane 1 contains SL3261 (pJLA506), except in panel C which contains 
SL3261 (pCG Vl), whilst lane 2 contains the recombinant single PT subunit expression plasmid in 
SL3261: panel A, SI; panel B, S2; panel C, S4; panel D, S5. Panel B lane 2’ contains SL3261 
bearing the S3 subunit expression plasmid. Lane 3 contains purified PT. PT subunits were detected 
using specific antiserum; panel A, anti-Sl; panel B, anti-S2 and S3; panel C, anti-S4; and panel D, 
anti-S5. The filled arrowheads indicate the processed PT subunits whilst the open arrowheads 
indicate PT subunit pre-proteins.
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3 .2 .2  Growth Rate of S. typhim urium  aroA  SL3261 Expressing 
Individual Pertussis Toxin Subunits
To determine whether PT subunit expression affected survival of S. typhimurium 
aroA SL3261, the growth rate of this strain following temperature induction at 42°C 
was investigated. All recombinant PT subunit expressing strains displayed some 
reduction in growth rate compared to vector only or plasmid-less strains (Figure 
21A-F). The growth rate of S. typhimurium aroA SL3261 expressing the SI subunit 
was least affected by temperature induction (Figure 21 A), whilst the S5 expressing 
strain showed the greatest decrease in growth rate following temperature induction at 
42°C (Figure 21F).
3 .2 .3  Simultaneous Expression of Pertussis Toxin Subunit Genes in 
S. typh im urium  aroA spp.
Following the expression of individual PT subunits in S. typhimurium aroA 
SL3261, the same strategy was used for simultaneous expression of subunits in this 
strains as for E. coli. A  number of different combinations of PT subunit genes were 
assessed for subunit production in S. typhimurium aroA SL3261 (Figure 22). The 
S2+S1 construct (pDP13) produced both subunits simultaneously but when S5 was 
added, expression of all three subunits was abolished (pDP15). However, when the 
S4 subunit was added to S5+S2+S1 (pDP17) expression of all subunits except S5 





Figure 21. Growth curves of S. typhimunum aroA SL3261 expressing the individual PT^subunits. 
Panel A, SL3261 and SL3261 (pJLA506); panel B, SL3261 (pJLA5(tf) and SL 326_1^A 506 S1); 
panel C, SL3261 (pJLA506) and SL3261 (pJLA506 S2); panel D, SL3261 (PJLA50Q and SL3261 
(pJLA506 S3); panel E, SL3261 (pJLA506) and SL3261 (pCGVl S4); panel F, SL3261 (pJLA506) 
and SL3261 (pJLA506 S5). Arrows indicate the time of induction.
SL3261
SL3261 (pJLA506) 
SL3261 (pJLA506 SI) 
SL3261 (PJLA506 S2) 
SL3261 (pJLA506 S3)
SL3261 (pCGVl S4) 
SL3261 (pJLA506 S5)
Time (min) Time (min)
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Figure 22. Western blot analysis o f SI subunit expression in S. typhimurium aroA SL3261. Lane 
1 contains SL3261 (pJLA506); lane 2, SL3261 (pJLA506 SI); lane 3, SL3261 (p D P ll); lane 4, 
SL3261 (pDP13); lane 5, SL3261 (pDP15); lane 6, SL3261 (pDP17); lane 7 contains purified PT. 
The SI subunit was detected using anti-Sl antiserum. The filled arrowhead indicated processed SI 
protein whilst the open arrowhead indicates SI pre-protein.
The addition of S2 to p D P ll abolished expression of S5 (pDP18). When S4 was 
added to S5+S1, expression of all subunits was maintained (pDP12). The addition 
of S2+S3 (pDP14) to this construct resulted in expression of the five PT subunits 
(S2+S3+S4+S5+S1) (pDP16). Similarly, the addition of S3+S2 (pDP19) to pDP12 
resulted in expression of the five subunit genes (pDP20) (Figure 23).
Expression of all subunits in the multiple PT expression constructs (pDP16) and 
(pDP20) was detected either at similar or lower levels to that of the individual 
recom binant PT subunits (results not shown). Western blot analysis of S. 
typhimurium aroA SL3261 (pDP20) indicated that the S2 subunit was poorly 
expressed from pDP20, additionally the growth rate of SL3261 containing pDP20 
was lower than that of SL3261 containing pDP16 (results not shown). Future 
expression studies therefore only utilised pDP16. The pDP16 construct was 
subsequently transformed in S. typhimurium aroA SL7207 (Table 5).
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Expression of individual subunits
SI S2 S3 S4 S5
pDP13 g > Q i >  + +
pDP15 - -
pDP17 + + -
pDP11 | 5 > f s T >  + +
pDP18 s > g > n > + +
-
pDP12 P ? > [ S 5 > f i T >  + + +
pDP14 m M O + +




g > g > i e > e > i s > + + + + +
Figure 23. Simultaneous expression o f multiple PT subunits in S. typhimurium aroA SL3261. PT 
subunit gene constructs are shown with their corresponding ability to express subunit proteins in S. 
typhimurium aroA. Recombinant PT subunit genes are given as open arrows; expression is indicated 
by a plus symbol (+) whilst no detectable expression is indicated by a minus symbol (-). The S4 
subunit has had the wild-type leader sequence replaced with a modified 6-lactamase leader sequence 
(open box).
8 4
This S. typhimurium aroA strain was used because it was considered less attenuated 
than SL3261 (C. Guzman, personal communication), therefore this strain should be 
theoretically better at engendering an immune response in subsequent immunisation 
studies. Analysis of the size of immunoreactive bands detected in Western blots 
indicated that in S. typhimurium aroA SL3261 (results not shown) and SL7207 
(Figure 24) containing the synthetic PT operon, S5 was completely processed and 
SI was partially processed, whilst S2, S3 and S4 remained unprocessed.
Figure 24. Simultaneous expression o f PT subunits in S. typhimurium aroA SL7207. In all panels 
lane 1 contains SL7207 (pJLA506), except in panel C which contains SL7207 (pCG Vl), whilst 
lane 2 contains SL7207 bearing pDP16. Lane 3 contains purified PT. PT subunits were detected 
using specific antiserum: panel A, anti-Sl; panel B, anti-S2 and S3; panel C, anti-S4; and panel D, 
anti-S5. The filled arrowheads indicate processed PT subunits whilst the open arrowheads indicate 
PT subunit pre-proteins.
3 .2 .4  G row th  R ate of S. typhim urium  aroA SL7207 (pDP16) 
follow ing T em p era tu re  Induction
The growth rate of S. typhimurium aroA SL3261 (pDP16) and SL7207 (pDP16) 
following temperature induction was determined. As was the case with the
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individually expressed subunits, S. typhimurium aroA SL3261 (result not shown) 
and S. typhimurium aroA SL7207 (Figure 25) expressing the recombinant PT 
operon showed a decrease in growth rate following temperature induction at 39.5°C 
or 42°C. The growth rate of S. typhimurium aroA SL3261 and S. typhimurium aroA 
SL7207 either alone or harbouring the expression plasmid pJLA506 were not 
adversely affected by temperature induction. Western blot analysis of the induced 
cultures indicated that at 37°C only the S1 subunit was detected, whilst at 39.5°C and 
at 42°C all subunits were expressed (results not shown). Thus 39.5°C was chosen as 
the induction temperature for S. typhimurium aroA SL3261 and 5. typhimurium  
aroA SL7207 since expression of all subunits was maintained and growth rate was 






Figure 25. Growth curve of S. typhimurium aroA SL7207 (pDP16) following temperature 
induction. Strains were grown at 30°C then subsequently temperature induced at 37°C, 39.5°C or 
42°C. The time of induction is indicated by an arrow.
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3 . 2 . 5  In tera c tio n s  o f  V accin e  S tra in s w ith  E u k aryote  C ells
To determine whether the expression of PT subunits in S. typhimurium aroA 
SL3261 or SL7207 had any affect on the ability of these strains to invade eukaryote 
cells, an in vitro eukaryote cell invasion assay (2.8.1) was undertaken by D r C. 
Guzman. The results presented in Table 9 show that vector only and plasmid-less 
strains o f S. typhimurium aroA SL3261 and S. typhimurium aroA SL7207 increased
1.6 to 10.7 fold in the number of CFU recovered between 4 h and 24 h. Similarly,
S. typhimurium aroA SL3261 (pDP16) and S. typhimurium aroA SL7207 (pDP16) 
induced at 37°C increased 8.3 and 8.6 fold respectively. However, S. typhimurium 
aroA SL3261 and S. typhimurium aroA SL7207 containing pDP16 induced for 1 h 
at 39.5°C decreased 11.5 and 10 fold respectively in invasive ability (Table 9).
Table 9. In vitro invasiveness o f vaccine strains and control strains after 1 h induction at 37°C and 39.5°C.
Strain Invasivenessa
4 h 24 h 4 h 24 h







1.8 x 105 ± 14800
2.2 x 105 ± 99200
2.4 x 105 ± 57500
1.9 x 105 ± 52300
1.4 x 105 ± 22300
2.2 x 105 ± 28500
1.4 x 106 ± 240000 
1.6 x 106 ± 365000
2.0 x 106 ± 526000
1.9 x 106 ± 201000
1.5 x 106 ± 303000
1.9 x 106 ± 178000
1.8 x 105 ± 14800
2.0 x 105 ± 37600
7.1 x 104 19500
3.9 x 105 ± 9000 
2.4 x 105 ± 24600
2.0 x 10* 4 ± 3000
5.2 x 105 ± 14200
4.3 x 105 ± 11000
6.2 x 103 ± 1060
1.2 x 106 ± 40000
4.0 x 105 ± 44000
2.0 x 103 ± 4040
aCFU of viable intracellular bacteria per well ± standard deviation. 
bstrains were grown overnight at 37°C.
cstrains were grown overnight at 30°C, then incubated at 37°C for 2 h and then 39.5°C for a further 1 h.
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3 .2 .6  Antibody responses specific for PT in vaccinated mice
The immunogenicity of S. typhimurium aroA SL7207 (pDP16) was determined by 
oral immunisation of mice with a bacterial suspension of vaccine preparation, using a 
vaccination schedule previously shown capable of generating antibody responses 
(Walker et aL, 1992). Mice were examined for the presence of antibodies specific for 
PT in sera and lung washes following oral immunisation (2.9) with S. typhimurium 
aroA  SL7207 (pDP16) or SL3261 (pDP16) induced at 37°C or 39.5°C for 1 h. 
Antibody responses against PT were not detected when SL3261 was used as the 
carrier strain (results not shown). A statisically significant (P<0.05) serum anti-PT 
IgG response was detected in mice immunised with S. typhimurium aroA SL7207 
(pDP16) induced at 39.5°C (Table 10) but not at 37°C (results not shown). Some 
mice immunised with SL7207 (pDP16) induced at 39.5°C also showed low levels of 
IgA in the sera (Table 10), however these responses were not statistically significant. 
Anti-PT antibodies were not detected in the lung lavages of any vaccinated mice 
(results not shown). Intraperitoneal immunisation with pertussis toxoid (Munoz et 
aL, 1980) generated high serum antibody responses. Western blot analysis was then 
performed to determine the PT subunit specificity of the antibody response. The sera 
from mice orally immunised with S. typhimurium aroA SL7207 (pDP16) induced at 
39.5°C for 1 h showed a detectable response only against the SI subunit protein of 
PT in five of ten mice (Table 10; Figure 26). Sera from mice immunised with 
pertussis toxoid showed a strong response against the SI subunit protein (Table 10; 
Figure 26), whilst only one mouse from this group responded strongly against SI 
and weakly against S4 and S5 (results not shown). Sera from mice orally immunised 
with S. typhimurium aroA SL7207 (pJLA506) induced at 39.5°C for 1 h or with 
PBS did not react against any of the five PT subunits (Figure 26).
8 8
Table 10. Summary of anti-PT titres. S. typhimurium SL7207 containing pJLA506 or pDP16 were 
induced for 1 h at 39.5°C prior to oral immunisation.





1 256 32 ++
2 256 256 ++
3 64 32 +
4 <16 32 -
5 <16 32 -
6 128 <16 +
7 64 <16 -
8 128 <16 -
9 512 <16 +
10 128 <16 -
1 182272 500 +++++
2 182272 256 ++++
3 91136 16 +++
4 45568 256 ++++
5 91136 32 +++
1 <16 <16 -
2 <16 <16 -
3 <16 <16 -
4 <16 <16 -
5 <16 <16 -
1 <16 <16 -
2 <16 <16 -
3 <16 <16 -
4 <16 <16 -
5 <16 <16 -
6 <16 <16 -
7 <16 <16 -
8 <16 <16 -
9 <16 <16 -
10 <16 <16 -
aResults for individual m ice are presented.
bNo detectable reactivity after western blot was scored as a *-* symbol, whilst detectable reactivity was 
scored in a range from *+* to ‘+++++’.
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1 2  3 4
Figure 26. Western blot analysis o f representative mouse sera specific for PT. Lane 1: S. 
typhimurium aroA SL7207 (pDP16) immunised mouse; lane 2: PT immunised mouse; lane 3: 
SL7207 immunised mouse; lane 4: PBS immunised mouse. The filled arrowhead indicates the SI 
subunit protein.
3 .2 .7  P ro tectiveness of 5. typhim urium  aroA SL7207 (pDP16)
V accine S tra in  in Mice
The ability of S. typhimurium aroA SL7207 (pDP16) to engender an antibody 
response against PT following oral immunisation of mice, necessitated that the 
protectiveness of this vaccine strain be investigated. Mice were orally vaccinated with 
this vaccine strain once at day 0 and then intracerebrally challenged with B. pertussis 
18-323 on day 14 (2.9.3). The number of surviving mice 14 days following 
challenge is shown in Table 11. These results indicated that S. typhimurium aroA 
SL7207 expressing  the five PT subunits was not p ro tec tive  in
mice following intracerebral challenge. The Australian standard C dose consists of 
killed B. pertussis cells formulated to give 50% survival of vaccinated mice in this 
assay.
Table 11. Number of surviving mice following intracerebral challenge.
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Vaccination group Number of mice/group Number of survivors
SL7207(pDP16) 21 2
Aust. Std. C dose 16 8
SL7207(pJL A506) 12 0
PBS 16 2
3 .2 .8  Discussion
Whooping cough is a serious respiratory disease of infants. Both the conventional 
whole cell and acellular anti-pertussis vaccines employ an intramuscular route of 
immunisation, mainly stimulating a systemic immune response. It may be considered 
more effective to develop anti-pertussis vaccines capable of stimulating an IgA 
response in the respiratory tract, the site of colonisation. The production of a local 
secretory antibody response may hinder bacterial attachment and subsequent 
colonisation of the respiratory tract, thus preventing disease. In addition to 
stimulating a lung mucosal immune response, the development of enteric delivery 
systems for pertussis antigens would also eliminate the need for purification of 
individual vaccine components thereby reducing production costs.
This research has shown that it is possible to express all five individual PT subunits 
in S. typhimurium aroA SL3261. A recombinant PT operon has been constructed 
and transferred into S. typhimurium aroA SL3261 and SL7207, where the 
simultaneous expression of the five PT subunits was detected. The SI subunit of
PT has previously been expressed in S. typhimurium aroA SL3261 (Walker et al., 
1992). Another group has recently expressed SI as a fusion protein using the amino 
or carboxyl terminus fused to the tetanus toxin fragment C in S. typhi aroA (Barry et 
al., 1996). All other PT subunits apart from SI have not previously been expressed 
in attenuated Salmonella spp.
In order to express the five PT genes in S. typhimurium aroA, a series of PT subunit 
expression plasmids were engineered. Results obtained indicated that the expression 
of each PT subunit was dependent upon the position of each subunit gene within the 
operon. In most instances, those constructs which expressed PT subunits in E. coli 
strains were also expressed in S. typhimurium aroA. The positioning of the subunit 
genes in the following order S2+S3+S4+S5+S1 (pDP16) resulted in production of 
all five PT subunits. Although another PT construct was also made containing the 
five PT subunits, expression of the S2 subunit in this construct was reduced 
compared to its expression in pDP16. Generally, signal peptide processing was 
found to be the same in both the S. typhimurium aroA strains investigated. In strains 
containing plasmids directing the expression of individual PT subunits, S5 was 
completely processed, whilst SI, S2, S3 and S4 were partially processed. In strains 
containing pDP16, S5 was completely processed, SI was partially processed whilst 
processed forms of S2, S3 and S4 were not detected.
The growth rate of S. typhimurium aroA strains containing pDP16 was also 
investigated. Results obtained indicated that the growth rate of both strains 
containing pDP16 was progressively reduced following induction at 37°C, 39.5°C or 
42°C compared to vector only or plasmid-less strains. This reduced growth rate 
indicated PT subunit expression was detrimental to cellular physiology. In order to 
achieve a balance between bacterial cell growth rate and PT subunit production, the 
use of different induction temperatures for the expression of individual PT subunits 
from pDP16 was investigated. These experiments showed that at 37°C, only SI
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expression was detectable, whilst at 39.5°C and 42°C expression of all five subunits 
was apparent. Thus 39.5°C was chosen as the optimum temperature for achieving a 
balance between strain growth rate and subunit expression. Results obtained in the 
eukaryote cell invasion assays correlated to that of bacterial growth rate. The 
invasiveness of strains containing pDP16 was significantly lower than vector only 
and plasmid-less controls at 39.5°C, whilst no significant differences were detected 
at 37°C.
Mice orally immunised with S. typhimurium aroA SL7207 (pDP16) showed a serum 
antibody response directed against the immunodominant SI subunit, whereas S. 
typhimurium aroA SL3261 (pDP16) failed to stimulate a detectable antibody 
response. Lack of reactivity to the B-oligomer may not necessarily mean antibodies 
are absent in sera; such antibodies may react only with conformational epitopes. 
Differences in the immune response of these two strains may reflect differences in 
the attenuation of S. typhimurium aroA SL3261 and S. typhimurium aroA SL7207. 
The protective ability of S. typhimurium aroA SL7207 (pDP16) was assessed in a 
mouse intracerebral challenge assay. This strain was found not to protect mice from 
challenge with B . pertussis 18-323.
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4. DISCUSSION
The expression of recombinant pertussis holotoxin in E. coli would provide a means 
of which to produce large amounts of a pertussis vaccine antigen in a background 
devoid of other potential factors that may be responsible for deleterious side effects 
of vaccine preparations currently in use. Additionally, using E. coli fermentation 
conditions would provide a cost effective means of production, in contrast to B. 
pertussis fermentation requirements. In this research, the five PT genes have been 
individually expressed in E. coli and a recombinant operon capable of simultaneously 
expressing the five PT genes has been constructed. Expression of the PT subunits 
was found to be variable and dependent on both the E. coli host strain used and more 
importantly the order of the PT genes with respect to one another within the 
recombinant operon. The recombinant PT plasmids constructed in this study were 
found to produce greater amounts of PT subunit protein compared to B. pertussis 
Tohama I.
In this study, the individual PT genes have been expressed with at least partial leader 
peptide processing of each subunit in E. coli. This is in contrast to a similar study 
where use of the native leader sequences resulted in complete processing of only the 
SI subunit, partial processing of S2 and S5 was observed, whilst S3 remained 
unprocessed and S4 was not expressed (Burnette et al., 1988a). Differences in the 
levels of processing described may be the result of differences in the bacterial strain 
used in the two studies. The previous study utilised E. coli FM5, a derivative of E. 
coli K-12 whilst in this study E. coli CAG629, EC538, H179, YA21, 876 were 
used. Individual PT subunit expression may be enhanced by further investigating the 
use of other protease deficient E. coli strains.
Results of this research indicated that expression of each subunit was dependent
upon the position of each subunit gene in the synthetic operon. The positioning of
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The expression of recombinant pertussis holotoxin in E. coli would provide a means 
of which to produce large amounts of a pertussis vaccine antigen in a background 
devoid of other potential factors that may be responsible for deleterious side effects 
of vaccine preparations currently in use. Additionally, using E. coli fermentation 
conditions would provide a cost effective means of production, in contrast to B. 
pertussis fermentation requirements. In this research, the five PT genes have been 
individually expressed in E. coli and a recombinant operon capable of simultaneously 
expressing the five PT genes has been constructed. Expression of the PT subunits 
was found to be variable and dependent on both the E. coli host strain used and more 
importantly the order of the PT genes with respect to one another within the 
recombinant operon. The recombinant PT plasmids constructed in this study were 
found to produce greater amounts of PT subunit protein compared to B . pertussis 
Tohama I.
In this study, the individual PT genes have been expressed with at least partial leader 
peptide processing of each subunit in E. coli. The results of periplasmic fractionation 
experiments indicated that the S3 subunit was also processed in pDP16, supporting 
the results obtained by western blotting experiments. This is in contrast to a similar 
study where use of the native leader sequences resulted in complete processing of 
only the SI subunit, partial processing of S2 and S5 was observed, whilst S3 
rem ained unprocessed and S4 was not expressed (Burnette et al., 1988a). 
Differences in the levels of processing described may be the result of differences in 
the bacterial strain used in the two studies. The previous study utilised E. coli FM5, 
a derivative of E. coli K-12 whilst in this study E. coli CAG629, EC538, H179, 
YA21, 876 were used. Individual PT subunit expression may be enhanced by further 
investigating the use of other protease deficient E. coli strains.
Results o f  this research indicated that expression o f each subunit was dependent
upon the position o f each subunit gene in the synthetic operon. The positioning o f
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the PT subunits in the following order, S2+S3+S4+S5+S1 (pDP16) and 
S3+S2+S4+S5+S1 (pDP20) resulted in expression of all five subunits. Signal 
peptide processing of the PT subunits was found to be dependent on the host cell 
strain used; the E. coli strain KS476 seemed to process the greatest amount of PT 
subunit protein especially for S4 and S5. Differential construct expression may have 
been the result of differences in mRNA stability or the formation of RNA secondary 
structure. In a study investigating the transcription and translation of the genes 
encoding the subunits of the E. coli H+ ATPase it was suggested that mRNA 
secondary structure may limit the rate of translation initiation (McCarthy and 
Bokelmann, 1988). It was shown that constructs with less extensive and stable 
secondary structures exhibited higher rates of translation, and the translational 
efficiencies of the genes were influenced by the length and sequence of the 
translation initiation region. This study also found that the expression level of one 
subunit was dependent on the presence of the upstream subunit gene.
A number of methods can be investigated in order to achieve greater levels of 
processing of those PT subunits which were only partially processed. Export of 
proteins depends on the properties of both the exported protein and the export 
machinery of the host bacterium. Firstly, examining the exported protein, the NH2 
leader peptide can be replaced with an E. coli leader sequence such as the modified 8- 
lactamase leader sequence used in this study that directs secretion of recombinant 
gene products. Use of this leader sequence in this study, resulted in complete 
processing of the S4 subunit in E. coli KS476 (pCGVl S4). Alternatively, the E. 
coli signal peptidase 1 could be over-expressed in the same bacterial system so as to 
increase the yield of processed PT subunits. The availability of E. coli signal 
peptidase 1 is a limiting factor in protein export in E. coli, particularly with respect to 
precursor proteins showing low signal peptide processing abilities. The over­
production of the E. coli signal peptidase 1 has been shown to result in increased 
rates of pre(A13i)-6-lactamase processing (Van Diji et aL, 1991). Additionally, E.
coli signal peptidase 1 has previously also been successfully over-expressed in E. 
coli MV1190 (Kim et al., 1995). Thus, this research indicates that it may be 
possible to use such an expression system in combination with that developed in this 
study, to achieve increased processing of PT subunit genes.
The bacterial export machinery of E. coli is presently the most well characterised 
secretion system, and optimisation of this pathway represents another method which 
may result in increased processing of those PT subunits that were only partially 
processed. In this Gram-negative bacterium, proteins destined for secretion must 
transverse the inner membrane into the periplasmic space. The majority of proteins 
secreted to the periplasm use the sec-dependent general secretory pathway (Pugsley,
1993). It is well established that although signal peptides may lack primary sequence 
homology, shared properties enable different signal peptides to interact with common 
elements in the general secretory pathway. To enable proper processing, proteins 
utilising this pathway must remain in a transport competent conformation before and 
during translocation, and the requirements on the signal sequence, determined by the 
host's transport system must be met. Chaperone proteins perform the function of 
maintaining the protein precursors in an export competent conformation by either 
stabilising an unfolded conformation or by preventing their aggregation (Pugsley, 
1993). It is known that some of these membrane proteins combine to form a 
translocase complex, whilst, the function of other export machinery components has 
yet to be determined. In E. coli, numerous different chaperones have been shown to 
interact with different proteins. The substrate specificity of the chaperone-protein 
interaction may require cloning and co-expression of a chaperone from the same 
heterologous organism for successful expression and processing of a heterologous 
extracellular protein in E. coli (Waldinger et al., 1988). When certain chaperones are 
missing or deficient in high-level expression systems, the transport through the inner 
membrane may become inefficient (Kane and Hartley, 1988). Several attempts have 
b een  m ade to overcom e th is  p rob lem  by co -o v e rp ro d u c in g
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components of the general secretory pathway. Results of this research indicate that 
whilst it is lethal to overproduce the transmembrane SecY (PrlA) protein in E. coli 
(Ito, 1990), over-expression of SecY and SecE simultaneously in E. coli maintained 
cell viability (Matsuyama et al., 1990). Increasing the SecB content of E. coli has 
previously been used to facilitate the export of a recombinant penicillin-binding 
protein in E. coli (Fraipont et al., 1994). In another study, it was found that the co­
expression of PrlA4, a mutant form of the SecY protein, and SecE resulted in 
increased yields of recombinant pre-(OmpA)-hIl-6 fusion protein in the periplasm of 
E. coli DH1 (Perez-Perez et al., 1994). Recent work has demonstrated that the over­
expression of prlF  increases cell viability and enzyme yields in recombinant E. coli 
expressing Bacillus stearothermophilius alpha-amylase (Minas and Bailey, 1995). 
The over-expression of the chaperone protein PrlF helps to overcome the lethal 
jamming of the transport system by B-galactosidase fusion proteins, increasing the 
efficiency with which secY translocates the fusion protein (Kiino et al., 1990; Kiino 
and Silhavy, 1984). Additionally, PrlF directly activates the Lon protease, involved 
in the degradation of precursors of exported proteins accumulated in the cytoplasm 
(Gottesman, 1989; Snyder and Silhavy, 1992). Other research has found that over­
production of SecB or DnaK plus DnaJ resulted in a marked increase of hGM-CSF 
secretion to the periplasm. This increase was found to be dependent on the signal 
peptide-heterologous protein-chaperone association involved, thus indicating the 
substrate specificity of chaperone proteins (Berges et al., 1996). The question of 
whether E. coli leader peptidases or chaperone proteins will be functional for all B. 
pertussis PT subunits has yet to be examined, however, such strategies may be 
investigated to improve the level of processing of those PT subunits that were 
unprocessed or partially processed.
The use of B. pertussis chaperones and/or leader peptides may be required if 
processing of the PT subunits is not improved by E. coli signals or chaperones. 
However, the B. pertussis signal peptidase 1 gene has yet to be cloned or
characterised. A chaperone from B. pertussis, has however been identified and 
immunogenically characterised. This chaperone termed cpn 60, has been shown to 
be very similar to the GroEL chaperone of E. coli (Bums et al., 1991). However, 
studies determining its effects on processing of B. pertussis proteins have yet to be 
undertaken.
PT assembly occurs following secretion of individual PT subunits to the periplasm 
(Johnson and Bums, 1994; Walker et al., 1991b). This is also the case for another 
typical A/B bacterial toxin, cholera toxin (Hirst and Holmgren, 1987). The excretion 
of pertussis holotoxin into the culture supernatant by B. pertussis is thought to 
involve nine accessory genes designated pertussis toxin liberation (ptl) genes (Farizo 
et al., 1996; W eiss et al., 1993). These genes are under the control of the PT 
promoter (Kotob et al., 1995; Ricco et al., 1996) which also directs the expression 
of the PT subunit genes. The cloning and expression of these accessory genes using 
strategies developed in this study may result in the export and excretion of 
recombinant PT holotoxin into the extracellular medium following assembly in the 
periplasm. Several lines of evidence suggest that once PT subunits are secreted into 
the bacterial periplasm, pertussis holotoxin will form without the aid of ptl gene 
products, chaperone proteins or other factors produced by B. pertussis. Firstly, the 
B-oligomer of PT has been reformed in vitro using recombinant subunits purified 
from E. coli, albeit with a relatively low yield (Burnette et al., 1992a). Secondly, an 
avirulent strain of B. bronchiseptica {bvg-negative) which contains a constitutively 
expressed PT operon has been constructed. Although PT was not excreted from this 
strain (which does not express p tl  nor other bvg-activated gene products), 
periplasmic extracts were found to contain pertussis holotoxin (Walker et al., 
1991b). Thus it seems likely that, once the five PT subunits are secreted into the 
periplasm of attenuated Salmonella spp., pertussis holotoxin will be formed. The 
possible requirement for increased amounts of the S4 gene product could be 
addressed by cloning an additional copy of this gene into the expression vector
construct. Procedures for the genetic detoxification of PT could then be employed 
(Nencioni et a l., 1990) in order to engineer attenuated vaccine strains for PT 
holotoxoid expression.
In addition to providing a means of producing a highly purified non-reactogenic 
acellular vaccine component, the cloning strategy developed in this study should also 
find utility in the construction of recombinant operons for the regulation and 
expression of other heterologous genes which are not normally transcribed and 
translated in E. coli. Such genes might include those involved in nitrogen fixation 
and the gene products of pathways involved in the degradation of aromatic 
compounds.
Current vaccines against whooping cough are administered parenterally, and generate 
a systemic immune response. An alternative to this approach is to stimulate mucosal 
and systemic immune responses by oral immunisation with live vaccine strains of 
Salmonella spp. The production of a local secretory antibody response may hinder 
bacterial attachment and subsequent colonisation of the respiratory tract, thus 
preventing colonisation and disease. In addition to stimulating a lung mucosal 
immune response, the development of enteric delivery systems for pertussis antigens 
would also eliminate the need for purification of individual vaccine components from
B. pertussis thereby reducing production costs.
This research represents the first case of expression of all individual PT subunits in 
5. typhimurium aroA and the subsequent simultaneous expression of all five PT 
subunits in this bacterium. Previously, recombinant S 1 had been expressed in S . 
typhimurium  SL3261 and S. typhi Ty21a (Walker et a l , 1992). Another group has 
recently expressed SI as a fusion protein using the amino or carboxyl terminus fused 
to the tetanus toxin fragment C in S. typhi aroC aroD CVD908 (Barry et al., 1996). 
All other PT subunits apart from SI have not previously been expressed in attenuated
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Salmonella spp.
In most instances, those constructs which expressed PT subunits in E. coli strains 
were also expressed in S. typhimurium aroA . Incomplete processing of subunits 
may have resulted from overloading of the bacterial secretion pathway. The decrease 
in number of bacteria recovered in the invasion assay for strains containing pDP16 
may be the result of blockage of the bacterial secretion pathway, and a consequential 
build up of unprocessed subunits in the cytoplasm. Such changes may result in a 
reduction in the secretion of proteins involved in eukaryote cell invasion, a decrease 
in bacterial growth, or both.
Mice orally immunised with SL7207 (pDP16) showed a significant serum antibody 
response directed against the immunodominant SI subunit, whereas SL3261 
(pDP16) failed to stimulate a detectable antibody response. Lack of reactivity to the 
B-oligomer may not necessarily mean that antibodies are not present in the sera; such 
antibodies may react only with conformational epitopes present of the native toxin. 
Differences in the immune response of these two strains may reflect differences in 
the attenuation of SL3261 and SL7207. Using a single oral dose of SL7207 (pDP16) 
induced at 39.5°C, the immune response engendered was not protective in an 
intracerebral challenge assay, possibly reflecting the lack of protective B-cell epitopes 
which are present on the native toxin (Burnette et al., 1992b). In a previous study, 
the SI subunit expressed in S. typhimurium SL3261 was found to engender both a 
lung and systemic immune response following oral immunisation (Walker et al., 
1992), however, the protective efficacy of this oral vaccine was not investigated. The 
growth and in vitro invasiveness of SL3261 (pDP16) in comparison with SL3261 
expressing only the S 1 subunit may account for the observed differences in the 
immune response; SL3261 expressing the SI subunit was found to be as invasive as 
plasmid-less controls (Walker et a l, 1992). In another recent study, mice immunised 
orally with S. typhi aroC aroD CVD908 producing a SI-tetanus toxin fragment C
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fusion protein did not elicit consistent serum or lung antibody responses (Barry et 
al., 1996). The lack of an antibody response in this study may have been due to 
strain growth, solubility of the foreign antigen or the masking of epitopes by the 
fusion protein which may have blocked immune responses against S I. The 
protective efficacy of this vaccine preparation was also not determined.
To improve processing of PT subunits in Salmonella spp. similar strategies that are 
proposed for improvement of processing in E. coli could be used. The signal peptide 
1 from S. typhimurium has been cloned and characterised at the molecular level (Van 
Diji et aL, 1992). Over-expression of this signal peptidase or that from E. coli may 
improve the processing of PT subunits. The problems of vaccine strain viability and 
immunogenicity encountered in this study may eventually be overcome using various 
strategies. For instance, strain growth may be improved by the use of in vivo- 
activated promoters that restrict expression of the heterologous antigen until the 
bacterial vector reaches the intestinal mucosa or has invaded eukaryote host cells. 
Several such promoter systems are being developed for this purpose (Dougan, 1994; 
Staendner et al., 1995). The anaerobically inducible nirB promoter has previously 
been used to immunise mice with a S. typhimurium aroA aroD vaccine strain 
expressing the fragment C of tetanus toxin. This construct was found to be stably 
inherited by bacteria growing or persisting in the tissues of immunised mice, in 
contrast to a construct which utilised the tac promoter. The nirB construct was found 
to generate antibody responses in these mice following boost, but the mice were only 
partially protected against tetanus toxin challenge (Chatfield et al., 1992). This 
promoter has also been used to express the P69 antigen of B. pertussis to levels of 
up to 30% of the total cell volume (Oxer et al., 1991). The improvement of strain 
growth using in vivo-activated promoters may also improve the subsequent immune 
response engendered against PT by strains containing the synthetic PT operon. In 
another study, genes encoding two E. coli envelope proteins, the outer membrane 
protein LamB and the periplasmic protein MalE, were placed under the control of the
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pnir promoter on pBR322 plasmid derivatives, and both proteins were expressed at 
high levels during anaerobic growth. This promoter was found to direct a four fold 
increase in the level of MalE expression relative to the level reached by the tac 
promoter construct. A MalE-HIV 1 hybrid protein was also over-expressed under 
pnir control, without apparent degradation of the hybrid protein. When this construct 
was expressed in S. typhimurium aroA SL3261, the plasmids carrying the foreign 
genes were found to be stable in vitro and in vivo (Newton et al., 1995). In another 
study the htrA  promoter was used to express LacZ in S. typhimurium  BRD915 
(SL1344 htrA), and expression significantly increased when S. typhimurium entered 
eukaryotic cells, including macrophages (Everest et al., 1995). Secondly, 
incorporation of the synthetic PT operon into the chromosome may improve the 
stability of antigen expression in vivo. In this approach, the expression of the foreign 
protein is reduced since the genes are only present in one copy, however, it is still 
possible to obtain a protective immune response (Dougan, 1994). Such a system that 
uses non-antibiotic resistant mini-transposons which allow the stable integration of 
foreign genes into the bacterial chromosome has been developed (Herrero et al., 
1990). In a similar approach, a defective transposable element which stably inserts 
into the bacterial chromosome has been used to express foreign genes in S. 
typhimurium aroA, and has been found to generate a cytotoxic T-cell response 
against the foreign antigen in mice (Flynn et al., 1990). Such strategies that involve 
the integration of foreign genes into the bacterial chromosome may be useful for the 
stable expression of PT genes. Finally, an attenuated strain of S. typhimurium  
expressing the cytokine interleukin-6 has been developed (Dunstan et al., 1996). 
Such studies may lead to the development of attenuated bacterial vectors co­
expressing a repertoire of cytokines which results in an improved immune response 
against heterologous antigens.
In this study, S. typhimurium aroA strains simultaneously expressing the five PT 
subunits have been characterised. Significant antibody responses in the sera of
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vaccinated mice were detected following oral immunisation with S. typhimurium  
SL7207 (pDP16) induced at 39.5°C. No protection was observed in vaccinated mice 
following intracerebral challenge with this vaccine. The findings of this study 
indicate that expression of PT subunits was detrimental to the host cell, which 
displayed decreased invasion and growth characteristics which is, probably in part, 
responsible for the low antibody response detected in mice immunised with this 
vaccine preparation. Although this study was limited to assessment of antibody 
responses following oral immunisation, it is recognised that cell mediated immunity 
does play a role in protection against disease following immunisation or infection 
with B. pertussis (Zepp et al., 1996). Such studies would need to be conducted in 
future trials. Despite these difficulties, the use of live oral vaccines expressing B. 
pertussis antigens remains an attractive alternative to parenterally administered 
pertussis vaccines, in stimulating a local immune response at the site of infection. 
Additionally this delivery system would be cost effective to produce and easily 
administered, thus being highly suitable for Third World vaccination programs.
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5. CONCLUSION
Pertussis toxin is the major virulence factor of B. pertussis. The inability to express 
PT in E. coli using the wild-type promoter and ribosomal binding site has hampered 
the development of new generation pertussis vaccines. A major aim of pertussis 
vaccine research is the over-production of PT in a background devoid of other 
compounds present in B. pertussis that may contribute to the side effects commonly 
observed following whole-cell pertussis vaccination. Additionally, the ability to 
express this antigen in attenuated Salmonella spp. would permit the development of 
orally administered pertussis vaccines. Such vaccines are considered superior to 
parenterally administered vaccines currently in use, due to their ability to invoke a 
mucosal IgA response in the lungs, the site of colonisation.
In this research the five PT genes have been individually and simultaneously 
expressed in E. coli. The results of this study indicate expression and signal peptide 
processing of the PT subunits was variable. In E. coli CAG629 S2, S3, S4 and S5 
were partially processed, whilst S5 was completely processed in this strain. An 
operon capable of simultaneously expressing the five PT subunits was subsequently 
constructed using a novel cloning strategy which enabled different combinations of 
the PT genes to be cloned. In E. coli KS476 (pDP16) SI and S4 were partially 
processed, S2 and S3 were unprocessed and S5 was completely processed. 
Subcellular fractionation studies detected SI and S3 in periplasmic extracts, whilst, 
S2, S4 and S5 were not detected in periplasmic extracts. The majority of all PT 
subunit proteins were found to be localised to the cytoplasm. E. coli K S476 
expressing the five PT subunit genes showed a decrease in viability following 
temperature induction at 42°C.
Using attenuated aroA derivatives of S. typhimurium, SL3261 and SL7207, the five 
PT subunits have been both individually and simultaneously expressed. As is the
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case with E. coli, signal peptide processing was variable. In SL7207 (pDP16) 
expressing the five PT subunits SI was completely processed, S2, S3 and S4 
remained unprocessed whilst S5 was completely processed. S typhimurium  SL7207 
(pDP16) displayed reduced viability and in vitro invasiveness for eukaryote cells 
compared to plasmid-less or vector-only strains. When this vaccine strain was used 
to orally immunise mice a significant anti-S 1 response was invoked, as detected by 
western blot analysis. The protectiveness of this vaccine strain was assessed in a 
mouse intracerebral challenge assay; results obtained indicated that this strain was 
non-protective following challenge with live B. pertussis.
Expression of a recombinant PT operon in E. coli and S. typhimurium  represents a 
significant achievement in the development of new generation whooping cough 
vaccines. The problems encountered in this research can be addressed with the 
development of new strategies aimed at optimising PT processing and expression in 
E. coli and  Salm onella spp ., thus potentially im proving strain viability and 
immunogenicity. Such strategies that will be investigated in future work include the 
use o f different leader peptides such as B-lactamase that direct the secretion of foreign 
gene products. Additionally, chaperone proteins which function in assisting the 
processing and secretion of proteins into the periplasm will be co-expressed in 
strains containing pDP16. In order to im prove the im m unogenicity of S. 
typhimurium spp. harbouring pDP16, the use of in vivo promoters such as nirB, that 
are activated following bacterial invasion of eukaryote cells will be utilised, such 
promoters have shown promising results in other studies.
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2YT agar contained tryptone, 16 g/1; yeast extract, 10 g/1; sodium chloride, 5 
gA; Agar, 15 g/1.
ii. X-gal Agar
X-gal agar was prepared by adding 2 ml of a 2% X-gal in DMF solution and 
0.4 ml of a 100 mM solution of IPTG to 11 of sterile, cooled 2YT agar.
iii .  BG Agar
BG agar contained Bordet Gengou agar base, 30 g/1; glycerol, 10 ml/1; 150 
ml/1 defibrinated horse blood was added to the cooled agar base.
iv . XP Agar
XP agar was prepared by the adding 5 ml of a 10 mg/ml XP in DMF solution 
and 0.4 ml of a 100 mM solution of IPTG to 11 of sterile, cooled 2YT agar.
v . Z Agar
Z agar contained glucose, 1.0 g/1; calcium chloride, 0.367 gA; sodium 
chloride, 2.5 gA; tryptone, 10.0 gA; yeast extract, 5.0 gA, agar, 15.0 gA.
vi. LB Broth
LB broth was used to inoculate all bacterial cultures, it contained tryptone, 10 
gA; yeast extract, 5 gA; sodium chloride, 10 gA.
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vii. SOC Media
SOC media was used in conjunction with the TA Cloning™ Kit. It contained 
tryptone, 2%; yeast extract, 0.5%; sodium chloride, 10 mM; potassium 
chloride, 2.5 mM. A 2 M stock of Mg2+, comprised of 1 M MgCl2 and 1 M 
MgSC>4 was filter sterilized, along with a 2 M glucose stock. These were 




TAE buffer (xlO) for agarose gel electrophoresis contained Tris-base, 48.44
g/1; sodium acetate, 27.22 g/1; EDTA, 7.44 g/1; pH 8.0.
ii. TBE Buffer
TBE buffer (x 10) for DNA sequencing contained Tris-base, 162 g/1; boric 
acid, 27.5 g/1; EDTA, 9.5 g/1. The pH of this solution is approximately pH 8 
and was not adjusted.
iii . SDS-PAGE Running Buffer
SDS-PAGE Running Buffer (x 8) contained Tris-base, 15 g/1; glycine, 72 g/1; 
SDS, 5 g/1. The pH of this solution is approximately pH 8.3 and was not 
adjusted.
iv. Western Transfer Buffer I
Western transfer buffer used for nitrocellulose filters contained Tris-base, 5.8 
g/1; glycine, 2.9 g/1; SDS, 3.75 g/1; methanol, 20%.
v. Western Transfer Buffer II
Western transfer buffer for PVDF contained Tris-base, 3.1 g/1; glycine, 14.4 
gA; methanol 20%.
vi. Phosphate Buffered Saline
Phosphate buffered saline contained NaCl, 8.0 g/1; KC1, 0.2 g/1; Na2HPC>4,
1.15 g/1; KH2P0 4 , 0.2 g/1. The pH of this solution is approximately pH 7.4 
and was not adjusted.
vii. Fractionation Buffer
Fractionation Buffer contained sucrose, 250 g/1; EDTA, 1 mM; Tris-HCl, 10 
mM; pH 8.0.
viii .  T4 DNA Ligase Buffer x 10 (Boehringer Mannheim)
The ligation buffer contained Tris-HCl, 660 mmol/1; MgCl2, 50 mmol; DTT,
10 mmolA; ATP, 10 mmolA; pH 7.5 (at 20°C).
ix . Dephosphorylation Buffer x 10 (Boehringer Mannheim)
The dephosphorylation buffer contained Tris-HCl, 0.5 molA; EDTA, 1 
mmolA; pH 8.5 (at 20°C).
x . T7 Polymerase Dilution Buffer (Pharmacia)
The T7 polymerase dilution buffer contained Tris-HCl, 20 mM (pH 7.5);
DTT, 5 mM; BSA, 100 pg/ml; glycerol, 5%.
x i. Annealing Buffer (Pharmacia)
The annealing buffer for DNA sequencing contained Tris-HCl (pH 7.6), 1 M;
MgCl2, 100 mM; D IT , 160 mM.
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xii .  PCR Reaction Buffer x 10 (Boehringer Mannheim)
The PCR buffer contained Tris-HCl, 100 mM; MgCl2, 15 mM; KC1, 500 
mM; pH 8.3 ( at 20°C).
xii i .  Labelling Mix-dATP (Pharmacia)
The d-ATP labelling mix contained dCTP, dGTP, dTTP, 1.375 |iM  of each; 
NaCl, 333.5 mM.
xiv.  Phosphate-Citrate Buffer
The phosphate citrate buffer was prepared by mixing 25.7 ml of 0.2 M NaPC>4 
with 24.3 ml of 0.1 M citric acid. pH to 5.0.
C. ACRYLAMIDE SOLUTIONS
i.  SDS-PAGE Stacking Gel
SDS-PAGE stacking gel (4%) contained 1.1 ml of a 35% acrylamide/0.8%bis- 
acrylamide solution; Tris-HCl 0.5 M (pH 6.8), 2.5 ml; 10% SDS, 0.1 ml; 
gdH20 , 6.3 ml; ammonium persulfate 10%, 0.05 ml; TEMED, 0.05 ml.
i i .  SDS-PAGE Resolving Gel
SDS-PAGE resolving gel (15%) contained 6.3 ml of a 35% acrylamide/0.8% 
bis-acrylamide solution; Tris-HCl 1.5 M (pH 8.8), 2.5 ml; 10% SDS, 0.1 ml; 
gdH20 , 3.4 ml; ammonium persulfate 10%, 0.05 ml; TEMED, 0.05 ml.
iii .  Sequencing Gel
Sequencing Gel (5%) contained 5 ml of a 50% 19:1 acrylamide/bis-acrylamide 
solution; TBE (x 10), 5 ml; urea, 23 g; ammonium persulfate 10%, 0.25 ml; 
TEMED, 0.05 ml; and was made up to 50 ml with gdH20.
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D . LOADING DYES
i . Agarose Loading Dye
Agarose gel electrophoresis loading dye consisted of Ficoll 400,15%; 
bromophenol blue, 0.25%.
i i .  PAGE Sample Buffer
PAGE sample buffer contained Tris-HCl (pH 6.8), 60 mM; SDS, 1%; B- 
mercaptoethanol, 10%; glycerol, 10%; bromophenol blue, 0.01%; pH 6.8.
iii .  Sequencing Stop Buffer (Pharmacia)
Sequencing stop solution contained bromophenol blue, 0.3%; xylene cyanol 
FF, 0.3%; 10 mM EDTA (pH 7.5); deionised formamide, 97.5%.
E. BUFFERS FOR PLASM ID EXTRACTION
i .  Buffer PI (Qiagen)
Buffer PI contained RNase A, 100 mg/1; Tris-HCl, 6.06 g/1; EDTA, 3.72 g/1; 
pH 8.0, store at 4°C.
i i .  Buffer P2 (Qiagen)
Buffer P2 contained NaOH, 8.0 g/1; 20% SDS, 50 ml A.
iii .  Buffer P3 (Qiagen)
Buffer P3 contained potassium acetate, 294.45 g/1.
iv . Buffer QBT (Qiagen)
Buffer QBT contained NaCl 43.83 g/1; MOPS, 10.46 g/1; ethanol, 15 ml;
Triton X-100, 0.15%; pH 7.0.
v . Buffer QC (Qiagen)
Buffer QC contained NaCl 1 M, 43.83 g/1; MOPS, 10.46 g/1; ethanol, 15%; 
pH7.0.
v i. Buffer QF (Qiagen)
Buffer QF contained NaCl, 73.05 g/1; Tris-HCl, 6.06 g/1; ethanol, 15%; pH 
8.5.
vii .  Alkaline Sucrose Solution
Alkaline sucrose solution contained sucrose, 150 g/1; EDTA, 18.5 g/1; Tris- 
base, 6.0 g/1; pH 8.5.
viii .  Alkaline Triton Solution
Alkaline triton solution contained Triton X-100, 1 ml/1; EDTA, 18.5 g/1; Tris- 
base, 6.0 g/1; pH 8.5.
G . SOLUTIONS
i .  Coomassie Blue Stain
The Commassie blue stain for protein gels contained Commassie brillant blue 
R250, 0.1%; methanol, 50%; acetic acid, 10%.
i i .  Destain Solution




iii .  ELISA Substrate Solution
The ELISA substrate solution contained 6 mg/ml tetramethylbenzidine 
dihydrochloride diluted in 0.1 M phosphate-citrate buffer (B.xiv). 2 |il of 
H2O2/IO ml of substrate solution was added immediately prior to use.
iv . Fixing Solution
The fixing solution for sequencing gels contained methanol, 10%; acetic acid,
10%.
v . Developer Solution (Kodak)
The developer solution for X-ray film contained developer, 25%.
v i. Fixing Solution (Kodak)
The fixing solution for X-ray film contained fixer 25%.
vii .  Western Blot Colour Development Solution
The colour development solution consisted of two separate solutions combined 
immediately prior to use. Solution A contained gdH20, 30 ml; H2O2, 20 pi. 
Solution B contained 4-chloro-l-napthol, 30 mg; methanol, 10 ml.
H . PRIMER MELTING TEMPERATURE
Melting temperature is that temperature at which 50% of the primer no longer 
hybridises to the template DNA. It depends on the specificity of the primer and 
the GC content.
less than 20 nucleotides: 2(AT) + 4(GC)
greater than 20 nucleotides % GC( 0.41) + 69.3 - 6£0
#bp
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PCR annealing temperatures were taken as being 5°C below the true Tm of the 
primers.
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I .  T H E  STANDARD G EN ETIC  CODE
U C A G
u u u Phe u c u Ser UAU Tyr UGU Cys U
u u u c Phe u c c Ser UAC Tyr UGC Cys c
UUA Leu UCA Ser UAA Stop UGA Stop A
UUG Leu UCG Ser UAG Stop UGG Trp G
CUU Leu CCU Pro CAU His CGU Arg U
c c u e Leu CCC Pro CAC His CGC Arg C
CUA Leu CCA Pro CAA Gin CGA Arg A
CUG Leu CCG Pro CAG Gin CGG Arg G
AUU lie ACU Thr AAU Asn AGU Ser U
A AUC He ACC Thr AAC Asn AGC Ser C
AUA ne ACA Thr AAA Lys AGA Arg A
AUGtMet ACG Thr AAG Lys AGG Arg G
GUU Val GCU Ala GAU Asp GGU Gly U
G GUC Val GCC Ala GAC Asp GGC Gly C
GUA Val GCA Ala GAA Glu GGA Gly A
GUG Val GCG Ala GAG Glu GGG Gly G
tAUG is part of the initiation codon as well as an initial methionine 
SYMBOLS FOR AMINO ACIDS
A Ala Alanine
B Asx Asparagine or aspartic acid
C Cys Cysteine
D Asp Aspartic Acid

















Z Glx Glutamine or glutamic acid
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